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Abstract 
Transcriptional enhancers and their associated transcription factors (TFs) have a 
profound impact in gene regulation during development. The TFs Ascl1 and the Sox 
factors play important roles in many aspects of neurogenesis in vertebrates. Ascl1 
induces neuronal differentiation in neural progenitor cells. Sox2 is an essential TF in the 
maintenance of neural stem cell characteristics, but also functions in the correct 
specification of neuronal subtypes. SoxC factors have a fundamental role in the 
establishment of neuronal traits in differentiating neurons. Data previously generated in 
our lab have identified genomic regions bound by both Ascl1 and Sox2 in close 
proximity through a ChIP-seq approach, raising questions about possible interactions 
between these TFs as transcriptional regulators. Here, I have characterised these regions 
as neural enhancers regulated by Ascl1, Sox2, and SoxC factors using NS5 cells as an 
in vitro model of neural stem cells through luciferase assays. Enhancers activated by 
overexpression of Ascl1 were classified as neuronal enhancers, since overexpression of 
this TF induces neuronal differentiation in NS5 cells. Cotransfection experiments and 
luciferase assays demonstrated that Ascl1 and Sox2 counteract each other in the 
regulation of the enhancers, whereas Ascl1 and SoxC factors synergistically activate the 
neuronal enhancers. Mutations of the binding motifs of these TFs and comparisons 
between the transcriptional activity of the wt and mutant enhancers suggest direct 
binding of Ascl1 on all the enhancers activated by this TF, but different mechanisms of 
regulation exist for the Sox factors on the different enhancers analysed. I have shown 
direct binding of Ascl1 on one of these enhancers, MSB4, by EMSA. In conclusion, I 
have identified a novel transcriptional regulatory network in the regulation of neuronal 
differentiation where Ascl1 and SoxC factors synergistically activate neuronal 
enhancers, and Sox2 counteracts Ascl1 in this activation.  
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1. Introduction 
Developmental progression and cell fates are established by highly regulated programs 
of gene expression, which are driven by interconnected gene regulatory networks. The 
identification of these transcriptional networks regulating stem cell division and 
differentiation is an essential step to understand how the balance between self-renewal, 
multipotency and differentiation is achieved. Transcriptional enhancers and their 
associated Transcription Factors (TFs) have a prominent role in the initiation of gene 
expression and its regulation. 
This thesis focuses on the identification and characterisation of neural enhancers 
regulated by the TFs Ascl1 and the Sox factors, in particular Sox2 and the SoxC 
members, Sox4 and Sox11. These proteins play important roles in many aspects of the 
neural development and neurogenesis in vertebrates. Neurogenesis is the generation of 
neurons from neural progenitor cells and is a tightly regulated genetic process 
controlled by the interplay of many different TFs. 
In this introduction, I first give an overview of the development of the Central Nervous 
System (CNS) with a focus on neurogenesis in vertebrates. Secondly, an overview of 
enhancers, their functions and their genomic identification is presented. Finally, the role 
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1.1 Development of the Central Nervous System in 
vertebrates 
1.1.1 Formation of the Neural Tube 
Neurulation is the embryonic process that leads to the formation of the neural tube, 
which will develop into the brain and spinal cord (Gilbert, 2006). It occurs at the end of 
gastrulation during embryonic development, around E7 in the mouse. 
The formation of the neural tube is a complex process in which cells need to change 
shape, migrate, and differentiate to transform a flat sheet of epithelial cells, the neural 
plate, into a hollow tube, the neural tube. This process involves morphogenetic events, 
controlled by distinct molecular pathways. 
The closure of the neural tube along the anterior/posterior axis occurs simultaneously in 
birds where it is initiated at the level of the future midbrain in a “zip-like” manner 
proceeding in both directions. In mammals, however, it is initiated at several places, 
usually three sites, along the anterior-posterior axis.  
Neural tube closure requires a complex interplay between genetic and environmental 
factors. Genes such as Pax3, Sonic hedgehog (Shh) and openbrain are essential for the 
formation of the mammalian neural tube. In addition, dietary factors such as cholesterol 
and folic acid seem to be of critical importance to the process. The failure of various 
parts of the neural tube to close leads to neural tube defects (NTDs). Among the most 
common forms of NTDs are anencephaly and spina bifida. The first results from a 
failure of the neural tube to close anteriorly in the cranial region. It is characterised by a 
partial or total absence of the cranial vault and cerebral hemispheres and is invariably 
lethal. The latter occurs when the most caudal region of the neural tube fails to close. It 
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leads to mild or severe lifelong physical and developmental disabilities, depending on 
how much of the spinal cord remains exposed (Gilbert, 2006).  
1.1.1.2 The anterior-posterior axis 
The early mammalian tube is a straight structure. However, as the formation of the 
neural tube proceeds during development, drastic changes occur along the tube. 
Initially, the neural tube bulges and constricts in three points generating three primary 
vesicles: the forebrain, midbrain, and hindbrain. Subsequently, the neural tube further 
subdivides in five secondary vesicles: the telencephalon and the diencephalon, 
originating from the forebrain; the mesencephalon from the midbrain; and the 
metencephalon and myelencephalon from the hindbrain. From these primitive vesicles 
all the structures of the brain and spinal cord will eventually form.  
Several signalling molecules control the anterior-posterior patterning of the central 
nervous system. The combinatorial code of their spatially and temporally distinct 
concentrations directs the expression of distinct TFs in different defined domains along 
the anterior-posterior axis. The Hox genes family is among the genes controlling the 
patterning, defining cell identity along the axis (Gilbert, 2006).  
1.1.1.3 The dorsal-ventral axis 
The neural tube is also polarised along its dorsal-ventral axis. The dorsal-ventral 
patterning is established by the expression of bone morphogenetic proteins (BMPs) 
dorsally, and Sonic hedgehog (Shh) ventrally (Figure 1.1A). BMP4 and BMP7, the 
dorsalising signals, are expressed and secreted from the roof plate whilst Shh is 
expressed and secreted from the floor plate. Overlapping gradients of these diffusible 
molecules induce the coordinated expression of mutually cross-repressive TFs along the 
Chapter 1 - Introduction 
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dorsal-ventral axis. For instance, cells adjacent to the floor plate that are exposed to 
high concentrations of Shh and hardly any BMPs express the TFs Nkx6.1 and Nkx2.2 
and become the ventral neurons of the V3 domain (Figure 1.1B). The cells dorsal to this 
domain, exposed to slightly less Shh and slightly more BMPs instead express the 
combination of Nkx6.1 and Pax6 TFs. They are the cells of the motor domain, which 
will become the motor neurons of the ventral spinal cord. The next two groups of cells, 
exposed progressively to decreasing concentrations of Shh, become the V2 and V1 
interneurons domains (Gilbert, 2006) (Figure 1.1B).   
Dorsal-ventral patterning in the forebrain is similarly established by Shh and BMPs. 
Moreover, fibroblast growth factors (FGFs), secreted from the anterior neural ridge and 
the rostral midline, also contribute to confer ventral identity to the progenitor cells in the 
forebrain. In the dorsal telencephalon, Wnt-signalling antagonises the ventral identity 
(Campbell, 2003). The dorsal-ventral patterning of the forebrain establishes two major 
progenitor domains: the dorsal domain, or pallium, which later forms the cerebral 
cortex, and the ventral domain, or subpallium, the precursor of the basal ganglia, the 
amygdala and the septum, and the origin of cortical interneurons. The patterning of the 
progenitor domains is an important mechanism in development to pre-determine and 
commit the fate of progenitor cells in the different specific regions of the central 
nervous system (Gilbert, 2006). 
Chapter 1 - Introduction 
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Figure 1.1 Dorsal-ventral specification of the neural tube. 
(A) The newly formed neural tube is patterned by two signaling molecules centers. The roof of the neural 
tube is exposed to BMP4 and BMP7 from the ectoderm; the floor of the neural tube is exposed to Shh 
from the notochord. Overlapping gradients of these diffusible molecules induce the coordinated 
expression of mutually cross-repressive TFs along the dorsal-ventral axis. The identity of the neurons in 
the spinal cord is determined by the combinatorial code of TFs that these cells express in their nuclei and 
that is established by their position along the dorsal-ventral axis and the exposure to different 
concentrations of the signalling molecules. Taken from Gilbert 2006. (B) Specification of neuronal 
identity in the ventral neural tube by Shh from the floor plate (FP). Relationship between Shh 
concentrations, the generation of specific progenitor domains and neuronal types in vitro, and the distance 
from the notochord. Taken from (Wang et al., 2003). 
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1.1.2 Neurogenesis  
1.1.2.1 Neural progenitor cells of the CNS 
The developing mouse cerebral cortex is one of the main model systems for 
neurogenesis. However, the mechanisms identified in this tissue also operate in a 
similar way in other regions of the developing brain and spinal cord.  
Neurons and glial cells derive from a pseudostratified neuroepithelium of ectodermal 
origins that line the cerebral ventricles of the developing embryo. The Neuroepithelial 
(NE) cells undergo rapid symmetric divisions to expand the neural plate.  
When cortical neurogenesis begins, around E9-E10 in mouse, the NE cells acquire 
features of Radial Glial (RG) cells. These cells express glial marker such as GLAST 
(Glutamate-Aspartate transporter) and BLBP (Brain lipid-binding protein). A series of 
changes mark the transition from NE cells to radial glial. However, like NE cells, RG 
cells maintain apical-basal polarity, line the lateral ventricles and undergo interkinetic 
nuclear migration within the ventricular zone (VZ), therefore maintaining the aspect of 
pseudostratified epithelium. RG cells persist and represent the principal neural 
progenitor cells during development of the embryonic CNS. These Neural Stem Cells 
(NSCs) will give rise to all types of neuronal lineages and macroglial cells, astrocytes 
and oligodendrocytes, of the brain and the whole CNS (Kriegstein and Alvarez-Buylla, 
2009, Martynoga et al., 2012). The progression of lineages from these NSCs occurs so 
that neurons are generated first, and astrocytes and oligodendrocytes at a later stage 
(Figure 1.2). During the cortical neurogenesis RG cells undergo asymmetric self-
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renewing cell divisions to generate another radial glia cell and a daughter cell that will 
differentiate into a neuron.  
The production of neurons from RG cells is not always a direct step. It can involve the 
generation of more fate-restricted progenitor cells, called Intermediate Progenitor Cells 
(IPCs), or Basal Progenitors (BP) (Figure 1.2). It has been showed that basal 
progenitors (BP) derive from asymmetric divisions of the RG cells (Haubensak et al., 
2004, Miyata et al., 2004, Noctor et al., 2004). Therefore, RG are NSCs that either 
produce neurons directly or through the generation of fate-restricted IPCs, which 
populate the sub-ventricular zone (SVZ).  Thus, the SVZ is a major site of neurogenesis 
in the developing brain producing neurons away from the ventricle. 
IPCs have a multipolar shape, and do not have processes contacting the pial surface or 
the ventricle. They do not undergo interkinetic nuclear migration. Unlike RG cells, 
which mainly divide asymmetrically, IPCs undergo symmetric divisions to generate two 
neurons or two other IPCs (Kriegstein and Alvarez-Buylla, 2009). The number of time 
IPCs divide to produce more IPCs before generating neurons can vary in different 
regions of the brain, which further varies between different species. In particular, it has 
been shown that primate corticogenesis is characterised by the appearance of a large 
SVZ. The distinguished area of the outer SVZ, the OSVZ, is seat of several mitosis of 
the IPCs, called outer RGs. These divisions expand the number of mitotic cells that will 
eventually produce neurons spanning the whole cerebral cortex. Therefore, these IPCs 
act functionally as transit amplifying cells present in the stem cell lineages of other 
tissues. Indeed, the expansion of the pool of IPCs producing neurons contributes to the 
cortical expansion observed in the gyrencephalic (large and highly folded) primate 
cortex. Conversely, lissencephalic species (with a smooth and non-folded cortex), such 
as the mouse and most other rodents, also have IPCs in the SVZ, but their number, and 
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therefore their contribution to the expansion of the cortical plate, is small (Lui et al., 
2011). Further supporting the importance of neurogenesis that takes place in the SVZ 
for the control of cortical size, a congenital disease known as microcephaly has been 
associated to the homozygous silencing of the gene Tbr2, a TF considered to be a 
selective marker for IPCs and functionally required for the SVZ neurogenesis (Sessa et 
al., 2008, Lui et al., 2011). 
 
Figure 1.2 Glial nature of Neural Stem Cells in cortical development. 
Three modes of neurogenesis: i) directly through asymmetric division; ii) indirectly through generation of 
neurogenic Intermediate Progenitor Cells (nIPC) and one round of amplification; iii) or again through 
nIPC but with more rounds of mitosis and amplifications. Radial Glia cells generate also astrocytes and 
oligodendrocytes at the end of neurogenesis. oIPC: oligodendrocytic IPC; NE: neuroepithelium; MZ: 
marginal zone; VZ: ventricular zone; SVZ: sub-ventricular zone; IZ: intermediate zone; CP: cortical 
plate. Taken from Kriegstein and Alvarez-Buylla, 2009. 
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1.1.2.2 Spatial and temporal mechanisms of neural progenitor specification 
In the developing forebrain, several signalling centres secrete diffusible molecules that 
form overlapping gradients and act as morphogens. Sonic hedgehog (Shh) is secreted 
from the ventral midline of the forebrain; members of the FGF family, such as Fgf8, 15, 
and 17, are secreted anteriorly by the midline of the telencephalon; members of the Wnt 
and BMP families are secreted from the medial and caudal area of the cortex. These 
signalling molecules establish the regionalised expression of homeobox and helix-loop-
helix TFs in progenitor cells. The combinatorial code of TFs eventually subdivides the 
telencephalon in a dorsal domain, or pallium, and a ventral domain, or subpallium 
(Campbell, 2003). These patterning TFs will induce other TFs, which eventually specify 
progenitors identity and neuronal fate and phenotypes. Following this principle of 
regionalisation, the pallium will eventually be subdivided into distinct architectonic and 
functional areas that later organise the cerebral cortex longitudinally during 
development.  
Collectively, RG cells generate the vast and diversified neuronal subtypes and glial cells 
of the brain and spinal cord. This is achieved through different signalling and gradients 
of morphogens, which interact to establish discrete territories of TFs expression, each 
associated with the production of different types of neurons (Figure 1.3). Thus, 
segregation of progenitor zones within the forebrain has been characterised, each 
associated with distinct transcription factor expression. Therefore, RG cells appear to be 
very heterogeneous in terms of their progenitor functions, depending on the 
transcription factors they express (Kriegstein and Alvarez-Buylla, 2009). Several 
studies have focused on the identification of the many TFs involved in the control of 
neurogenesis, implicated in the proliferation of neural progenitors, and in the control of 
the tight balance between proliferation and differentiation in the developing brain 
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(Martynoga et al., 2012).  Defects in progenitor divisions and brain growth have been 
described for mice mutant for the paired homeobox factor Pax6, the homeobox proteins 
Lhx2 and Arx, the winged-helix protein Foxg1, and the nuclear receptor Tlx (Jacobs 
and Dinman, 2004, Cahill et al., 1994, Lin et al., 2007, Natesan et al., 1997, Orphanides 
et al., 1996).  
 
The basic helix-loop-helix (bHLH) proneural transcription factors are critical regulators 
of neurogenesis. Among these, the Neurogenins, Ngn1 and Ngn2, and Ascl1/Mash1 are 
expressed in RG cells of the developing cerebral cortex, already at the time of NE to RG 
transition (Martynoga et al., 2012). It has been proved that cortical neurogenesis is 
considerably damaged in embryos deficient for these proneural factors, both in vivo and 
in vitro (Nieto et al., 2001). These same proneural factors are also sufficient to induce a 
full program of neurogenesis. Indeed, overexpression in vivo or in vitro of either Ngn2 
 
Figure 1.3 Spatial mechanisms of progenitor cells specification in the 
telencephalon. 
Combinatorial codes of TFs expressed in restricted dorsal or ventral domains establish the neuronal fate 
and identity of progenitor cells in the developing telencephalon. Signaling molecules, such as BMPs, 
FGFs, and Shh proteins, influence the expression of these different TFs in sharp domains/boundaries. See 
text for more details. CGE: Caudal Ganglionic Eminence; LGE: Lateral Ganglionic Eminence; MGE: 
Medial Ganglionic Eminence. Adapted from Martynoga et al., 2012.  
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or Ascl1 can induce a full neuronal differentiation (Mizuguchi et al., 2001, Nakada et 
al., 2004, Berninger et al., 2007). Moreover, their requirement for neuronal 
differentiation can be further supported by their reprogramming capabilities. For 
instance, Ascl1 can respecify fibroblasts into neurons, with greater efficiency if it is 
overexpressed with the other TFs Brn2 and Myt1l (Vierbuchen et al., 2010). 
Other TFs, such as Ngn2, Insm1 and AP2γ have been implicated in the generation of 
BPs from RG cells. They all induce Tbr2, the specific marker of intermediate 
progenitors required for their generation (Sessa et al., 2008). Finally, TFs such as Foxg1 
and Ascl1 control the division of the BPs in the cortex and the ventral telencephalon, 
respectively, activating cell cycle regulators such as E2f1 and cyclin-dependent kinases 
(Siegenthaler et al., 2008, Castro et al., 2011).  
In addition to location, temporal patterning in development must determine the different 
type of neurons generated from neural progenitors. Referring again to the mammalian 
cerebral cortex as model, this is radially organised in six different layers of neurons, 
characterised by the expression of distinct molecular markers and projection patterns to 
and from different areas of the brain. There is a correlation between the location of 
neurons in different layers and the time of their birth. In particular, neurons in the 
deepest layers are generated first, and neurons in the upper layers are generated 
progressively later in development (McConnell, 1995b, McConnell, 1995a). 
Dynamic programs of transcription factor expression are involved in this process of 
specification. For instance, the TFs Fezf2 and its activated target Ctip2 have a critical 
role in the specification of the neurons of the layer V of the cerebral cortex and in the 
specification of their correct pattern of axonal projections (Arlotta et al., 2005, 
Molyneaux et al., 2005). Ctip2 is a specific marker of layer V neurons, so 
Chapter 1 - Introduction 
26  
unsurprisingly the correct specification of both earlier-born and later-born neurons 
requires the repression of Ctip2. Tbr1 represses Ctip2 for the specification of layer VI 
neurons, and Satb2 represses Ctip2 for the specification of layer II/III. Therefore, it 
appears evident that networks of cross-interacting and/or cross-repressing TFs also play 
a critical role in the temporal specification of neuronal fates from a common progenitor 
cell in the control of neurogenesis in the developing cerebral cortex.  
1.1.2.3 Switch from neurogenesis to gliogenesis 
1.1.2.3.1 Radial Glia to astrocytes transition 
RG cells persist in the VZ throughout the period of cortical development, as NSCs in 
neurogenesis and also representing the scaffolding glia for the migration on new-born 
neurons. At the end of the developmental period, and perinatally in mouse, most radial 
glia cells lose their attachment to the ventricle and migrate to the cortical plate: this 
represents a new transformation: the radial glia to astrocytes transition. In this 
transition, RG cells change from bipolar or unipolar cells with only a radial process to a 
multipolar shape without radial processes acquiring astrocytic morphology. Some 
astrocytes might undergo symmetric divisions locally to amplify their number before 
terminal differentiation, therefore representing a population of IPCs with astrocytic fate. 
In some vertebrate species, the transition of RG to astrocytes does not occur, and RG 
cells persist postnatally as glia cells (Kriegstein and Alvarez-Buylla, 2009).  
1.1.2.3.2 Generation of oligodendrocytes 
RG generate oligodendrocytes in addition to neurons during development. 
Oligodendrocytes originate in different locations in three distinct developmental waves. 
The earliest wave originates in the VZ from Nkx2.1-expressing progenitor cells of the 
medial ganglionic eminence (MGE) and the anterior entopeduncular area (AEA) around 
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E12 in mouse and entering the developing cortex around E16. A second wave follows, 
originating from Gsh2-expressing progenitor cells of the lateral and/or caudal 
ganglionic eminence (LGE/CGE) around E16-E18. Finally a third wave originates 
postnatally from Emx1-expressing progenitors from the dorsal cortex itself (Kessaris et 
al., 2006). 
The origin of the oligodendrocytes from RG confirm the idea of these cells as the NSCs 
generating all neurons and glia cells of the entire CNS (Kriegstein and Alvarez-Buylla, 
2009).
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1.2 Gene regulation by distant-acting enhancers and Gene 
Regulatory Networks in Embryonic Stem Cells and Neural 
Stem Cells  
1.2.1 Enhancers as cis-regulatory elements 
Gene expression is regulated through the integrated activity of many regulatory 
elements, including promoters and promoter proximal elements, and elements that are 
located at a greater distance from Transcriptional Start Sites (TSS), such as enhancers, 
silencers and insulators.  Enhancers and their transcription factors have a prominent role 
in the initiation and transcriptional regulation of gene expression.  
Transcriptional enhancers are non-coding regulatory sequences that activate promoter-
mediated transcription of their target genes. They can be located at great distances, tens 
to hundreds of thousands of base pairs away from their target genes. Moreover, they can 
be located upstream, downstream or even within their target gene and can modulate its 
expression independently of their orientation in respect to the TSS direction. Enhancer 
sequences are characterised by a dense clustered aggregation of Transcription Factor 
Binding Sites (TFBSs). Upon the right occupancy of TFs and their interplay, 
recruitment of transcriptional coactivators and chromatin remodelling proteins occur on 
the enhancers. There, the protein complexes are thought to facilitate DNA looping, 
which brings the protein complexes on the enhancer into close physical proximity to 
those on the promoter (Figure 1.4). This conformational change allows promoter-
mediated gene activation (Visel et al., 2009b).  
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Figure 1.4 Transcriptional regulation by promoters and enhancers. 
General transcription factors (green ovals) bind to core promoter regions through recognition of elements 
such as the TATA boxes and Initiators (INR). Sequence-specific TFs (red trapezoid) bind cis-elements 
(dark blue box) in the proximal promoter region and stabilize the recruitment of the transcriptional 
machinery through direct interaction with general transcription factors on the promoter. Promoter activity 
is further stimulated to higher levels of transcriptional activity (represented by ++) by enhancer elements 
(light blue box), which can be located at far distance from the promoter region. Sequence-specific TFs 
(orange octagon) bind enhancer elements and can stimulate transcription by recruiting a histone-
modifying enzyme (for example, a histone acetyltransferase (HAT)) to create a more favourable 
chromatin environment for transcription (for example, by histone acetylation (Ac)). Upon binding of TFs, 
enhancers relocate in physical proximity with the promoter through DNA looping and activate promoter-
mediated transcription. Adapted from Farnham, 2009.  
 
Some characteristics of the enhancers, such as their capability to activate the expression 
of their target genes independently of their location and orientation in respect to the 
TSS, were already described when the first enhancer was discovered over thirty years 
ago (Banerji et al., 1981). Banerji and colleagues reported that the expression of a ß-
globin gene could be strongly enhanced by a 72 bp repeated sequence element of the 
viral SV40 DNA when this element was included in the ß-globin -plasmid recombinants 
transfected into HeLa cells. The viral DNA element could enhance the expression of the 
ß-globin gene independently from its orientation and at many positions from the gene 
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TSS including being located either 1400 bp upstream or 3300 bp downstream of the 
TSS. The element was named an enhancer as it is capable of enhancing the expression 
of a gene. A reorganisation of the chromatin structure by the enhancer element was 
already hypothesised to be the possible mechanism of regulation of the gene expression 
(Banerji et al., 1981).  
1.2.2 TF binding patterns and different models of enhancer activity 
Individual enhancers are small sections of DNA, typically a few hundred bp long, that 
serve as operational platforms to recruit TFs. TFs recognise and bind specific DNA 
sequences on the enhancers, the TFBSs or motifs, to regulate transcription and gene 
expression. Different combinations of several TFs can bind the enhancers in different 
spatial domains of expression in a developing embryo or at different developmental 
stages. This combinatorial binding can result in discrete and precise patterns of 
transcriptional activity (Spitz and Furlong, 2012).  
The organisation of the TFBSs within an enhancer in terms of motif composition and 
motif positioning is referred to as enhancer architecture, and these properties have been 
investigated in detail leading to the establishment of different models of enhancer 
activity. In some cases motif positioning, that is the relative order, orientation and 
spacing of TF motifs within an enhancer, appear as strict sequence constraints of the 
TFBSs or different modules within the regulatory elements. A very well studied 
example of this enhancer architecture model is the interferon-ß enhancer, which led to 
the “enhanceosome” model of enhancer activity (Panne et al., 2007, Panne, 2008) 
(Figure 1.5A). In this model 8 TFs bind to a DNA sequence of 55bp in a highly 
cooperative manner and small changes within the regulatory sequence are sufficient to 
alter binding of all TFs and eliminate enhancer activity. The TFs recruited form a highly 
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ordered protein interface that requires a strict positioning of TF binding motifs relative 
to each other along the DNA. The overlapping of TF binding sites creates a composite 
element that ensures that the enhancer operates as a single unit of regulation, in an 
on/off switch manner. The sharp switch-like activation of this enhanceosome is strictly 
dependent from the tight organisation and positioning of TFBSs within the regulatory 
element. Enhancers like the interferon-ß do not display functional redundancy, and 
indeed the interferon-ß enhancer sequence is well conserved.  
However, most developmental enhancers do not conform to this model, displaying a 
much more relaxed and independent recruitment of TFs to autonomous modules within 
the enhancer sequence. This allows a more flexible positioning of motifs and has led to 
the “billboard” model of enhancer activity, in which enhancers behave as “information 
display” elements where distinct TFs might bind either cooperatively or independently 
from one another with only few constraints in the enhancer architecture of the binding 
motifs (Arnosti and Kulkarni, 2005) (Figure 1.5B). It is worth noting that the 
enhanceosome and the billboard models of enhancer activity represent the two extreme 
ends of a continuum spectrum of enhancer architectural diversity.  
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Figure 1.5 Two models of enhancer activity: the Enhanceosome and the Billboard. 
(A) In the enhanceosome model, TFBSs within the enhancer sequence are strictly constrained in term of 
motif positioning. This is to allow a high cooperative assembly and interaction between all the TFs 
(coloured ovals in the cartoon) recruited on the regulatory element, leading to gene activation. Disruption 
or displacement of even one only TFBS or loss of one TF binding causes the enhancer to be inactive and 
transcription to be turned off. (B) In the Billboard model, the enhancer contains independent activating or 
repressing modules that can regulate gene expression independently from one another. Independent TFs 
can activate or repress the activity of the enhancer when they interact with the transcriptional machinery 




1.2.3 Genome-wide approaches of enhancer identification 
1.2.3.1 Comparative genomic approaches 
An extensive identification of enhancers was initially achieved through comparative 
genomic studies. These approaches are based on the notion that genomic regulatory 
sequences are under negative evolutionary selection as changes in functional sequences 
might have negative consequences (Visel et al., 2009b, Dickel et al., 2013). Therefore, 
conservation in non-coding sequences could be the first way to identify potential 
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enhancers throughout the genome of different species. Thus, analysis and statistical 
measures of evolutionary sequence constraint provide a tool to identify potential 
enhancers within the big portion of non-coding sequence in the genomes of vertebrates 
(Visel et al., 2009b).   
Pennacchio et al. give an example of the application of this approach in a work, where a 
large set of ancient human-to-fish conserved and human-to-rodents ultra-conserved 
elements were computationally filtered and identified as putative enhancers and a subset 
of them were tested for their activity in vivo in transgenic mouse enhancer assays 
performed at E11.5 (Pennacchio et al., 2006). Briefly, in this assay the genomic 
conserved fragment is linked to a minimal promoter fused to a lac-Z reporter gene. The 
transgenic construct is transiently transfected into the developing embryo. Following to 
this, ß-Gal staining of the whole-embryo is performed to assess the spatial enhancer 
activity of the cloned element in vivo. 29% of ancient human-to-fish conserved, and 
61% of human-to-rodents ultra-conserved elements tested were validated as active 
enhancers in vivo. The entire enhancer dataset from this study was submitted to the 
VISTA enhancer browser. This is a database of tissue-specific human enhancers 
identified through comparative genomics and experimentally validated through in vivo 
lac-Z transgenic mouse enhancer assays (Visel et al., 2007).    
Although comparative genomics led to successful identification of genome-wide 
enhancers, it has some limitations. For instance, conservation cannot predict when and 
where enhancers are active in development or an adult organism, always requiring 
experimental validations of their identification that is hard to achieve on a genome-wide 
scale (Visel et al., 2009b).  
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1.2.3.2 Epigenetic and chromatin marks for enhancer identification 
As a strategy alternative and complementary to comparative genomics, the generation 
of genome-wide maps of specific chromatin marks powerfully allows the identification 
of enhancers and other regulatory elements. This approach became possible thanks to 
the improved development of techniques such as ChIP-ChIP and ChIP-seq, which allow 
the generation of a genome-wide binding profile of DNA binding proteins and 
chromatin remodelling complexes enriched at specific regulatory elements. A 
description of these techniques is given in the next paragraph 1.2.4. 
Several studies provided insights of the epigenetic marks found at specific categories of 
regulatory elements, allowing a precise discrimination among them. Relevant to the 
identification of enhancers in particular, monomethylation at lysine residue 4 of histone 
H3 (H3K4me1) was found to mark enhancers and specifically discriminate them from 
promoters marked by tri-methylation at the same position (H3K4me3). Moreover, 
acetylation at lysine 27 of histone H3 (H3K27ac) has also been associated to enhancers 
and more precisely it distinguishes active enhancers from poised elements containing 
H3K4me1 alone. (Heintzman et al., 2007, Heintzman et al., 2009, Creyghton et al., 
2010). Interestingly, in a study by Mikkelsen et al., ChIP-seq of different epigenetic 
marks recruited on promoters allowed the generation of “chromatin-state maps” for 
pluripotent and lineage committed mouse cells where active, poised or repressed 
promoters could be discriminated at the different developmental cell states according to 
the chromatin-state and marks recruited (Mikkelsen et al., 2007). The study shows that 
developmental programs from pluripotent to terminally differentiated cells driven by 
change in gene expression and transcriptional competence are paralleled by 
characteristic chromatin-state changes. This work by Mikkelsen et al was also one of 
the first examples of the application of the ChIP-seq to locate and identify genome-wide 
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enhancers and to generate chromatin maps of different cell types in a multicellular 
organism.  
Also the acetyltransferase and transcriptional coactivator p300 is a protein associated to 
the enhancers. In a work by Visel et al., the genome-wide distribution of this protein 
was determined by ChIP-seq directly from developing mouse tissues, in particular the 
forebrain, midbrain and limb. This study is particularly worth noticing as the  
recruitment of the protein p300 was determined in vivo from developing tissues, rather 
than in cell culture, but more importantly because the tissue-specific occupancy of p300 
could in most cases accurately predict the in vivo pattern of expression driven by these 
enhancers, providing an important advantage over comparative genomic methods for 
enhancer identification (Visel et al., 2009a). To further prove the strength of this 
method over comparative genomics to identify active enhancers, the same research 
group reported the identification of weakly conserved heart enhancers that escaped 
comparative approach for their identification, employing the same p300 ChIP-seq 
approach from developmental heart tissue (Blow et al., 2010).  
All together the studies presented here represent the first maps of histone marks and 
protein p300 and dataset available to identify and predict the activity of transcriptional 
enhancers throughout the genome. Despite the importance and the progress made in the 
identification and characterisation of the non-coding genome in the regulation of gene 
expression, in vivo and in vitro biological studies are still necessary to understand the 
function and the mechanisms of regulation by non-coding enhancers and the interplay 
of TFs involved in their activation. An overview of the current techniques available to 
study enhancer activity is given in the next paragraph.  
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1.2.4 Techniques and assays to study enhancer activity and functions 
1.2.4.1 ChIP-chip and ChIP-seq 
The methods of ChIP-chip and ChIP-seq have allowed the identification of enhancers 
on a genomic scale through detecting the binding of chromatin marks and cofactors on 
the regulatory sequences. These methods are based on traditional ChIP experiments 
with different downstream analysis. Briefly, ChIP involves crosslinking of DNA-
binding proteins with the DNA by treating cells with formaldehyde and shearing 
chromatin usually by sonication. An immunoprecipitation of the cross-linked chromatin 
is performed using an antibody against the specific TF or protein of interest. This results 
in the identification of all the binding sites in the genome for the protein of interest. 
After reversal of the crosslink and purification of the precipitated chromatin fragments 
the sample can be analysed by PCR to study particular gene. However, genome-wide 
analysis can be performed by microarray (ChIP-chip) or sequencing (ChIP-seq). For 
ChIP-chip the immunoprecipitated sample and the input chromatin, as a control, are 
labeled with fluorescent dyes and are hybridized to microarrays. For the ChIP-seq 
instead the immunoprecipitated DNA fragments are sequenced through next-generation 
sequencing techniques, and computationally mapped to a reference genome. The results 
from ChIP-seq are based on statistical analysis of read counts and advanced 
computational ChIP-seq analysis tools are available to identify ChIP-seq peaks. The 
ChIP-seq analysis covers the entire mappable portion of the reference genome without 
need to restrict the analysis to its subregions, as it happens instead in the ChIP-chip by 
hybridization to microarrays. Mainly this improvement has contributed to the success of 
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the ChIP-seq as method of choice compared with the ChIP-chip, together with lower 
cost of the experiments and an unambiguous identification of the peaks (Farnham P. J., 
2009, Visel et al., 2009b).  
Although techniques like the ChIP-chip and ChIP-seq are very successfully for the 
identification of enhancer elements genome-wide, they make use of indirect properties 
of the regulatory elements (such as the occurrence of chromatin marks or binding of 
specific TFs of interest) rather than assessing their functionality and activity.  
1.2.4.2 Transgenic gene reporter assays in vivo and in vitro 
Transgenic reporter assays provide a more functional approach to test enhancers, by 
addressing their ability to drive gene expression. In a typical transgenic reporter assay a 
putative enhancer fragment is cloned upstream of a reporter gene driven by a promoter, 
which has a minimal or no activity by itself, but that respond to the input of the adjacent 
enhancer. In this way the activity of the enhancer is revealed by the expression of the 
reporter gene.  
In vivo transgenic mouse reporter assays are one of the most used techniques to detect 
enhancer activity in vivo. In these experiments the enhancer to test is linked to the 
reporter gene, typically LacZ, and then the transgene construct is delivered into mouse 
zygotes through pronuclear injection. The resulting transgenic embryo will be tested for 
ß-gal activity to visualise the expression pattern and in vivo activity of the enhancer 
element in the embryonic tissues.  
In vivo transgenic mouse assay can’t be used for quantitative analysis of the enhancer 
activity nor to detect modest alteration to enhancer intensity or quantitative effects of 
enhancer mutations. These effects and a quantitative measure of enhancer activity have 
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been studied predominantly using in vitro reporter assays, where the enhancer is 
coupled to a luciferase reporter gene and transiently transfected into cells. The 
transgenic reporter gene intensity can be measured quantitatively with the use of a 
luminometer (Rosenthal, 1987, Naylor, 1999, Schenborn and Groskreutz, 1999).  
The luciferase assay can allow quantification of the gene expression driven by an 
enhancer element in different cell lines for instance to test the specificity of the 
enhancer in different cell context that might be similar or very different according to the 
choice of the experimental systems and the purposes of the comparison. In the same 
way, the effect of the input of specific TFs activity on the enhancer can be measured by 
gain or loss of function of the TF of interest or by manipulating the amount of the same 
TF. Finally, effects of mutations in the enhancer sequence, for instance in the consensus 
motifs of known TFBSs, can be detected and quantified. For these applications, the 
luciferase assay persists as one of the best techniques to study and assess the biological 
function of enhancers and to characterise the functions of the several modules that 
makes the enhancers and the effect of specific TFs recognising and binding to the 
TFBSs. Despite the advances of large-scale genome-wide techniques to identify and 
characterise enhancers in vivo, luciferase assay experiments are still needed in parallel 
to these approaches to understand the biological function of enhancers, and the 
mechanisms of their activation and regulation by TFs. The work presented in this thesis 
demonstrates the advantage of the application of this technique.   
1.2.4.3 Chromosome Conformation Capture (3C) assay  
A big remaining challenge in the study of enhancers is to determine the relationship 
between enhancers and their target genes. Although comparisons between ChIP-chip or 
ChIP-seq with transcriptome data from microarray and RNA-seq can give clues in the 
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association enhancer-target gene, they can’t give evidence of a direct interaction 
enhancer-promoter and therefore enhancer-target gene which would be necessary in the 
establishment of gene regulatory networks on a genomic scale. Current views support 
the idea that most enhancers establish direct physical interactions with their target gene 
promoters (Symmons and Spitz, 2013). These interactions can be detected by 
chromosome conformation capture assay (3C) and its derivative technologies. This 
technique is based on a biochemical strategy that allows representation of the 3D 
organisation of the DNA and the chromosome topology. Subsequent steps of fixation, 
digestion, and re-ligation of fixed chromatin followed by quantification of the ligation 
junctions allows obtaining a one dimension cast of the 3D chromatin structure (Zhu et 
al., 2013, de Wit and de Laat, 2012). Overall, the main picture emerging from studies 
based on these approaches is that both promoters and enhancers are frequently engaged 
in multiple interactions so that enhancer-promoter interactions are not exclusive. For 
most genes, the elements that regulate their expression will be found in cis, although at 
distances that could be hundreds of kilobases. However, enhancers have been reported 
to act also promiscuously, activating neighbouring but biologically irrelevant genes 
(Symmons and Spitz, 2013). In conclusion, these studies are pointing out that many 
current approaches taken to associate enhancers with their target genes, such as the 
previously mentioned comparison of ChIP-seq data with transcriptome data, might be 
misleading and new approaches need to be developed.  
1.2.5 Gene Regulatory Networks in Embryonic Stem Cells and Neural 
Stem Cells 
I have discussed in the previous paragraph that enhancers are characterised by a dense 
cluster of TFBSs and that the right occupancy of TFs and their interplay on the 
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enhancers is an essential step in the control of gene regulation. In accordance with this 
notion, several studies in the past few years have generated binding profiles of TFs 
genome-wide and have highlighted that many of them co-bind and co-regulate a 
common set of targets in the establishment of transcriptional gene regulatory network 
(GRN) that underpin the cell state and its maintenance.   
To gain insight into the GRN in embryonic stem cells (ESCs) for instance, Chen and co-
workers have used ChIP-seq to map the binding of 13 TFs with relevant roles in ES 
biology as key regulators of pluripotency and self-renewal (Chen et al., 2008). 
Remarkably, this study has identified two clusters of TFs. One cluster includes the TFs 
Nanog, Sox2, Oct4, Smad1, and STAT3 that tend to co-occur and co-bind quite often a 
common set of target genes. Likewise, the second cluster includes n-Myc, c-Myc, E2f1, 
and Zfx, which co-bind a second set of distinct targets. The first cluster with Oct4 binds 
to MTLs (Multiple TFs binding Loci), genomic regions with high dense TFBSs spots, 
which exhibit characteristics of enhancers. Indeed, they recruit the transcriptional 
coactivator p300 together with the TFs listed; they are associated with H3K4me3 mark, 
and show specific luciferase activity in ES cells. The high dense cluster of TFBSs 
within relative compact genomic segments, and the requirement of the TF Oct4 as key 
regulator for the recruitment of Smad1 and Stat3 suggest that the MTLs identified have 
characteristics of enhanceosomes. Interestingly, ES cell specific gene expression is 
associated with binding of many of the factors studied. Precisely, the cluster with Oct4, 
Sox2, Nanog, Smad1 and STAT3 is thought to be mainly involved in the regulation of 
the pluripotency genes, while the Zfx, E2f1, Myc cluster often regulates genes involved 
in self-renewal, including the promotion of cell division. Therefore, based on an 
association between TFs binding and gene expression, the authors of this study have 
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constructed a GRN model in ESCs, which underpins the features of pluripotency and 
self-renewal typical of this cell state.  
The work of Chen and colleagues has identified Oct4, Sox2 and Nanog as key players 
in the cluster of TFs underpinning pluripotency in the mouse ESCs. Interestingly, this is 
consistent with the findings of a previous work by Boyer and co-workers, which pose 
the same three TFs at the top of the GRN controlling pluripotency and self-renewal in 
human ES cells (Boyer et al., 2005). In a genome-scale location analysis using ChIP-
chip, Boyer et al. revealed that these three TFs co-occupy the promoters of a large 
population of genes, usually other downstream TFs, involved in the maintenance of the 
stem cell state. Oct4, Sox2, and Nanog regulate also transcription of their own genes 
and therefore establish autoregulatory and feedforward loops circuitry contributing to 
pluripotency and self-renewal in the human ESCs (Boyer et al., 2005). The mechanisms 
of cooperativity and interactions between Oct4 and Sox2 in the regulation of their target 
genes are discussed in more details in paragraph 1.4.3 “Molecular interaction of Sox2 
with other TFS”.  
In more recent years there have been studies attempting to establish transcriptional gene 
regulatory networks also in neural stem cells (NSCs). For instance, a work by Southall 
and Brand in Drosophila has identified a common set of target genes involved in the 
self-renewal and differentiation of the NSCs co-regulated by the TFs Asense, one of the 
Ascl1 ortholog in Drosophila, Deadpan, Snail, and Prospero (Southall and Brand, 2009). 
This study unveiled NSC transcriptional networks essential for the balance between 
self-renewal and differentiation.  
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The TFs Ascl1 and the Sox factors, in particular Sox2, are involved in the regulation of 
several transcriptional networks and developmental programs in the NSCs in 
cooperation with other TF-partners.  
In the next paragraphs, I give an overview of the biochemical characteristics and 
biological functions of Ascl1 and the Sox factors in neural development. 
 
1.3 Proneural proteins and the TF Ascl1 in vertebrate neural 
development 
1.3.1 Biochemical properties 
Proneural proteins are basic helix-loop-helix (bHLH) transcription factors. Many bHLH 
TFs have important role in the generation and differentiation of tissues throughout the 
all animal kingdom. Proneural proteins, in particular, have a prominent role to initiate 
the development of neuronal lineages and to promote the differentiation of committed 
neural progenitor cells. The TF Ascl1, also known as Mash1 in mouse, is among these 
proneural proteins, and its role in neural development is described in the next 
paragraphs.  
This big class of TFs is characterised by the presence of the bHLH domain, the 
structural motif responsible for their DNA-binding and dimerization properties (Murre 
et al., 1989) (Figure 1.6). Proneural proteins, like all other bHLH TFs, bind the DNA as 
heterodimers that are formed with ubiquitously expressed bHLH proteins, the E 
proteins, such as E12 and E47 in mammals. The bHLH heterodimers are formed by 
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interactions of the two helices of each (TF) partner to form a four-helix bundle (Figure 
1.6).  
The class of the bHLH TFs, including the proneural proteins, specifically bind a core 
hexa-nucleotide DNA sequence motif, CANNTG, called E-box. The basic region 
contacts the main groove of the DNA and confers sequence-specificity of the binding, 
while the HLH region is responsible for the dimerization with other bHLH proteins 
(Massari and Murre, 2000). 
 
Figure 1.6 Structure of bHLH proteins and dimerization with E proteins. 
(A) Schematic representation of the structure of a bHLH dimer bound to the DNA. The basic region 
binds to the major groove of the DNA while the two α-helices of both partners in the dimer form a 
four-helix bundle. (B) bHLH proteins bind the DNA as heterodimers with the E proteins, which are 
ubiquitously expressed bHLH proteins. Adapted from Bertrand et al., 2002. 
 
Proneural proteins and most bHLH TFs act mainly as transcriptional activators. In the 
case of the Neurogenins, Ngns, transcriptional activation is induced through recruitment 
of the transcriptional coactivator and acetyltransferase p300 (Koyano-Nakagawa et al., 
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1999, Sun et al., 2001, Lee et al., 2009). Identification of the cofactors that interact with 
other proneural proteins, such as Ascl1, is indispensable to understand their 
mechanisms of transcriptional regulation. 
 
1.3.2 Cellular functions of proneural proteins and Ascl1 
Proneural proteins are expressed almost exclusively in progenitor cells where they 
specify neuronal fate and initiate programmes of differentiation. Since this thesis is 
focused on the transcription factor Ascl1 as transcriptional regulator in neural stem 
cells, and since the developing cerebral cortex was presented as main model for 
neurogenesis in the previous paragraphs, this section describes the functions of 
proneural proteins, in particular Ascl1, mainly in the telencephalon where Ascl1 and the 
two Neurogenins, Ngn1 and Ngn2, are the only proneural proteins expressed.  
Loss of function (LoF) and Gain of function (GoF) studies of proneural proteins in vivo 
and in neural stem cultures in vitro revealed the biological functions of this class of 
bHLH TFs in neural development. 
1.3.2.1 Notch signalling 
The activation of the Notch signalling pathway is one of the earliest functions of 
proneural proteins in neural development. This proneural function is well conserved in 
the development of the nervous system from Drosophila to vertebrates (Casarosa et al., 
1999, Bertrand et al., 2002).  
Both proneural proteins Ascl1 and Ngn2 have been shown to induce the expression of 
Dll1, the Notch ligand, in progenitors expressing the proneural factors (Castro et al., 
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2006). The expression of Dll1 induces Notch signalling in the neighbouring cells 
preventing them from differentiating, in a process known as “lateral inhibition”.  
Upon activation of the signalling, the transmembrane protein Notch is cleaved and 
releases the Notch intracellular domain (NICD), which moves to the nucleus, where it 
forms a complex with the DNA-binding protein RBPj. The NICD-RBPj complex then 
induces the expression of the bHLH repressor factors Hes1 and Hes5, the Notch 
effectors, which repress the expression of proneural genes. Thus, proneural genes 
inhibit their own expression in adjacent cells. The Notch signaling is therefore very 
important to maintain the pool of progenitor cells. In the absence of this pathway, all 
neural progenitors differentiate prematurely altering the balance between differentiating 
and proliferative stem cells and leading to depletion of the full spectrum of diverse cells 
born at later stages. An analysis of Ascl1 mutant mice in the ventral telencephalon 
revealed a loss of expression of the Dll1, Dll3, and Hes5 genes. This study proved the 
role of Ascl1 as important regulator of neurogenesis in the ventral telencephalon, where 
it specifies neural precursor and controls the timing of their specification (Casarosa et 
al., 1999).     
The Notch signaling is also responsible for the typical salt and pepper expression 
pattern of the proneural genes. In particular, a recent new view of the Notch signaling 
proposed by Kageyama and colleagues confers the salt and pepper expression pattern of 
Ngn2 in cortical VZ cells to oscillating expression of Hes1, causing a consequent 
oscillating expression of Ngn2 and its target Dll1 in an opposite phase, in a dynamic 
process of lateral inhibition (Kageyama et al., 2008, Shimojo et al., 2008). 
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1.3.2.2 Inhibition of glial fate 
Proneural genes such as Neurogenins and Mash1 are expressed almost exclusively in 
progenitor cells in the ventricular zone of the telencephalon since E8.5 in mouse 
(Guillemot and Joyner, 1993, Sommer et al., 1996). They also are expressed almost 
exclusively in a complementary manner, with Neurogenins expressed at high level 
exclusively in the dorsal telencephalon, and Ascl1 expressed at high level in the ventral 
telencephalon, and at low level in the dorsal telencephalon (Fode et al., 2000). This 
restricted and mainly non-overlapping patterns of expression of Ascl1 and Ngns is also 
suggestive of their role in the specification of distinct neuronal identities.  
Indeed, Ascl1 null mutant embryos present defects in neurogenesis particularly in the 
MGE of the ventral telencephalon. Discrete neuronal populations of the basal ganglia 
and cerebral cortex, originated by progenitors located in the MGE, are subsequently 
affected. This study proved the role of Ascl1 as a determinant gene for the specification 
of neuronal identity in the ventral telencephalon (Casarosa et al., 1999).  
In the same way, Ngn2 single and Ngn1; Ngn2 double mutants present defects in the 
neurogenesis of the dorsal telencephalon, where populations of early born lower-layers 
cortical neurons lose expression of dorsal-specific markers, such as Tbr1, Math2, Nscl1 
and Nscl2 (Fode et al., 2000). The analysis of Ngns mutant mice proved the role of this 
proneural factor in the specification of cortical neurons.  
Interestingly, loss of both Ngn2 and Ascl1 in Ngn2; Ascl1 double mutant mice resulted 
in a severely affected neurogenesis in the developing cerebral cortex with premature 
onset of astroglial generation. Importantly, in vitro cultures obtained by Ngn2; Ascl1 
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double mutant cortical progenitors proved that either Ngn2 or Ascl1 is required in the 
radial glial cells of the cerebral cortex to maintain their neurogenic potential and 
suppress a premature activation of the astrocytic programme. Therefore, inhibition of 
the glial fate in an early stage of cortical neurogenesis is one of the main functions of 
the proneural genes Ascl1 and Ngns (Nieto et al., 2001).  
1.3.2.3 Neuronal subtype specification  
I have already mentioned that the proneural genes Ngns and Ascl1 have another 
important function in the vertebrate neurogenesis, which is the neuronal subtype 
specification of the neural progenitors, with Neurogenins imparting a dorsal cortical 
phenotype and Ascl1 specifying ventral identity of precursor and the subsequent 
generation of specific neurons with different molecular characteristics.  
In particular, analysis of neurogenin2 mutant mice has proved that this proneural factor 
is critical for the specification of glutamatergic cortical projection neurons of the lower 
layers of the cortex. In contrast, specification of cortical projection neurons in the upper 
layers appears to be independent from Ngn2 activity (Schuurmans et al., 2004). A 
microarray analysis of the Ngn1; Ngn2 double mutants showed that many targets of 
these proneural genes include TFs specifically involved in the determination of a 
glutamatergic cortical projection neuron lineage such as Neurod1, Neurod2, Neurod6, 
and Tbr2 and also in the expression of the vesicular glutamate transporters vGlut1 and 
vGlut2 (Schuurmans et al., 2004). Therefore Ngns are the proneural factors responsible 
for the establishment of a glutamatergic differentiation programme in cortical 
progenitors.      
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In parallel, studies of Ascl1 mutant have proved its role in the specification of ventrally 
generated basal ganglia neurons and cortical interneurons (Casarosa et al., 1999). The 
ventral telencephalon is also the domain of highest expression of Ascl1, only expressed 
at low level in the VZ of the dorsal telencephalon. Interestingly, Ngns mutants exhibit 
an overexpression of Ascl1 in the cortical neural progenitors and a subsequent ectopic 
expression of ventral markers such as Dlx1, Dlx2, Dlx5, and GAD67, a gene encoding 
an enzyme for the synthesis of the GABA neurotransmitter (Fode et al., 2000). 
Therefore, Fode and colleagues showed that Ngns function is required also to repress 
dorsal expression of Ascl1 and the establishment of a ventral GABAergic differentiation 
programme, and to maintain the two separate expression domains of the proneural 
genes. In this study the phenotype of a double mutant Ngn2; Ascl1 was also analysed, 
and the use of a mouse line with a replacement of Ngns by Ascl1 in dorsal progenitor 
was employed to dissect the role of proneural factors in neuronal subtype specification 
in the telencephalon. Analysis of these mutants demonstrated that ectopic expression of 
Ascl1 is required and sufficient to confer a GABAergic ventral identity to neurons in 
the developing cerebral cortex. Indeed, the expression of ventral markers is lost in 
Ascl1; Ngn2 double mutants showing that is the ectopic expression of Ascl1 to confer 
this ventral phenotype.  
To further confirm the role of Ascl1 in the specification of GABAergic telencephalic 
neurons, Berninger and colleagues demonstrated that overexpression of Ascl1 in neural 
stem cell cultures or cortical astrocyte cultures generates neurons with molecular and 
electrophysiological characteristics of GABAergic neurons (Berninger et al., 2007, 
Heinrich et al., 2010). Altogether, the studies here presented illustrated that the 
specification of neuronal subtype is another important function of the proneural 
proteins.  
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1.3.2.4 Regulation of neuronal migration 
The proneural proteins Ngn2 and Ascl1 have been implicated in the regulation of 
neuronal migration in the embryonic cerebral cortex. Impaired neuronal migration has 
been described in the cortex of single progenitor cells where the proneural functions 
were lost by Sh-RNA-mediated silencing or electroporation of Cre-recombinase in 
conditional mutant embryos (Heng et al., 2008, Pacary et al., 2011). 
At molecular level, both proneural proteins Ngn2 and Ascl1 control neuronal migration 
through down-regulation of RhoA-signalling. This is achieved by activation of Rnd 
genes, a family of a small group of atypical GTP-binding molecules. Ngn2 directly 
activates Rnd2, and Ascl1 directly activates Rnd3. Sh-RNA mediated knock-down of 
Rnd proteins also exhibited neuronal migration defects. Both Rnd proteins then achieve 
regulation of neuronal migration through down-regulation of RhoA-signalling. Rho-A 
signalling can control neuronal migration due to its role in regulating the actin 
cytoskeleton. 
Indeed, as Heng and colleagues and Pacary and colleagues have shown, aberrant 
phenotypes of neuronal migration in cortical neurons mutant for expression of the 
proneural proteins can be rescued by suppression of the RhoA-signalling either by 
restoring the expression of Rnd2 and Rnd3 (Heng et al., 2008, Pacary et al., 2011) or by 
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1.3.3 Molecular mechanisms of proneural genes activity 
1.3.3.1 Transcriptional targets of the proneural gene Ascl1 and its dual role in cell 
proliferation and neuronal differentiation  
The characterisation of the direct transcriptional targets of the proneural genes provides 
in-depth understanding of their functions and of the programmes of neurogenesis they 
regulate. A work by Castro and colleagues characterised on a genome-wide scale the 
transcriptional programme regulated by Ascl1 in the embryonic brain by combining 
location analysis of Ascl1-bound sites in developing telencephalon and neural stem cell 
cultures with expression profiling of genes deregulated by overexpression or deletion of 
the proneural gene (Castro et al., 2011).  
The results of this analysis showed that Ascl1 regulates a large number of target genes 
with diverse biological functions, including for instance genes that control early steps of 
lateral inhibition, cell fate commitment and specification, and later steps of neuronal 
differentiation, such as synthesis of the neurotransmitter and axonal morphogenesis. 
Also the molecular functions of the target genes are very diverse, as Ascl1 can broadly 
activate genes whose functions are transcriptional activity, signal transduction, 
transporter activity and cytoskeletal activity. In conclusion, Ascl1 can directly control 
all phases (early and late) and aspects of the neurogenic program.  
Surprisingly, the analysis also pointed out that Ascl1 can activate a large number of 
positive cell cycle regulator genes, involved in the progression of the cell cycle and in 
mitosis, such as E2f1, Cdk1, Cdk2, Skp2, Cdc25b. Indeed, loss of function analysis in 
embryo and in NS cell cultures confirmed that Ascl1 is required for normal progenitor 
divisions. As expected, target genes involved in the cell cycle arrest, a known function 
Chapter 1 - Introduction 
 51 
of Ascl1, were also identified, including new and previously identified targets, such as 
Fbxw7, Gadd45g, Ccng2, Hipk2, and Prmt2. Thus, a new dual role emerged for Ascl1 
in neurogenesis as the same TF can control opposite aspects of the cell cycle, its 
progression and its withdrawal, and link together cell proliferation and expansion of 
neural progenitors and their cell cycle exit and neuronal differentiation. Evidence 
related to the spatial and temporal pattern of expression of the cell cycle arrest genes 
suggest that they are activated by Ascl1 at a later phase of neurogenesis. 
 It is surprising that the same TF can activate the two opposite processes in the same 
lineage. Interestingly, also a work by Southall and Brand has reached the same 
conclusion for Asense, one of the Ascl1 ortholog in Drosophila, which can promote 
neuroblast self-renewal, besides its known role in inhibiting cell divisions of neuroblast 
daughter cells and its pro-differentiation role (Southall and Brand, 2009). This suggests 
that the dual role of Ascl1 might be evolutionary conserved. As the authors of the paper 
pointed out, the advantage of having the same TF activating genes with opposite roles 
in the regulation of the cell cycle might be a rapid switch from a progenitor state to a 
neuronal differentiated state ensuring that the two programmes underpinning these two 
states are mutually exclusive (Castro et al., 2011).  
In conclusion, a new uncharacterised function of Ascl1 as regulator of genes associated 
with a neural stem cell undifferentiated state has emerged. The mechanisms by which 
the same TF Ascl1 can select and activate the two different set of targets in subsequent 
phases are unknown. The formation of complexes in which Ascl1 interacts with 
different TFs and cofactors can be one possibility. 
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1.3.3.2 Interaction of the proneural protein Ascl1 with other transcription factors 
Transcription factors regulate the expression of target genes as part of large 
transcriptional protein complexes, which include both other TFs and cofactors. Given 
the big diversity of target genes and programs of differentiation regulated by the 
proneural factors, it is possible that interactions with different TFs, occurring at 
subsequent phases of the developmental process or in different cell compartment, might 
be responsible for this selection of target genes. It is known that interactions between 
TFs play an essential role in this selection and account for the specificity towards a 
different subset of targets at different times.  
A work by Castro et al., has shown that the regulation of the gene encoding the Notch 
ligand, Delta1, involves cooperative binding of Ascl1 and the Brn factors (Brn1 and 
Brn2 (Alvarez-Bolado et al., 1995)) to an evolutionary conserved motif in this gene 
(Castro et al., 2006). The study demonstrated that Ascl1 and the Brn factors recognize 
and bind (both in vivo and in vitro) adjacent motifs on the enhancer of the Delta1 gene, 
respectively an E-box and an octamer, and that this interaction is required for the 
activation of the enhancer and its function. The cooperative binding reflects recruitment 
by Pou protein of Ascl1 to the E-box of the Delta1 enhancer. Moreover, Castro et al. 
have shown that this cooperation can occur also to regulate the expression of other 
target genes besides Delta1. By searching for conserved Ascl1-Brn-like motif in the 
whole genome and by performing ChIP with chromatin prepared from embryonic 
telencephalon, they identified other genes associated with this conserved consensus 
sequence, and therefore candidate targets of a synergistic regulation by Ascl1 and the 
Brn proteins. These genes are involved in Notch signaling, cell cycle progression, cell 
differentiation, and cell migration (Castro et al., 2006). This study provides an example 
of interaction of the proneural factor Ascl1 with another family of TFs to control the 
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regulation of gene expression and access to a specific subset of targets, coordinating 
different programs of neurogenesis. 
1.3.4 Proneural proteins and Ascl1 in reprogramming 
Recent reprogramming studies are highlighting the essential role of fate determinant 
transcription factors in the specification of differentiated cell types and in the 
transcriptional program they control, besides their therapeutic potential and 
applications. For instance, the well-known role of the bHLH factors Ascl1 and Neurog2 
as neurogenic factors in the specification of neuronal lineages has been further 
strengthened by these studies.   
Initially, studies where neural stem cell cultures expanded in vitro (of adult SEZ origin) 
or cortical astrocytic cultures could be induced to generate fully differentiated and 
functionally synapse-forming neurons from forced expression of both proneural 
proteins Ascl1 and Neurog2, via retrovirus mediated transduction, had confirmed their 
neurogenic potential, as previously mentioned elsewhere in this introduction (Berninger 
et al., 2007, Heinrich et al., 2010). These studies have shown how the expression of 
these single factors alone was sufficient to confer the neuronal lineages. Later on, 
combinatorial expression of specific TFs was proved to generate fully differentiated and 
functional neurons from mouse embryonic fibroblasts (MEFs) and hepatocytes, 
therefore cells with an endodermal embryonic origin rather than ectodermal. In 
particular, the combination of Ascl1, Brn2, and Myt1l, named as BAM pool of genes, 
was identified as essential gene regulatory network capable of inducing a transcriptional 
program typical of functional neurons, and surprisingly to fully silence and “repress” 
the donor/origin cells transcriptome. The molecular mechanisms underpinning these 
reprogramming processes are not known. As the authors of these studies suggest, a new 
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gene regulatory network must be established downstream of strong cell-fate-
determining TFs that strengthens the induced transcriptional program. Changes in the 
transcriptional activity might determine also reorganisation of chromatin and epigenetic 
features in term of DNA methylation, histone modification and chromatin remodelling 
complexes, which stabilise the new transcriptional network.  Therefore the importance 
of interactions between different TFs and cofactors in the establishment of GRNs and 
determination of cell fate, which was discussed in the previous paragraphs, is further 
highlighted in these reprogramming studies (Vierbuchen et al., 2010, Marro et al., 
2011). 
 
1.4 Sox factors in vertebrate neural development 
Transcription factors of the Sox family are well-established players of the stem cell state 
and cell fate decision during development. Sox factors take part in many developmental 
processes indeed. Several situations have been reported where many Sox proteins are 
simultaneously expressed, as in the case of Sox2, Sox9, and Sox21 in the NS5 cells 
(Martynoga, unpublished data) or the SoxB1 and SoxB2 members in vivo (Bylund et al., 
2003, Sandberg et al., 2005). In some cases they act redundantly, in some others they 
are antagonistic or involved in different aspects of the developmental process (Bylund 
et al., 2003, Sandberg et al., 2005). In this thesis, I mainly focus on the biological and 
molecular functions of Sox2 and the SoxC members, in particular Sox4 and Sox11, in 
neural development because these factors are the transcriptional regulators involved 
with Ascl1 in the regulation of the enhancers identified in this study.  
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1.4.1 Biochemical properties of the Sox factors 
1.4.1.1 The HMG domain and its architectural role 
The first Sox gene identified was the mammalian testis-determining factor Sry (Gubbay 
et al., 1990, Sinclair et al., 1990), which opened the study on the family of the Sox 
factors (Sry box containing factors). Like the Sry protein, all Sox factors carry the 
characteristic HMG domain, which is responsible for binding the DNA. This domain 
consists of three α-helices arranged in an “L” shape and an N-terminal beta strand 
(Werner et al., 1995, Wegner, 1999, Lefebvre et al., 2007) (Figure 1.7). Unlike most 
binding domains of other TFs, the L-shaped HMG domain binds the DNA in the minor 
groove and induces a significant bend of the of the DNA helix. Thus, HMG domain-
containing proteins can act as architectural proteins as they can alter the conformation 
of the DNA and increase its protein accessibility. In this unique feature lies the ability 
of the HMG-containing proteins in recruiting other TFs on the DNA, also factors 
binding on non-adjacent sites, to form active transcriptional complexes (Wolffe, 1994, 
Werner and Burley, 1997, Wegner, 1999, Lefebvre et al., 2007).  
Most Sox proteins have also other functional domains besides the HMG domain. These 
domains are generally highly conserved among members of the same group, whereas 
they are different among proteins from distinct groups. Among these domains there are 
the transactivation (TA or TAD), transrepression, and dimerization domains (Lefebvre 
et al., 2007).   
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Figure 1.7 Structure of the Sox factors and the HMG domain. 
(A) Structure of the mouse Sox proteins and their functional domains. Sox proteins are represented as 
boxes. Black box represents the HMG domain, which binds the DNA; transactivation domain (TA) 
represented as vertical stripes, in the C-terminal portion of the protein. Position of the first and last amino 
acid residues and boundaries of functional domains are indicated. (B) Schematic representation of the 
HMG domain bound to the DNA. The domain folds into an L shape composed of three α-helices. It fits 
into the minor groove of the DNA and bends it creating an angle varying between 30° and 110°. Two 
HMG domains are shown binding on the DNA in opposite orientation. The α-helices are represented as 
cylinders. N-terminal and C-terminal sequences to the HMG domain and sequences linking the helices 
are represented as thin rods. The DNA bending angle is also illustrated in the figure above the HMG 
domains. Adapted from Lefebvre et al., 2007. 
 
1.4.1.2 Classification of the Sox proteins 
Proteins containing an HMG domain with 50% or higher amino acid (aa) similarity to 
the sequence of the HMG domain of Sry are classified as Sox proteins. Up to date, 20 
Sox genes have been identified (Schepers et al., 2002). Moreover, two Sox-like genes 
have been found also in the unicellular organism Monosiga brevicollis, suggesting the 
ancient origin of the Sox proteins (Guth and Wegner, 2008).  
Sox proteins are divided in groups or subfamilies termed A to H and the classification is 
based purely on sequence comparisons (Schepers et al., 2002). Proteins of the same 
group share usually more than 80% aa sequence similarity in their HMG domain (see 
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Figure 1.7 for representation of the structure of the Sox factors). Moreover, proteins in 
the same group have similar biochemical properties and thus tend to act redundantly 
when coexpressed, whereas proteins from different groups usually perform different 
functions, despite recognising the same DNA consensus motif (reviewed in Wegner 
2010) (Wegner, 2010). 
1.4.1.3 Sox consensus motif and diverse mechanisms of DNA recognition 
All Sox proteins bind to a common consensus motif 5’-(A/T)(A/T)CAA(A/T)G–3’ 
(Harley et al., 1994). This heptameric motif is short and degenerate and fails to 
discriminate between different Sox proteins. However, Sox proteins differentially bind 
and recognise their target genes through different binding sites suggesting that the 
mechanism of recognition does not rely exclusively on the sequence of the consensus 
motif. Target gene selectivity by different Sox proteins can be achieved and influenced 
by differential affinity for particular flanking sequences next to the Sox consensus sites, 
interaction with other cofactors and TFs, homo and heterodimerization with other Sox 
proteins, post-translational modifications of the Sox factors (reviewed in Wegner 2010). 
These mechanisms allow recruitment of Sox factors on many and very different binding 
sites throughout the cell genome, which probably account for the very different 
molecular and biological functions that the same Sox factor can exhibit in different 
biological context. Furthermore, these mechanisms also allow regulatory regions to 
discriminate and recruit a specific Sox factors rather than others. The two mechanisms 
relevant to the topic of this thesis are discussed in the two following paragraphs.   
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1.4.1.3.1 Differential affinity of Sox factors for flanking sequences in the DNA 
recognition 
Sox proteins show preferences for specific bases within the sequence flanking the 
consensus motif with an effect on the selection of the binding sites. For instances, 
binding affinity for binding sites where some specific nucleotides where flanking the 
Sox sites were identified for Sox9, Sox10 and Sox4, as briefly reviewed in Wegner 
2010. Also different preferences for bases within the heptameric consensus help to 
discriminate binding sites. Different affinity in the binding of Sox4 to primary and 
secondary motifs with two different nucleotides in the sequence were analysed in a 
work by Jauch and colleagues in a novel approach aiming to elucidate the effect of 
alternative motifs in the binding profile of TFs in the genome (Jauch et al., 2012).  
1.4.1.3.2 Interactions with other TFs in the DNA recognition 
Sox factors are known to interact with a high number of different TFs and it is believed 
that these interactions can help in the selection of the binding sites. Very often Sox 
binding sites are found in the immediate vicinity of binding sites for other TFs in a 
conformation termed composite elements. Thus, protein-protein interaction might 
determine which Sox factor is recruited on the composite element and also influence the 
affinity of a specific Sox partner for that binding site in a cooperative binding between 
the two TFs on the composite element. The best characterised examples of composite 
elements recruiting Sox2 factors are the Sox2-Pax6 interaction in the regulation of the 
lens-specific δ-crystallin enhancer (Kamachi et al., 2001) and Sox2-Oct4 composite 
element identified in the regulatory regions of many ESCs genes, such as Fgf4, Nanog 
and some others (Yuan et al., 1995, Rodda et al., 2005, Remenyi et al., 2003). The 
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biological implications of these molecular interactions are discussed in paragraph 1.4.3 
“Molecular interaction of Sox2 with other TFs”.  
1.4.1.4 Members of the SoxB2 family act as transcriptional repressor 
Although most Sox genes act as transcriptional activators, Sox14 and Sox21, members 
of the SoxB2 subgroup, are known to act as transcriptional repressors, in contrast to 
their close related factors of the SoxB1 subgroup (Uchikawa et al., 1999). They have a 
transrepression domain in their C-terminal portion of the protein. A work by Sandberg 
et al. has shown that Sox21, acting downstream of proneural proteins, counteracts the 
functions of the coexpressed SoxB1 members to induce neurogenesis in the chick 
developing neural tube. Sox21 competes with SoxB1 proteins for binding the same 
target gene promoters and repressing their activity (Sandberg et al., 2005).   
 
1.4.2 Biological functions of Sox2 in vertebrate neural development 
1.4.2.1 Role of Sox2 in ESCs and NSCs as stem cell related gene 
Sox2 is active in the embryonic nervous system from the early stages of development. It 
is expressed in mouse already in the presumptive neuroectoderm (Avilion et al., 2003). 
It is indeed essential to the formation of the neuroectoderm and acts as a neural 
competence factor, as shown by studies in Xenopus where microinjection of dominant 
negative version of Sox2 (Sox2dn) suppresses the expression of regional neural markers 
and inhibits the neural differentiation of the ectoderm (Kishi et al., 2000). In the early 
neuroectoderm, all three members of the SoxB1 group, Sox1, Sox2, and Sox3 proteins, 
are expressed in an overlapping manner and act redundantly probably due to their 
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biochemical and functional similarities. Therefore they compensate for the loss of each 
other and do not show evident phenotypes in the single mutant of each factor, as 
reviewed in Wegner and Stolt (Wegner and Stolt, 2005).  
All three SoxB1 factors universally mark neural progenitor stem cells in the whole 
CNS. In chick, constitutive expression of Sox2 inhibits neuronal differentiation and 
maintains progenitors in a stem cell state. In contrast, inhibition of Sox2, mediated by 
Sox2EnR electroporation in the developing spinal cord, causes the loss of neural 
progenitors from the VZ, cell cycle exit and early onset of neuronal differentiation, as 
demonstrated in a work by Graham and colleagues (Graham et al., 2003). 
Particularly relevant to the work of this thesis is a study by Bylund et al. showing that 
vertebrate neurogenesis, initiated by the activity of the bHLH proneural proteins, is 
counteracted in vivo by the activity of the SoxB1 TFs, Sox1, Sox2, and Sox3, which 
show overlapping expression pattern and redundant functions (Bylund et al., 2003). The 
work of Bylund and colleagues has found that Sox1-3 factors keep neural cells 
undifferentiated, as overexpression of these factors in chick neural tube by in ovo 
electroporation is associated to a lack of expression of pan-neuronal markers such as 
p27kip1, NeuN, or Tuj1 in the marginal zone of transfected cells. Therefore Sox1-3 
prevent cells from upregulating post-mitotic neuronal markers. Interestingly, Sox1-3 
factors do not repress the expression of the bHLH proneural factors but rather repress 
differentiation events downstream of these. Conversely, proneural proteins induce 
neurogenesis by suppression of Sox1-3 expression in neural progenitors, a critical step 
in the acquisition of a neuronal fate. I have already mentioned in the previous paragraph 
1.4.1.4 that the repressor activity of Sox21 can induce neurogenesis possibly by 
repressing the activation of the same target genes of Sox1-3, downstream of the 
proneural proteins (Sandberg et al., 2005). In conclusion, in vivo studies from Jonas 
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Muhr lab in the chick developing neural tube have shown how critical is the balance 
between Sox1-3 and Sox21 factors in neural progenitors either to keep them in an 
undifferentiated state or to promote neurogenesis possibly through control of the same 
target genes. An important activity of the proneural proteins in their induction of 
neurogenesis seems to be the upregulation of Sox21 as essential step towards the 
suppression of Sox1-3 activity and commitment of progenitor cells to the neurogenic 
program. Together, these studies have therefore identified the critical interplay between 
bHLH proneural proteins and the SoxB1 and SoxB2 factors in the establishment of the 
neurogenesis in vivo (Bylund et al., 2003, Sandberg et al., 2005).     
1.4.2.2 Role of Sox2 in neuronal differentiation  
Interestingly recent gene targeting studies investigated the function of Sox2 in two 
neuronal systems: the developing eye and brain. These studies uncovered a role for 
Sox2 not only in the maintenance of neural stem cells, but also in the differentiation of 
specific neuron sub-types (Pevny and Nicolis, 2010).  
Neural stem cells from the brain (telencephalon) of Sox2 hypomorphic mutant mice 
show a specific defect in neuronal differentiation, with comparatively normal self-
renewal (Cavallaro et al., 2008). Sox2-deficient neural stem cell cultures generate 
normal numbers of beta-tubulin-positive cells, yet these are poorly arborized, and are 
negative for mature markers such as MAP2, NeuN, and Calretinin (a marker of 
GABAergic differentiation). The in vivo counterpart to this includes reductions in cell 
number and arborisation, and the delayed migration of GABAergic interneurons from 
two areas: cortical interneurons originating from the embryonic ganglionic eminences, 
and olfactory bulb interneurons, generated postnatally. The differentiation defect could 
be rescued, in vitro, by a Sox2-expressing lentivirus at early (proliferating) but not late 
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(postmitotic) stages of differentiation. Sox2-deficient differentiating cells coexpress 
markers of neuronal (beta-tubulin) and glial (GFAP) differentiation, contrary to wild 
type cultures. Ectopic Sox2 expression by the lentivirus represses endogenous GFAP 
expression, and the GFAP gene is a direct target of Sox2. Thus, Sox2 acts in neuronal 
progenitors to downregulate genes of an alternative (glial) differentiation fate 
(Cavallaro et al., 2008).  
Parallel study of complete Sox2 ablation and hypomorphic mutations in the retina also 
demonstrated profound defects in neuronal differentiation (Taranova et al., 2006). 
Indeed, while complete Sox2 ablation leads to a major loss of neural progenitors and 
terminally differentiated cells downstream to them, hypomorphic/null heterozygotes 
revealed specific differentiation defects in one important type of neuron, the retinal 
ganglion cell (RGC), whereas other neuronal types remain comparatively normal, 
although they are mislocalized. RGCs (positive for the mature markers Neurofilament, 
Brn3b, Islet1) are indeed absent in mutant postnatal retina: young mutant RGC are 
initially born during embryogenesis (as recognized by positivity for beta-tubulin and 
Brn3b), but fail to terminally mature, reach their appropriate location, or to 
appropriately develop axons that enter the optic nerve (Taranova et al., 2006).  
In these studies the use of mutant allelic series to decrease/abolish Sox2 expression led 
to the recognition of a marked dosage-dependence of Sox2 function. Furthermore the 
effects of Sox2 deficiency are variable and context and species dependent. These are 
important aspects to consider when assessing the role of Sox2 in the regulation of its 
target genes. Complex interactions of Sox2 with other regulatory factors, as well as 
possible redundancy with other SoxB1 genes, can affect the outcome of Sox2 deficiency 
and its role in gene regulation (Pevny and Nicolis, 2010).  
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Several interactions of Sox2 with different cofactors have been reported, and, as for 
Ascl1, both roles in NSC maintenance and neuronal differentiation have been reported. 
This might give rise to multiprotein-DNA complexes with specific functional 
properties, where the recruitment of different cofactors results in different 
transcriptional outcome. Besides TFs and cofactors recruitment, chromatin-modifying 
enzymes may also be important partners in Sox2 function (Pevny and Nicolis, 2010). 
Interactions of Sox2 with other TFs are discussed in the next paragraph, where some 
examples of the best-characterised and more relevant interplay of factors have been 
selected and presented. 
1.4.3 Molecular interactions of Sox2 with other TFs 
Sox2 interacts with many TFs, whose binding sites are often in the vicinity of the Sox 
site. There are evidence supporting a model in which the transcriptional regulatory 
function of Sox2 is dependent on cooperation with another TF and the establishment of 
a pair Sox2-partner (Yuan et al., 1995, Kamachi et al., 2001, Kondoh and Kamachi, 
2010). The selection of the partner in the pair depends from the DNA sequence flanking 
the Sox site, and the availability of the partner factor in a specific cellular context 
(Kondoh and Kamachi, 2010). The biological consequences of this mechanism of 
regulatory function by Sox2, and all Sox factors more in general, is that each Sox-
partner TF pair appears to select a specific set of regulatory target genes. The resulting 
gene expression patterns characterise a particular cell state and subsequent 
differentiation. For instance, Sox2-Oct4 pair (Oct4 was previously named Oct3; from 
here the name Oct3/4 sometimes used in this thesis and in the referenced literature) 
selects and regulates the expression of a set of genes active in the ESCs, necessary to 
the establishment of the stem cell state, such as the previously mentioned Fgf4, Nanog, 
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Utf1, Fbx15 and the same Sox2 and Pou5f1, the gene encoding the Oct4 protein (Yuan 
et al., 1995, Rodda et al., 2005, Chew et al., 2005, Remenyi et al., 2003, Tokuzawa et 
al., 2003). In the NSCs instead, the alternative pair Sox2-Brn2 activates the Nestin 
enhancer, and also a Sox2 enhancer (SRR2 enhancer) regulating the expression of this 
gene specifically in the NSCs of the telencephalon (Tanaka et al., 2004, Miyagi et al., 
2004, Miyagi et al., 2006). Alternatively, the pair Sox2-Pax6 selects and regulates other 
lens-related genes together with the previously mentioned DC5 enhancer of the δ-
crystallin gene, therefore inducing initiation of the lens differentiation process (Kondoh 
and Kamachi, 2010, Kamachi et al., 2001). Moreover, a wide range of different Sox 
factors and different partners could be mentioned and involved in the specification of 
different cell types, or in the activation of targets in different cellular context. For 
instance, the pair Sox11-Brn2 regulates the activity of the previously mentioned Nestin 
enhancer specifically in the SVZ of the developing spinal cord, thus replacing the pair 
Sox2-Brn2 that regulates the activity of the same enhancer exclusively in the VZ of the 
developing spinal cord (Tanaka et al., 2004). Thus, when any component of the Sox-
partner TF pair is exchanged with alternative factors, either the Sox factor or its partner, 
a transition of the gene expression occurs in a cell, leading to progression of the 
developmental processes.  
The Sox2-Oct3/4 pair also activates their own genes in a co-regulatory loop, so that the 
cell state is maintained and stabilised. A major enhancer of Pouf51 gene (the gene 
encoding the Oct4 protein) is activated by the Sox2-Oct3/4 pair in the ES cells, and the 
same pair also activates a Sox2 enhancer regulating the expression of Sox2 in the same 
stem cell context (Chew et al., 2005, Okumura-Nakanishi et al., 2005, Masui et al., 
2007, Tomioka et al., 2002).  
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Two main molecular mechanisms underlie Sox-partner TF interactions: cooperative 
DNA binding; and protein interactions (dependent upon DNA binding), which bring to 
the formation of potent transactivation complexes. Sox2 and Oct4 bind cooperatively to 
the enhancer of the Pou5f1, Utf1 and Fbx15 genes to regulate their expression, for 
instance, so that the affinity of one factor for the binding site is enhanced by the binding 
of the other factor (Remenyi et al., 2003, Tokuzawa et al., 2003). Moreover, protein-
protein interactions induce the formation of potent transactivation complexes required 
for the activation of the target genes. In the case of the activation of the Nestin enhancer 
in neural stem cells for instance, Sox2 and Brn2 can establish protein-protein interaction 
that are independent from DNA binding leading to the synergistic activation of the 
regulated enhancer (Tanaka et al., 2004). The activation of the DC5 enhancer of the δ-
crystallin gene in the lens development requires instead cooperative binding of Sox2 
and Pax6 to the DNA sequence, which is indispensable for the formation of a potent 
transactivation complex and the establishment of protein-protein interaction between the 
two TFs (Kamachi et al., 2001). The work of Kamachi and colleagues has demonstrated 
that Pax6 undergoes Sox2-interaction dependent and DNA binding sequence-dependent 
conformational changes that are necessary to the formation of the active transactivation 
complex and to the synergistic activation of the δ-crystallin enhancer by the two TFs. 
The configuration of the binding motifs in the sequence appears to be indispensable for 
the conformational changes of Pax6, as demonstrated by insertion of bases in the 
sequence sufficient to the loss of the transactivation potential (Kamachi et al., 2001). 
The prominent role of Oct4 in the maintenance of the pluripotent state has been well 
established. However, Oct4 can also specify and regulate the primitive endodermal 
lineage (Niwa et al., 2000). Aksoy and colleagues have demonstrated that Oct4 can 
regulate endodermal specification by an alternative partnering with Sox17 rather than 
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Sox2 on an alternative “compressed” Oct-Sox motif associated with endodermal genes 
(Aksoy et al., 2013, AlFatah Mansour and Hanna, 2013). This is in contrast with the 
recruitment of the Oct4-Sox2 pair on the “canonical” Oct-Sox motif identified in the 
regulation of the pluripotency genes in ESCs. Therefore, Oct4 can drive alternative 
developmental programs of pluripotent or endodermal fate by shuffling Sox partners 
and selecting alternative enhancers. This study is a further example of the alternative 
pairs of TFs and members of the Sox family for the selection of binding sites and 
regulatory circuits that drive differentiation during development.      
Another important aspect in the gene regulation by Sox2 is the possible interaction with 
chromatin remodelling complexes. Interestingly, Engelen and co-workers have 
demonstrated that Sox2 interacts directly with Chd7, a chromatin remodelling ATPase 
complex (Engelen et al., 2011). Chd7 was identified as interactor of Sox2 through mass 
spectrometry, and their direct physical interaction was confirmed by co-
immunoprecipitation. The two factors share many binding sites genome-wide, as proved 
by ChIP-seq experiments, and regulate a set of common target genes, as proved by 
knockdown of each factor and microarray analysis.  
1.4.4 Sox2 in reprogramming 
The role of Sox2 and its interplay with Oct4 and Nanog in the establishment and 
maintenance of the ESCs characteristics has been previously discussed in this thesis. 
Takahashi and Yamanaka have shown that the combination of Sox2 with Oct4, c-Myc, 
and Klf4 is essential to reprogram mouse embryonic and adult fibroblast into induced 
Pluripotent Stem cells (iPS), ES-like cells with morphology, properties, and expression 
of cell marker genes typical of the ESCs (Takahashi and Yamanaka, 2006).  
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Relevant to this thesis, a work by Karow and colleagues shows that the combination of 
Ascl1 and Sox2 can induce reprogramming of human pericytes derived from the adult 
cerebral cortex into fully functional neurons (Karow et al., 2012). Pericytes are a cell 
type involved in the establishment and maintenance of the blood-brain barrier and 
regulation of the local blood flow (Armulik et al., 2011). Remarkably, pericyte cultures 
used in the work by Karow and colleagues lack completely expression of neuronal 
markers such as βIII-tubulin, neural stem cell markers such as Sox2 or prominin, and 
neurogenic determinant such as Ascl1 and Pax6. In this cellular context, retrovirus 
mediated co-expression of Ascl1 and Sox2 was sufficient to induce a full neuronal 
phenotype, whereas Ascl1 or Sox2 alone failed. The authors of the study hypothesised 
two possible scenarios to explain the synergism of the two TFs Ascl1 and Sox2 in the 
induction of the neuronal phenotype. They speculate that Sox2 might predispose the 
somatic genome of the pericytes to the neurogenic activity of Ascl1 or that the two TFs 
might interact in the regulation of common targets. 
 
1.4.5 SoxC factors in neural development 
1.4.5.1 Biological functions of the Sox C factors 
Sox4, Sox11, and Sox12 constitute the group C of the family of Sox TFs. These genes 
have been highly conserved among vertebrate, and their biochemical similarities 
together with their expression pattern suggest that they act quite redundantly. Their 
expression has been found widespread and extensively overlapping in mouse embryo 
since mid-organogenesis. The highest RNA levels of these genes have been found in 
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post-mitotic neuronal progenitors throughout the nervous system, and also at lower 
level in mesenchymal cells of many developmental organs, (Penzo-Mendez, 2010).      
As reviewed in Penzo-Mendez, it has been emerging that the SoxC genes have a critical 
role in the development of many organs, as consistent with their widespread expression. 
Sox4-null embryos and Sox11-null new-born die from major heart defects, and Sox11-
null mutants display multiple defects in many other organs such as eyes, palate and lips, 
and lung. Sox4 is also required for the differentiation of B lymphocyte, pancreatic beta 
cells and osteoblast. Thus, the Sox factors are relevant for the differentiation of many 
cell lineages.  
They also appear overexpressed in many types of cancer, and therefore they have been 
used as cancer markers, especially Sox11. These proteins are overexpressed in most 
medulloblastomas and gliomas, although their roles in cancer are not clear, as data 
reported are conflicting (Penzo-Mendez, 2010).  
1.4.5.2 Molecular characteristics of the SoxC factors 
The SoxC factors are single-exon genes, with the HMG DNA-binding domain in the N-
terminal half of the protein and the transactivation domain (TAD) in the C-terminal side 
(Figure 1.7). Preferential binding of Sox4 HMG has been identified for more than one 
alternative motifs by EMSA experiments, as already mentioned in paragraph 1.4.1.2.1 
and further reviewed in Penzo-Mandez (Penzo-Mendez, 2010). Interestingly, Sox4 
binds more efficiently than Sox12 in EMSAs, and Sox11 binds very weakly (Dy et al., 
2008). Different conformations of the TAD of the three SoxC proteins have been related 
to a different potent activation of their target, as proved by transient transfection 
reporter gene assays. In accordance with this observation, Sox11 is the most potent and 
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Sox12 the least potent of the three proteins in the activation of their targets (Dy et al., 
2008). This is consistent with the fact that Sox12 is the less relevant and critical SoxC 
TF in the control of the differentiation processes in which these proteins have been 
implicated. It is also the factor showing the milder phenotype in knockout studies 
compared with the close related members of the same family.  
SoxC proteins have been shown to cooperate with other TFs as partners. Intriguingly, 
like SoxB1/Sox2 factor(s), they strongly synergise with the POU domain TFs Brn1 and 
Brn2 in the activation of the Fgf4 enhancer on the adjacent Sox-Pou binding motif (Dy 
et al., 2008) . In the same way and as already previously mentioned (par 1.4.3), either 
Sox2 or Sox11 can synergistically activate in vitro the Nestin enhancer active in the 
early neural tube by binding the Sox-Pou motif there contained. In vivo, Sox2 and 
Sox11 are not coexpressed, but each of them is coexpressed with Brn2 and Nestin, 
further suggesting that the SoxC proteins and POU factors might synergise in vivo 
(Tanaka et al., 2004).    
1.4.5.3 SoxC factors in neuronal differentiation 
SoxC factors, Sox4 and Sox11, can also induce neuronal differentiation. A work by 
Bergsland and colleagues has shown that Sox4 and Sox11 have a critical role in the 
establishment of pan-neuronal proteins expression and neuronal traits (Bergsland et al., 
2006). The authors have shown in their work that the ectopic expression of Sox11 (and 
equally Sox4), by in ovo electroporation, in the developing chick spinal cord can induce 
ectopic precocious expression of neuronal markers such as Tuj1 and Map2. 
Interestingly, the authors have proved that the SoxC factors act as transcriptional 
activators in the case of one of the neuronal proteins, more precisely by direct binding 
and activation of the promoter of the Tubb3 gene. Sox4 and Sox11 motifs have been 
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identified in the promoter of Tubb3 and the direct binding of the two SoxC TFs has 
been demonstrated in EMSA experiments. Also the transcriptional activation of the 
Tubb3 promoter by the SoxC factors has been demonstrated by transient transfection 
and transcriptional reporter gene assay in vitro. Sox4 and Sox11 can initiate the 
expression of neuronal markers in cells that are still proliferating; therefore their control 
on the establishment of pan-neuronal properties in committed progenitor cells is 
independent from mechanisms that control cell cycle exit. Moreover, the authors have 
also shown that Sox4 and Sox11 are induced and act downstream of the proneural 
proteins, Ngn2 and Ascl1. In the same study, the transcriptional repressor protein 
REST/NRSF has been shown to control and restrict the domain of expression of the 
SoxC factors in post-mitotic differentiating neurons. Thus, the concomitant activity of 
proneural proteins and REST establish the pattern of expression of Sox4 and Sox11 in 
post-mitotic differentiating neurons in the developing chick spinal cord. In this way, the 
SoxC factors can control the program of neuronal differentiation and the establishment 
of neuronal traits downstream of the proneural proteins.  
In analogy with their role in embryonic CNS, evidence shows that Sox4 and Sox11 
induce neuronal differentiation also in the adult hippocampus in mouse. A work by Mu 
and colleagues has shown that SoxC factors are essential regulators of the genetic 
network controlling neuronal differentiation in adult neurogenesis (Mu et al., 2012). 
The expression of Sox4 and Sox11 is initiated at the time of neuronal fate commitment 
of hippocampal neural progenitors (in late Type2a and Type 2b cells) and is maintained 
in immature neurons. Retrovirus mediated overexpression of Sox4 and Sox11 promote 
in vitro neurogenesis from adult NSCs, as proved by the expression of neuronal markers 
such as DCX and Tubb3 besides the proliferating-enhancing culture conditions of 
transduced cells compared with the control. Conversely, retrovirus Cre recombinase-
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mediated deletion of Sox4 and Sox11 prevents in vivo and in vitro neurogenesis, as 
proved by depletion of the same neuronal markers in the Sox4-Sox11 double 
conditional knockout mice transduced with the Cre-retrovirus. Furthermore, in the same 
study the authors have shown that SoxC factors target the promoter of the neuronal 
differentiation gene DCX, as shown in ChIP experiments and luciferase assays. 
Therefore, another neuronal gene has been identified as direct target of Sox4 and Sox11, 
following the identification of Tubb3 by Bergsland et al., in the establishment of a 
neurogenic network of differentiation controlled by SoxC factors. Finally, it is worth 
noting that in this same study by Mu and colleagues, reprogramming of astroglia into 
neurons induced by Neurogenin2 is strongly enhanced by Sox4 and Sox11 factors. 
Surprisingly indeed, Neurog2-induced reprogramming is impaired in Sox4-Sox11 
double conditional knockout astrocytes. These results show an essential role for Sox4 
and Sox11 in neuronal reprogramming of astrocytes, providing further support for the 
view of SoxC factors as key regulators of the transcriptional network underlying 
neuronal differentiation.   
1.4.6 Sequential binding of Sox factors in the specification of neural 
lineage 
The overview of the literature on the Sox factors discussed in the previous paragraph 
has highlighted the notion that different classes of Sox factors are expressed during 
neurogenesis and act in different processes of the neural development from early 
lineage specification to neuronal differentiation.  
A “priming” role has emerged for the Sox factors as regulators of the neurogenesis 
(Figure 1.8). This consists in the sequential occupation of common targets by different 
Sox factors at different stages of neurogenesis with the purpose of preselecting and 
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priming the bound genes for the activation at a later stage. Indeed, Bergsland and 
colleagues demonstrated in a genome-wide binding study that Sox2, Sox3 and Sox11 
exhibit an notable sequential binding to a common set of neural genes (Bergsland et al., 
2011). The binding profile of the three factors was exploited by ChIP-seq generating 
and comparing binding dataset for Sox2, Sox3 and Sox11 in mouse ESCs, ES cell-
derived NSCs, and neurons as cellular sources (Figure 1.8). Interestingly, data has 
shown that in ESCs Sox2 binds and preselects for silent neural lineage-specific genes, 
which will be bound and activated later by Sox3 in NSCs. With an analogous pattern, in 
NSCs Sox3 binds and preselects genes that are later bound and activated by Sox11 in 
differentiating neurons. Genes preselected by the Sox proteins are in a poised state 
associated with a bivalent chromatin signature, which is then changed into a permissive 
chromatin state with the binding of the activating Sox factors. Thus, the entire 
neurogenesis can be controlled through an ordered succession of a group of Sox factors 
on a common set of target gene enhancers, a process to which Wegner referred as “Sox-
session” in his commentary to the paper by Bergsland et al. published on the same issue 
of Genes and Development (Wegner, 2011). In conclusion, the paper of Bergsland and 
colleagues has proposed a pre-binding function for the Sox proteins involved in the pre-
selection of targets that will be activated at a later stage of development. The priming 
factors might work by having an impact on the chromatin structure and epigenetic state 
of the preselected but not yet active target genes. This influence on the chromatin state 
has been proved at least for Sox3 in the conversion of a poised state of the neuronal 
enhancers still inactive in the NSCs.   
Also in the specification of the B cells, Sox2 preselects the enhancer λ5-V preB1 that is 
later activated by Sox4, as described in a paper by Liber et al (Liber et al., 2010). 
Finally, Fox family of TFs has shown to operate a similar mechanism of regulation in 
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the activation of the liver-specific Albumin enhancer during development (Xu et al., 
2009).  
The new notion of the Sox factor family with members acting in succession in the 
establishment of the neurogenic program is a view that needs to be kept in consideration 
when investigating the molecular interactions of TFs and the Sox factors in the 
regulation of neural enhancers in development. Interactions between Ascl1 and Sox 
factors are the object of investigation in this thesis. 
 
 
Figure 1.8 The Sox-session. 
Model illustrating the sequential binding of Sox proteins to common downstream gene targets in the 
establishment of the neural lineage from ESCs to differentiating neurons. The cartoon also highlights the 
association between Sox pre-binding and bivalent histone modifications. Taken and adapted from 
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1.5 Use of NS5 cells as neural stem cell model system 
The study of neural enhancers regulated by TFs Ascl1 and Sox factors presented in this 
thesis has used an in vitro cell line with characteristics of neural stem cell as model 
system. The NS5 cells used in this study were first described in a work by Conti and 
colleagues (Conti et al., 2005). (The name NS5 refers to one of the first clones of the 
homogeneous adherent culture population for which the neural stem cell characteristics 
were analysed in details.)  
Neural stem cells (NSCs) were first generated from mouse ES cells following neural 
induction upon serum withdrawal from the medium in adherent monolayer culture. The 
maintenance of NSC is strictly dependent on the presence of the growth factors EGF 
(epidermal growth factor) and FGF2 (fibroblast growth factor 2) in the culture medium. 
Upon the establishment of these culture conditions, in vitro NSCs independent from 
stem cell niche can be maintained and expanded as they undergo symmetric self-
renewing divisions. They represent a pure homogeneous culture of neural stem cells. 
Even after prolonged expansion, they remain capable to differentiate into neurons and 
astrocytes in vitro with electrophysiological characteristics of functional neural cells. 
Withdrawal of FGF2 and EGF from the medium is sufficient to induce differentiation. 
The NS5 cells express morphological, cell biological and molecular features of radial 
glia cells. Indeed, NSCs can also be obtained from foetal mouse forebrain. Among the 
molecular features resembling radial glia, the neural stem cells express Pax6, GLAST, 
BLBP mRNA, and are immunopositive for nestin, RC2, vimentin, Pax6 and prominin 
among ragial glia markers. Furthermore, they express neural precursor markers such as 
Sox2, Sox3, Emx2, and the bHLH TFs Olig2 and Ascl1. Indeed, coexpression of Ascl1 
and Sox2 has been shown in NS5 cells by immunofluorescence staining for the purpose 
of the study presented in this thesis (Figure 1.9). While the expression of Sox2 was 
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strong and uniform among all cells, Ascl1 showed the typical “salt and pepper” 
expression pattern.  
The expression of the TFs Ascl1 and Olig2, together with a shown preference for 
differentiation into GABAergic neurons, exhibits a biased telencephalic ventral identity 
of the NS5 cells. These features might be the consequence of an ex-vivo environment 
and an effect of the exposure to FGF2 in culture. This aspect is suggestive of limitations 
generated by the in vitro environment and the impossibility to establish a connection 
between neural stem cells in culture and populations of radial glia progenitor cells in 
vivo in the CNS. Indeed, NS culture systems should be best regarded as an environment 
that force high rate of proliferation and repress regional or cell type specific 
differentiation. Moreover, the sustained exposure to growth factors in culture condition 
might alter the transcriptional and cellular phenotypes (Conti and Cattaneo, 2010). 
Alternative protocols for the derivation of radial glia in vitro in FGF and EGF-free 
culture conditions have been described with the generation of dorsal forebrain 
glutamatergic neurons. However, these cells are not easily expandable in vitro (Bibel et 
al., 2007, Bibel et al., 2004). Where other protocols have been considered, different 
drawbacks have emerged in the methods, as reviewed in Conti and Cattaneo, 2010 
(Conti and Cattaneo, 2010).  
Altogether, this suggests that beyond the limitations imposed from the culture 
conditions, the NS5 cells represent a good model of neural stem cells in vitro. They are 
high proliferating mitotic precursors, readily expandable cells, which divide nearly 
every 24 hours. Moreover, they can be transiently or stably transfected by 
electroporation, or lipofection, or viral transduction. In conclusion, they are versatile 
and easily manipulated (Conti et al., 2005). Therefore, they are well suitable to study 
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the regulation of gene expression by prominent TFs expressed in neural stem cells, 
which is the purpose of the study in this thesis.  
 
 
Figure 1.9 Coexpression of Ascl1 and Sox2 TFs in vitro in NS5 cells by 
immunofluorescence staining. 
Sox2 shows a broad expression uniformly in all cells, whereas Ascl1 shows a typical “salt and pepper” 
expression pattern, as discussed elsewhere in chapter 1.3 Proneural proteins and the TF Ascl1 in 
vertebrate neural development. Images taken during this work. 
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1.6 Objectives of the thesis 
This work aims at characterising transcriptional enhancers regulated by interplay 
between Ascl1 and Sox factors. It also aims to understand the mechanism of regulation 
by these TFs and the nature of their interactions. 
Molecular data previously generated in our lab through a ChIP-seq approach identified 
genomic regions in NS5 cells, an in vitro model of neural stem cells, where Ascl1 and 
Sox2 bind in close proximity. In this work, a small group of nine regions selected from 
those identified by ChIP-seq were characterised as enhancers in vitro in NS5 cells 
through luciferase assays. This work also demonstrated that these enhancers are 
regulated by Ascl1 and Sox factors, in particular Sox2, SoxC, and Sox8.  Luciferase 
assays of wt and mutant enhancers carrying disrupted binding motifs of Ascl1 and Sox 
factors were performed to identify and propose mechanisms of transcriptional 
regulation by these TFs through direct or indirect DNA binding to the identified motifs. 
Finally, luciferase assays were also performed after simultaneous overexpression of 
these TFs in NS5 cells to understand the nature of their interactions, for instance if they 
synergise or counteract each other in the regulation of the enhancers here identified.  
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2. Materials and Methods 
2.1 Cell culture 
2.1.1 NS5 cell culture 
NS5 cells were maintained in NSC basal medium containing Euromed-N medium 
(Euroclone) supplemented with 1% L-glutamine (Gibco), 0.1% BSA (Gibco), 1% N2 
supplement (100X) (R&D System), 1% penicillin and streptomycin (Pen/Strep) 
(Gibco), fibroblast growth factor-2 and epidermal growth factor (FGF2, EGF) 
(Peprotech), and laminin (Sigma), as described in Conti et al., (Conti et al., 2005). NS5 
cells were cultured at 37°C in 5% CO2 for 95% air humidified incubator. 
2.1.2 Hek 293T cell culture 
Hek 293T cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) 
(Sigma) supplemented with 10% Foetal Calf Serum (Hyclone), 1% L-glutamine 
(Gibco), 1% penicillin and streptomycin (Pen/Strep) (Gibco). Cells were cultured at 
37°C in 5% CO2 for 95% air humidified incubator (Graham et al., 1977).   
 
2.2 Chromatin immunoprecipitation (ChIP) and quantitative 
PCR (ChIP-qPCR) 
2.2.1 Chromatin preparation 
NS5 cells were fixed with Di-(N)-succinimydyl glutarate (DSG) and paraformaldehyde 
which establishes covalent links between proteins and DNA. Then, cells were lysed in 
Chapter 2 – Materials and Methods 
 79 
presence of SDS (1%). Chromatin was extracted with chloroform and sonicated with 
Bioruptor Sonicator (Diagenode), 200W, 30s ON/ 30s OFF, in an ice-cooled water bath 
for 15 min. 
2.2.2 Chromatin immunoprecipitation (ChIP) 
Chromatin input per immunoprecipitation (IP) was 50µg. The whole amount of 
chromatin needed for one IP was calculated depending on the number of conditions 
tested. A step to preclear the chromatin was performed, and chromatin was incubated 
for 2 hours with magnetic protein Dynabeads (Invitrogen) at 4°C. Magnetic beads were 
captured on a magnetic bar and the precleared chromatin was divided between IP tubes. 
A specific antibody was added and incubated overnight at 4°C. A commercial antibody 
(rabbit polyclonal p300 SantaCruz) to precipitate the protein p300 was used at 3µg/µl, 
after being tested at 3, 6 and 12 µg/µl. No antibody was added to the mock condition 
used as control. 50µg/µl of magnetic beads were added to capture immunocomplexes 
overnight. The protein beads have a strong affinity and specifically bind the antibodies 
allowing immunocomplexes to stay stacked on the magnetic bar between the washes. 
Before the washes, an input of chromatin was taken from the mock condition and 
diluted at 1%, 0.1% and 0.01% to establish the standard curves in the qPCR. 
After the overnight IP chromatin was washed 3 times with reduced SDS buffer (50 mM 
HEPES-KOH, pH7.5; 150 mM NaCl; 2 mM EDTA; 1% TritonX-100; 0.1% NaDOC; 
0.1% SDS), once with reduced buffer added with 0.35 M NaCl, twice with NP-40 wash 
buffer (10 mM Tris-HCl, pH8.0; 0.25 M LiCl; 1 mM EDTA; 0.5% NP-40; 0.5% 
NaDOC); once with TE solution. Then immunocomplexes were separated from protein 
beads with elution buffer (SDS 1%, Tris-HCl 50 mM, EDTA 10 mM) for 15 min at 
65°C.  
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Then, cross-links were reversed to separate the proteins from DNA fragments by 
digesting with Proteinase K (100 µg/µl) in NaCl (200 µM) for 2 hours at 42°C and 
overnight at 65°C. Finally, the DNA fragments were extracted with phenol-chloroform, 
precipitated with glycogen and resuspended in water. (A similar protocol was followed 
for Ascl1 and Sox2 ChIP performed by Ben Martynoga, with specific antibody for the 
protein of interest used at the required concentration.) 
2.2.3 Quantitative PCR (ChIP-qPCR) 
Absolute qPCRs with specific forward and reverse primers listed in Table 2.1 were 
performed to amplify isolated DNA fragment from ChIP. SYBRGreen based kit for 
qPCR (iQ Supermix Biorad) was used for the amplification reactions. The same 
procedure described here for the p300 ChIP-qPCR was used also to amplify and 
quantify the targets in the Ascl1 and Sox2 IP chromatins from NS5 cells obtained from 
the ChIP-seq performed by Ben Martynoga.  Standard curves were generated by serial 
dilutions of input DNA. IP efficiency was measured and expressed as fold enrichment, 
which was calculated as the fold change between the amounts of precipitated sequences 
for one target region divided by the amount of precipitated sequences of negative 
control regions (Delta1-ORF and/or Fbwx7-ORF). 
2.3 Plasmids and cloning 
2.3.1 Cloning the enhancer-regions into the luciferase reporter vector 
The enhancer-regions tested in luciferase assay were amplified from mouse genome by 
PCR with high fidelity Pfu DNA polymerase (Stratagene). Specific primers flanking the 
regions of interest were designed, using the primer3 website 
(http://frodo.wi.mit.edu/primer3/). Primers are listed in Table 2.2. Restriction enzyme 
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sites for SalI and NheI (Roche) were added at the 5’ end of the forward and reverse 
primers respectively, to digest and subclone the amplified inserts. The UCSC genome 
browser was used to determine the length of the enhancer-regions to clone. Usually the 
whole conserved chromatin regions among vertebrate species were chosen for cloning, 
likely to have a regulatory function to test, as described in the Results. The enhancer-
regions amplified were cloned into a TOPO-Blunt vector (Invitrogen) using TOP10 
competent cells (Invitrogen) and the Zero Blunt Topo PCR Cloning Kit according to the 
manufacturer’s instructions. Subsequently, they were digested with SalI and NheI and 
subcloned into a p-ß-Globin-Luciferase vector, also digested with SalI and NheI 
upstream of the ß-Globin minimal promoter, ready to be tested in a luciferase assay.  
2.3.2 Site-Directed Mutagenesis 
Mutations to the E-boxes and Sox motifs of the enhancers were introduced using the 
QuikChange II XL Site-Directed Mutagenesis Kit from Stratagene according to 
manufacturer’s instructions. Briefly, mutated primers listed in Table 2.3 carrying 
mutations in the sequence of the motifs were designed using the web software provided 
by Stratagene (http://labtools.stratagene.com/QC). The point mutations in the E-box and 
Sox motifs were designed as described in Castro et al., Tanaka et al., and in more details 
in Chapter 4 of the Results (Castro et al., 2006, Tanaka et al., 2004). Topo-vectors 
containing the wild-type enhancer-sequences were used as templates in the mutagenesis 
PCR. The resulting mutated enhancer-sequences were then subcloned into the p-ß-
Globin-Luciferase vector via digestion with restriction enzymes as described in the 
previous paragraph for the wild-type sequences. Mutated enhancers generated with this 
strategy were then tested for transcriptional activity in NS5 cells in luciferase assays 
performed as described in paragraph 2.4 for the wild-type constructs.  
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2.3.3 TFs expression vectors  
The expression vectors listed in Table 2.5 were used to overexpress TFs of interest, in 
particular Ascl1 and the Sox factors, in NS5 cells and test the effect of their GoF on the 
activity of the enhancers in transcriptional assays. For the dominant repressor versions, 
the DNA binding domains of Ascl1 or Sox2 were fused with the Drosophila Engrailed 
repressor domain to generate pCAGGs-Ascl1-EnR or pCAG-Sox2-EnR vectors. These 
constructs were already available in the lab.      
2.4 Luciferase assay 
Prior to performing the transfection, NS5 cells were plated in 48 well plates containing 
NSC media. Around 150-200,000 cells were plated in each well. Luciferase constructs 
containing the enhancer-regions were tested in different conditions in triplicate or 
quadruplicate. Each condition contained the luciferase reporter vector (0.125 µg/µl) 
with or without the specific cloned enhancer-region, the pCMV-ß-gal control vector 
(0.25 µg/µl) and either one or two TF expression vector(s) (0.25 µg/µl). Opti-MEM 
(Gibco) and Plus Reagent (Invitrogen) were used to complex the DNA plasmids over an 
incubation time of 15 minutes. The DNA complexes so formed were incubated for 
further 15 minutes and integrated into complexes with lipofectamine (Invitrogen). The 
complete NSC medium was removed from the wells and replaced by Opti-MEM 
medium to facilitate the transfection. The lipofectamine - DNA mix (0.625 µg/µl total 
DNA) was then added to the cells into the wells and incubated for 5 hours in 5% CO2 at 
37°C. After this first incubation, NSC medium replaced the Opti-MEM medium in the 
wells and the incubation was carried on overnight at 37°C. 
After 24 hours the cells were finally lysed with Passive Lysis Buffer (Promega) and 
frozen at -80°C. A luminometer was used to measure the activity of the luciferase 
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enzyme after adding luciferine substrate (Promega) and the enzymatic activity of the β-
gal by adding β-gal base solution supplemented with ONPG (Sigma) and DTT. 
The luciferase activity was normalized to correct for variations in transfection efficiency 
for each condition between triplicates or quadruplicates, by dividing the luciferase 
activity for the ß-gal signal obtained in corresponding wells. Data were then presented 
as the mean fold change relative to the negative control, that is the luciferase vector 
containing the enhancer region to test plus GFP expression vector only. The mean fold 
change of the basal activity of each regulatory region was also measured relatively to 
the activity of the empty vector. 
 
2.5 Electrophoretic Mobility Shift Assay (EMSA) 
2.5.1 Protein synthesis 
2.5.1.1 In vitro transcription and translation  
The full-length cDNA clones of the transcription factors listed in Table 2.6 were used as 
template for in vitro protein synthesis. Proteins were produced using the TnT T7 Quick 
Coupled Transcription/Translation rabbit reticulocyte lysate system (Promega) in a 50 
µl reaction containing 40 µl of TnT rabbit reticulocyte lysate Master Mix and 1 µg of 
DNA template, according to manufacturer’s instructions. The reactions were incubated 
at 30°C for 90 minutes in a thermomix, according to manufacturer’s instructions. Upon 
completion, reactions were snap frozen in liquid nitrogen and stored at -80°C until 
required.  
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2.5.1.2 Protein expression in 293T cell line 
2.5.1.2.1 Transfection in 293T cells 
293 cells were seeded in 10 cm Petri dishes in a number of 6 Millions in DMEM 
medium. After 24 hours, cells were transfected with pcDNA3.1-Ascl1-E47, pcDNA3.1-
Sox2, or pCAG-Sox2 expression vectors. For transfection, 24 µg of plasmid DNA was 
mixed with Opti-MEM (Gibco) and Lipofectamine 2000 (Invitrogen) (pre-mixed and 
incubated for 5 minutes) and incubated for 20 minutes at room temperature. The 
DMEM medium was removed from the Petri dish and replaced with OPTI-MEM to 
facilitate the transfection. The lipofectamine - DNA mix was then added to the cells into 
the Petri dish and incubated for 5 hours in 5% CO2 at 37°C. After this first incubation, 
fresh pre-warmed DMEM medium replaced the Opti-MEM in the dish and the 
incubation was carried on overnight at 37°C.  
2.5.1.2.2 Cell lysis 
After 24 hours, cells were washed and harvested in PBS with complete EDTA-free 
protease inhibitor (Roche), resuspended in lysis buffer (20 mM Hepes, pH 8.00; 100 
mM KCl; 0.83 mM EDTA; 1.66 mM DTT; 1x complete EDTA-free protease inhibitor 
(Roche); 0.5% NP-40) (This buffer was modified from (Chew et al., 2005)) and rotated 
at 4°C for 30 minutes. After centrifugation at 13,000 rpm at 4°C for 15 minutes, the 
resulting supernatant was divided into 40 µl aliquots, which were snap frozen in liquid 
nitrogen and kept at -80°C until required. The total protein concentration in the lysate 
was quantified by performing Bradford Assay (Bio-rad) according to manufacturer’s 
instructions (Bradford, 1976).  
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2.5.2 Radiolabelling of double stranded oligonucleotides 
2.5.2.1 Annealing of the single stranded oligonucleotides 
The single stranded oligonucleotides listed in Table 2.4 were resuspended in H20 to a 
final concentration of 100 mM. Complementary oligonucleotide pairs were mixed in a 
1:1 ratio (10 µg of each oligonucleotide) in TNE annealing buffer (10 mM Tris, pH 
8.00; 50 mM NaCl; 1 mM EDTA) in a total volume of 100 µl. The mixture was heated 
to 95°C for 5 minutes in a hot block before being allowed to return to room temperature 
over a period of 2-3 hours. Annealed stocks were stored at -20°C.  
2.5.2.2 Radiolabelling reaction 
The 5’ end of annealed oligonucleotides was radiolabelled by the addition of 
phosphorus 32 (32P) using T4 polynucleotide kinase. A 20 µl reaction containing 200 ng 
of oligonucleotide, 1x T4 polynucleotide buffer (New England BioLabs), 10 U of T4 
polynucleotide kinase (New England BioLabs), and 2 µl of 32P-γATP (3000 Ci/mmol at 
10 mCi/ml; PerkinElmer) was incubated at 37°C for 30 minutes. 80 µl of TNE buffer 
was added to the reaction before purification on an illustra microspin G-50 column (GE 
Healthcare) according to manufacturer’s instructions. Radiolabelled oligonucleotides (at 
final dilution of 2 ng/µl) were stored at 4°C and used within one half-life (14 days). 
2.5.3 Gel Shift Assay (EMSA) 
Binding reaction included 2 µl of 5x binding buffer A, 1 µl of 1 µg/µl poly (dI-dC) 
(Thermo Scientific), 3 µl of in vitro translated protein (Ascl1-E47) or 2 µl of 293T cell 
lysate (overexpressing Ascl1-E47 or Sox2), and 1 µl of radiolabelled oligonucleotides 
(MSB4 probe) in a final volume of 10 µl. (The binding buffer A contains 20 mM Hepes, 
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pH 8.00; 100 mM KCl; 0.83 mM EDTA; 1.66 mM DTT; 1x complete EDTA-free 
Protease inhibitor (Roche); 20% glycerol). Binding reactions were incubated for 20 
minutes at room temperature. Supershift assays were performed by adding 1 µg of 
primary antibody to the binding reaction with an incubation of further 20 minutes 
(mouse α-Ascl1 BD Biosciences) (goat α-Sox2 Santa Cruz sc-17320x). The addition of 
the antibody could be either before or after the addition of the radiolabelled probe to the 
binding reaction, as no differences were observed in the results in both cases. 
Competition assays were performed by the addition of a 200-fold excess non-labelled 
probe (cold probe) in the reaction. After incubations, the binding reaction mixtures were 
resolved on pre-run 5% non-denaturing polyacrylamide gel in 0.5x Tris-buffered EDTA 
(TBE). Electrophoresis was carried out at 200 V for over 2 hours in the cold room 
(4°C). The gel was dried under vacuum at 80 °C for 1 hour and exposed to X-ray film 
(Kodak) for 2 to 16 hours (depending on the strength of signal achieved). Films were 
developed for 2 minutes using a FPM-3800A processor (FujiFilm) and scanned with a 
Bio-rad GS800 densitometer (Bio-rad).  
2.6 Western Blot 
To assess protein synthesis either from using the in vitro TnT system or plasmid 
transfection in 293T cells, protein expression was analysed by SDS-PAGE protein 
separation and immunoblotting. Equal amounts of proteins from samples in SDS gel 
loading buffer were loaded onto 4% to 12% gradient polyacrylamide gel (NuPAGE bis-
Tris gels) (Invitrogen) and separated by electrophoresis according to their molecular 
weight, under reducing conditions. Proteins were then transferred onto nitrocellulose 
membranes (GE Healthcare) under a current of 250mA in transfer buffer (transfer 
buffer per litre: 3 g trizma base, 14.4 g glycine, 150 ml methanol). Membranes were 
blocked in Tris-Buffered Saline-Tween (TBS-T) with 10% milk (TBS-T per litre: 1.21 
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g trizma base, 11.68 g NaCl, 0.5 ml tween, pH to 7.4 with HCl) for 30 minutes at room 
temperature and then incubated overnight with the primary antibody diluted in TBS-T 
with milk at 4°C (Primary antibody: mouse α-Ascl1 1:200 Hybridoma Bank; goat α-
Sox2 Santa Cruz 17320x 1:500). Membranes were washed with TBS-T, incubated with 
the appropriate secondary antibody diluted in TBS-T for 2 hours at room temperature 
(Secondary antibody: HRP-conjugated anti-mouse or HRP-conjugated anti-goat 
1:10.000, DAKO). After further washes, chemiluminescent detection was performed 
using Amersham ECL (GE Healthcare) according to manufacturer’s instructions. Films 
were developed for 2 minutes using a FPM-3800A processor (FujiFilm) and scanned 
with a Bio-rad GS800 densitometer (Bio-rad).  
2.7 Computational analysis 
UCSC genome browser and PhastCons program were used to assess the sequence 
conservation of the genomic regions bound by Ascl1 and Sox2 (identified by ChIP-seq) 
among vertebrate species (http://genome.ucsc.edu/) (Siepel et al., 2005). The search for 
the Ascl1 and Sox2 binding motifs consensus was performed using the TESS 
(Transcription Element Search System) database (http://www.cbil.upenn.edu/cgi-
bin/tess/tess), searching for consensus position weight matrices from the TRANSFAC 
database (Wingender et al., 1996). The expression pattern of the genes associated to 
Ascl1 and Sox2 bound regions was screened using Genepaint 
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2.8 Statistical analysis 
One-way ANOVA followed by Dunnett’s post-test was used for the analysis of data 
from the basal luciferase activity of wt or mutant enhancers (where the activity of each 
enhancer was compared to the activity of the empty vector used as control) (Figures 3.7 
and 4.2). Two-way ANOVA was employed for the analysis of the luciferase activity of 
enhancers (wt or mutant enhancers) following overexpression of TFs. In cases where all 
columns are compared to each other (where various combinations of TFs were 
overexpressed), a Tukey’s post-test was used (Figures 3.8, 3.11, and 4.4). Where each 
column was compared to its control column (for example, where the activity of mutant 
enhancers following overexpression of a given TF were compared to the activity of the 
wt enhancer following overexpression of that same TF), a Dunnett’s post-test was used 
(Figures 4.3, 4.5, 4.6, and 4.7). Differences were considered statistically significant at * 
p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. All data are presented as the 
mean ± SD. Values were calculated using GraphPad Prism 6.0c.        
   




Oligonucleotides and Plasmids 
Table 2.1 ChIP-qPCR primers  
Primers to amplify ChIP and ChIP-seq identified regions bound by Ascl1, Sox2, and 
p300 in IP chromatin from NS5 cells  
Primers Primer Sequence (5'-3)' 
MSB 4 For AGGTAGACAGGACGGAAAGG 
MSB 4 Rev TTTCACACCCAACAATGGAT 
MSB 9 For CAGACACTACTCCAGCAGAGG 
MSB 9 Rev AGACTAAAGGGAAGGCAGGA 
MSB 10 For GAGTGTGCCCATTGTTCTTT 
MSB 10 Rev GTGCCAAGATAGGTGACAGG 
MSB 11 For AGGGACTCACAGACACCAGA 
MSB 11 Rev ATAAAACAGCCATCGGACCT 
MSB 18 For GGTGAGGGGAAGTAGGAAGA 
MSB 18 Rev ATGAGAAGGCGCTGTTTAGA 
MSB 22 For ATGGGCAGAGTGTCATCAAT 
MSB 22 Rev ACCTGACTTCCTTCCTCCAG 
MSB 23 For GCATCTAAAGGGCCAGTATG 
MSB 23 Rev TGGTTCCTGGTTTGACTCTG 
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MSB 24 For GGGTCCTGCACAATAGCTC 
MSB 24 Rev CCTTACCTCCAAAACCCAAG 
MSB 25 For TTGGGGTAAAGCTACATTGC 
MSB 25 Rev GCCTGTGTTTAGTCCCTCCT 
MSB 26 For GCTGCTACTAAAGCCAAGGTT 
MSB 26 Rev CATTCACAGCACAGCCATC 
NB 1 For CCAATAAAAAGGCTGTGGAA 
NB 1 Rev ACACAAATCTGGGGTTGGTA 
NB 2 For ACTTTGTAGGCAGAGGCAGA 
NB 2 Rev CCAGTGCTGAGATCAAGACA 
NB 3 For GGCCTAGATCGAATGTGAAG 
NB 3 Rev GGGCAGTAAAAGCAGAAACA 
NB 4 For CTCAGGCAGGTGTAGTCTGG 
NB 4 Rev CTCTTAGCAATGGTCACTTGG 
 
Table 2.2 Cloning primers 
Primers for cloning enhancer-regions in p-β-Globin-luciferase vector 
Primers Primer Sequence (5'-3)' 
MSB 4 For CATGTAGTCGACAGGACTCACTGGGAACCTCT 
MSB 4 Rev GATCTAGCTAGCCATCAGGGGGATGGATCT 
MSB 10 For CATGTAGTCGACCAGTGTGGTTTATGGTTTTGG 
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MSB 10 Rev GATCTAGCTAGCCAGAAAATTAAAGTGCGACCTC 
MSB 11 For CATGTAGTCGACAAAGAACTCGGAAGTGGACA 
MSB 11 Rev GATCTAGCTAGCCCATTTGGTCCTGTGAGATG 
MSB 18 For CATGTAGTCGACGCCAGGGCTTTACAGAGAA 
MSB 18 Rev GATCTAGCTAGCGGGTTGGAGTGAGTTTTTCC 
MSB 22 For CATGTAGTCGACCCCCTCCCTACACACATACA 
MSB 22 Rev GATCTAGCTAGCGAGGAAAAACACCACACCTG 
MSB22-short For GTCGACAGGGAGTGTGTGCTGGAAT 
MSB22-short Rev GCTAGCGAGCCTATGTCAATGGGTACA 
MSB 23 For CATGTAGTCGACCTGACCCAGACAGGACAAAC 
MSB 23 Rev GATCTAGCTAGCAGGGACCTTGGAGTCGTAAT 
MSB 24 For CATGTAGTCGACGGTCTCCATTTCTCCTTTGC 
MSB 24 Rev GATCTAGCTAGCTTGACCCCCTGACTGATTTA 
MSB24-short For GTCGACCCCAGAGGAAGAGAAAAAGG 
MSB24-short Rev GCTAGCTTGACCCCCTGACTGATTTA 
MSB 25 For CATGTAGTCGACCATCTGTTTTGCCTTTGTGTC 
MSB 25 Rev GATCTAGCTAGCCCATGCTAAATTCCTAGTGAGC 
MSB 26 For CATGTAGTCGACCGGGAAGAAGAAAGTGGAAC 
MSB 26 Rev GATCTAGCTAGCTGATTAGGAATGCTCCAGAAAC 
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Table 2.3 Primers for site-directed mutagenesis 
Primers for site directed mutagenesis of the TF binding motif sequences to generate 
mutant enhancers 
Primers Primer Sequence (5'-3)' 
MSB4-M1 For GCTCTCTCTCCAGTGTAGCCTCCAGGCCCTTGCTGC 
MSB4-M1 Rev GCAGCAAGGGCCTGGAGGCTACACTGGAGAGAGAGC 
MSB4-M2 For CTCTGAGTCCCCTGGGGCTCATCCAGCACTGGGTGTGAAAGCAG 
MSB4-M2 Rev CTGCTTTCACACCCAGTGCTGGATGAGCCCCAGGGGACTCAGAG 
MSB11-M1 For CCGGACTGTCCACATCTAGCCTGAGGAGCCAACACTGT 
MSB11-M1 Rev ACAGTGTTGGCTCCTCAGGCTAGATGTGGACAGTCCGG 
MSB11-M2 For GAGCCCCAAAGAACAAAGCCAATAGCCTTCTTTTCAGGTCCGATG 
MSB11-M2 Rev CATCGGACCTGAAAAGAAGGCTATTGGCTTTGTTCTTTGGGGCTC 
MSB11-M3 For CTGTTCTTGTGTGTTCTGCTTGAGCCCCAAAGAGTGCTGCCAACAGCTGTCTTTT 
MSB11-M3 Rev AAAAGACAGCTGTTGGCAGCACTCTTTGGGGCTCAAGCAGAACACACAAGAACAG 
MSB11-M5 For CTGTTCTTGTGTGTTCTGCTTGAGCCCCAAAGAGTGCTGCCAATAGCCTTCTTTT 
MSB11-M5 Rev AAAAGAAGGCTATTGGCAGCACTCTTTGGGGCTCAAGCAGAACACACAAGAACAG 
MSB18-M1 For CTTTCATGCCCCCAAGTAGCCTGTGCCACTCCAGACTC 
MSB18-M1 Rev GAGTCTGGAGTGGCACAGGCTACTTGGGGGCATGAAAG 
MSB18-M2 For TGCCTGCCTTGTGCTAGCCTCTCCCAGCTGCCCT 
MSB18-M2 Rev AGGGCAGCTGGGAGAGGCTAGCACAAGGCAGGCA 
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MSB18-M3 For GTGCCAGCTGCTCCTAGCCTCCCTGGCTGCAGGC 
MSB18-M3 Rev GCCTGCAGCCAGGGAGGCTAGGAGCAGCTGGCAC 
MSB18-M4 For GAAGGACCAGGCCAGAAACTGATTGTGCTGTCCCTCCAGGGGCCCC 
MSB18-M4 Rev GGGGCCCCTGGAGGGACAGCACAATCAGTTTCTGGCCTGGTCCTTC 
MSB18-M5 For CAGCTGGTGCCACTCCAGACTCGTGCTGGGAGGCTCATTCTAAACAGCG 
MSB18-M5 Rev CGCTGTTTAGAATGAGCCTCCCAGCACGAGTCTGGAGTGGCACCAGCTG 
MSB22s-M1 For GAGTGTCATCAATGTGGTTGTAGCCTCAGGGACTGTTCTCTGTGTG 
MSB22s-M1 Rev CACACAGAGAACAGTCCCTGAGGCTACAACCACATTGATGACACTC 
MSB22s-M2 For TCTGTGTGGTCCAAGTCACTCACTAGTGCTGCTGTCTTCTTGTATCCAGTC 
MSB22s-M2 Rev GACTGGATACAAGAAGACAGCAGCACTAGTGAGTGACTTGGACCACACAGA 
MSB22s-M3 For GTGTTTGTTCAGCATCTCTTGGCGTGCTGGGCAGAGTGTCATCAATGTGG 
MSB22s-M3 Rev CCACATTGATGACACTCTGCCCAGCACGCCAAGAGATGCTGAACAAACAC 
MSB24s-M1 For CTTTCAGCCTCTGCAGTAGGCTTTGGGAGGGCTCTGGA 
MSB24s-M1 Rev TCCAGAGCCCTCCCAAAGCCTACTGCAGAGGCTGAAAG 
MSB24s-M2 For GATGCAAAATCTGGACTGGATTTAAGTCCACTAGTGCAGGATTGAGTCTCTGCTTG 
MSB24s-M2 Rev CAAGCAGAGACTCAATCCTGCACTAGTGGACTTAAATCCAGTCCAGATTTTGCATC 
 
Table 2.4 DNA Oligonucleotides probes for EMSA experiments 
Probe Sequence (5'-3') 
MSB4-wt For ccagtgcagctgccaggcccttgctgcctctgagtcccctggggctcatccattgttgggtgt 
MSB4-wt RevCom acacccaacaatggatgagccccaggggactcagaggcagcaagggcctggcagctgcactgg 
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MSB4-M1 For ccagtgtagcctccaggcccttgctgcctctgagtcccctggggctcatccattgttgggtgt 
MSB4-M1 RevCom acacccaacaatggatgagccccaggggactcagaggcagcaagggcctggaggctacactgg 
MSB4-M2 For ccagtgcagctgccaggcccttgctgcctctgagtcccctggggctcatccagcactgggtgt 
MSB4-M2 RevCom acacccagtgctggatgagccccaggggactcagaggcagcaagggcctggcagctgcactgg 
 
 
Table 2.5 Expression vectors used in transfection and luciferase assays 
Plasmid Full-length cDNA Sources 
pCAGGs-Ascl1 rat Ascl1 Guillemot's lab 
pCAG-Sox2 mouse Sox2 Guillemot's lab 
pCMV-Sox11 mouse Sox11 Guillemot's lab 
pcDNA3.1-Sox4 mouse Sox4 Lovell-Badge's lab 
pCAGGs-Sox8 chick Sox8 Briscoe's lab 
pCAGGS-Ascl1-EnR† Guillemot's lab 
pCAG-Sox2-EnR† Guillemot's lab 
p-β-Globin-luciferase*  Guillemot's lab 
pCMV-β-Gal  Guillemot's lab 
 
† The cDNA sequence of Ascl1 or Sox2 is fused with the Drosophila Engrailed repressor domain. 
* All enhancer-containing-β-Globin-luciferase vectors used in the luciferase assays were generated as 
described in paragraph 2.3.1 and 2.3.2 for mutant enhancers. 
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Table 2.6 Expression vectors for protein synthesis for EMSA assays 
Plasmid Full-length cDNA Sources 
pcDNA3.1-Ascl1-E47 rat Ascl1 tethered to mouse E47 Guillemot's lab 
pcDNA3.1-Sox2 mouse Sox2 Cloned during this work 
pcDNA3.1-Sox4 mouse Sox4 Lovell-Badge's lab 
pcDNA3.1-Sox11 mouse Sox11 Cloned during this work 
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3. Genome-wide identification of neural enhancers 
regulated by Ascl1 and Sox2 
 
3.1 Introduction 
The work of this thesis aims to investigate interactions between the TFs (Transcription 
Factors) Ascl1/Mash1 and several Sox factors, primarily Sox2 as transcriptional 
regulators of neural enhancers in neurogenesis. Molecular data obtained in our lab 
through a genome-wide ChIP-seq approach (Chromatin Immunoprecipitations followed 
by high throughput sequencing) identified genomic elements in NS5 cells where Ascl1 
and Sox2 bind in close proximity. We first wanted to validate the ChIP-seq results and 
identify and characterise a discrete group of regulatory elements bound and regulated by 
Ascl1 and Sox2. For this purpose, we selected a group of genomic regions commonly 
bound by Ascl1 and Sox2 with ideal characteristics such as association to genes 
showing deregulation by the perturbation of the two TFs in microarray experiments. 
Following this, to strengthen the possibility that the bound regions identified act as 
regulatory elements, I analysed the expression pattern in the CNS, the telencephalon in 
particular, of the genes associated to the bound regions and the conservation of the 
genomic sequences among vertebrate species. Finally, to test the transcriptional activity 
of the identified genomic elements and dissect whether they could act as enhancers or 
repressive elements in neural stem cells I performed luciferase assays. In this chapter, 
selection of the bound regions and their features and characteristics are discussed. 
Results to prove their transcriptional potential are presented. 
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3.2 ChIP-seq identification of genomic regions bound by Ascl1 
and Sox2: computational analysis (Ben Martynoga’s data) 
The genomic elements characterized in this study were identified through a ChIP-seq 
approach. The first step towards the identification of genomic regions bound and 
regulated by Ascl1 and Sox2 is the validation of the data from ChIP-seq experiments, 
and the selection of elements with putative regulatory functions. ChIP-seq experiments 
were performed in the lab on NS5 cells to identify genome-wide regions bound by 
Ascl1 and Sox2. Dr. Ben Martynoga, a post-doc in our lab, performed the ChIP-seq 
experiments. This paragraph discusses the computational analysis that Ben Martynoga 
carried out in order to identify regions bound by both TFs. 
NS5 cells have characteristics of neural stem cells and endogenously express the TFs 
Ascl1 and Sox2 (Conti et al., 2005, Castro et al., 2011) (Figure 1.9 in Introduction). 
Antibodies against Ascl1 and Sox2 were used in two independent ChIP-seq experiments 
to obtain an Ascl1 immunoprecipitated chromatin and a Sox2 immunoprecipitated 
chromatin. Using this method, in an early ChIP-seq dataset 3154 bound regions were 
identified for Ascl1 and 3838 bound regions for Sox2. Aiming to identify genomic 
regions commonly bound by Ascl1 and Sox2, Ben Martynoga identified 281 elements 
where Ascl1 and Sox2 peaks (regions of significant binding defined by the MACS 
peak-caller - Model-based Analysis of ChIP-Seq data) overlapped by at least 1bp, 
suggesting that these two TFs might bind in close proximity on these regions (Figure 
3.1) (Zhang et al., 2008). Next, the bound regions were associated with their closest 
gene, upstream or downstream, since the purpose of the analysis was the identification 
genome-wide of the regions bound by the two TFs and their regulated genes. The 
assumption made is that the closest gene to the TF binding site is the most likely one to 
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be regulated by it. According to this, a list of 281 genes associated to genomic regions 
potentially bound by Ascl1 and Sox2 was generated. To further focus on genes likely to 
be directly regulated by Ascl1 and Sox2, the list of 281 genes associated to the bound 
regions was compared with 4304 genes showing de-regulation following perturbation of 
Ascl1 or Sox2 in microarray experiments in NS5 cells (previously performed in our 
lab). In these experiments either Ascl1 or Sox2, and their dominant repressive versions, 
Ascl1EnR or Sox2EnR, were overexpressed in NS5 cells and the effect on gene 
expression was analyzed. Ascl1-EnR and Sox2-EnR vectors consist of only the DNA 
binding domain of the TFs fused to the Drosophila Engrailed repressor (EnR) domain, 
which is able to repress the transcriptional activity of a bound region. As a result of the 
intersection of the ChIP-seq data and the microarray data, 40 genomic regions were 
finally identified as potentially bound and regulated by Ascl1 and Sox2 (Figure 3.1). 
About their genomic location, 50% of the 40 regions were intergenic and 50% were 
located within introns (data not shown). Also, in term of their distance from the 
transcriptional start site (TSS) of the closest gene, 30% of the regions were located at a 
distance farther than 100 Kb from the TSS (>100 Kb), 37.5% were between 10 and 100 
Kb, and finally 32.5% of them were located within 10 Kb from the TSS (<10 Kb). The 
40 regions of this early ChIP-seq dataset and their characteristics, such as their genomic 
coordinates, name of the closest gene associated to them, and distance from TSS, are 
listed in Table 3.1. Each genomic region has been given an arbitrary name or region ID 
as shown in the table. Hereafter in this thesis, the bound regions identified by ChIP-seq 
are named after their ID names.  
In conclusion, Ben Martynoga obtained from the computational analysis a list of 40 
regions bound and regulated by Ascl1 and Sox2 in an early ChIP-seq dataset available 
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when I started my project (Figure 3.1). A final dataset has been obtained by Ben 
Martynoga later during my project, as explained in paragraph 3.3.2  
  
 
Figure 3.1. Computational analysis of Ascl1 and Sox2 ChIP-seq data. 
The Venn diagrams show the computational analysis of the ChIP-seq data to identify candidate regulatory 
regions co-bound and regulated by Ascl1 and Sox2. Regions bound by Ascl1 and Sox2 were identified in 
two independent ChIP-seq experiments. 281 regions were identified as co-bound by both TFs (regions 
where Ascl1 and Sox2 peaks overlapped by at least 1 bp). The 281 co-bound regions were associated to 
the closest genes. The list of 281 genes was compared with a list of 4304 genes de-regulated by 
perturbation of Ascl1 and/or Sox2 obtained by microarray experiments previously performed in the lab. 
The purpose was to focus on genes likely to be regulated by the two TFs. As a result of the intersection of 
ChIP-seq and microarray data, 40 regions were identified as potentially bound and regulated by Ascl1 and 
Sox2. From Ben Martynoga, unpublished data. 
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Table 3.1. Genomic regions co-bound by Ascl1 and Sox2. 
The table shows the 40 regions co-bound and regulated by Ascl1 and Sox2 identified through 
computational analysis of ChIP-seq data. For each bound region, genomic coordinates, name of the 
closest gene associated to the region, and distance from the Transcriptional Start Site (TSS) are shown in 
the table. An arbitrary name was given to each region. This is shown in the first column of the table as 
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3.3 Selection of putative regulatory elements from Ascl1 and 
Sox2 co-bound regions identified by ChIP-seq 
Next, we aimed to identify candidate regulatory elements bound and regulated by Ascl1 
and Sox2 among the 40 regions identified by ChIP-seq. We randomly selected a 
discrete number of regions, in order to limit the number of elements to validate 
functionally in further experiments, as the initial number of 40 was too high. Moreover, 
for the regions randomly selected, we set out to determine whether they have properties 
of bona fide enhancers in terms of expression pattern of the associated genes, sequence 
conservation, and chromatin signature. These characteristics of the selected regions are 
described over the next four paragraphs. 
3.3.1 Expression pattern in the telencephalon of the genes associated to 
the bound regions 
For the bound regions selected, we considered the expression pattern of their associated 
genes. We focused on genes that are expressed in the mouse developing CNS, 
particularly in the telencephalon, since their expression pattern can be consistent with a 
regulation by Ascl1 and Sox2, also expressed in the telencephalon. Moreover, their 
expression can be indicative of a function in the development of the CNS.  We carried 
out an analysis of the expression patterns of these genes using publicly available in situ 
hybridization (ISH) data from the database Genepaint (http://www.genepaint.org/).  
The following 14 bound regions were chosen: MSB4, MSB9, MSB10, MSB11, 
MSB18, MSB22, MSB23, MSB24, MSB25, MSB26, NB1, NB2, NB3, and NB4. They 
are all associated to genes that are expressed in the telencephalon, as shown in Figure 
3.2. Therefore, they represent a good dataset of bona fide candidates for regulation by 
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Ascl1 and Sox2 (NB: The 3 peaks NB1, NB2 and NB3 are associated to the same 
closest gene: E030030I06Rik). From the 12 genes, 10 are expressed in the ventricular 
zone of the mouse telencephalon at embryonic stage E14.5, in the same expression 
domain of Ascl1 and Sox2. The other 2 genes, Lrp11 and Plxna2 (associated to peaks 
MSB22 and MSB24 respectively), show expression in the mantle zone (MZ) of the 
mouse telencephalon at the same stage E14.5 (Figure 3.2). 
We also analysed the sequence conservation of the selected bound regions among 
vertebrate species. This analysis is described in paragraph 3.3.3 since, for each element 
selected, it was extended to the entire larger putative regulatory region cloned into the 
reporter vector and tested for transcriptional assays rather than only to the ChIP-seq 
bound region identified, as better explained later. 
 
Figure 3.2. Expression pattern of the genes associated to the candidate bound 
regions. 
Mouse telencephalon sections, E14.5, ISH, from Genepaint. For each gene, gene name/region ID name is 
labeled at the bottom of the picture. Lrp11 and Plxna2 are expressed in Mantle Zone (MZ). All other 
genes are expressed in the Ventricular Zone (VZ). Expression pattern of Ascl1 and Sox2 at the same stage 
is also shown. 
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3.3.2 Validation of the selected Ascl1 and Sox2 co-bound regions by 
ChIP-qPCR 
To ensure the reliability of the ChIP-seq data and confirm recruitment of Ascl1 and 
Sox2, we performed ChIP-qPCR on the 14 bound regions selected as putative 
regulatory elements. 
Primers flanking the bound regions (Table 2.1 in Materials and Methods) were used to 
amplify these elements in chromatin from NS5 cells immunoprecipitated either with an 
α-Ascl1 antibody or with an α-Sox2 antibody compared with a mock 
immunoprecipitated chromatin as control. Delta1 and Fbw7 coding sequences (Dll1 
ORF and Fbw7 ORF) not precipitated by Ascl1 and Sox2 antibodies were used as 
negative controls (Figure 3.3). Enrichment of each region was given as fold change over 
the enrichment of negative controls. A threshold value of 2 was set, so that regions with 
enrichment higher than 2 were considered as positive and bound by Ascl1 and Sox2. 
For each region, values are shown in mock, α-Ascl1 and α-Sox2 immunoprecipitated 
chromatins for comparison. Hom2 and Sox21 represented positive controls as enhancers 
known to be regulated by Ascl1 and Sox2, respectively (Castro et al., 2006). Indeed, 
they were highly enriched in the respective α-Ascl1 and α-Sox2 immunoprecipitated 
chromatins, as shown in Figure 3.3.   
The following nine regions, MSB4, MSB10, MSB11, MSB18, MSB22, MSB23, 
MSB24, MSB25, and MSB26, were strongly enriched in both α-Ascl1 and α-Sox2 
immunoprecipitated chromatins, with values higher than 2, and therefore considered 
bound by Ascl1 and Sox2. Region MSB9 instead showed enrichment in α-Ascl1 
immunoprecipitated chromatin, but had a value lower than 2 in α-Sox2 
immunoprecipitated chromatin, therefore was excluded from our group of candidates, as 
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we were looking for genomic regions commonly bound by the two TFs. Finally, regions 
NB1, NB2, NB3, and NB4 were not precipitated compared to the negative controls and 
were therefore excluded from our group of candidates, as not bound by the two TFs. 
 
 
Figure 3.3. Validation of selected regions bound by Ascl1 and Sox2 by ChIP-
qPCR. 
Chromatin from NS5 cells immunoprecipitated with α-Ascl1 and α-Sox2 antibody compared to the mock 
immunoprecipitated chromatin.  Negative controls and positive controls on grey and violet background 
respectively. A total of 14 regions were tested, of which 10 were validated as bound by the 2 TFs, with 
fold enrichment values higher than 2, set as threshold (fold enrichment over the negative controls). 
Regions NB1, NB2, NB3, and NB4 were validated as not bound by Ascl1 and Sox2. 
 
These results of the ChIP-qPCR are consistent with final ChIP-seq data generated from 
Ben Martynoga later during my project (Figure 3.4). In his final dataset, Ben identified 
2910 regions co-bound by Ascl1 and Sox2. This result suggests that Ascl1 and Sox2 co-
binding occurs quite commonly in the neural stem cell genome.  When the 40 original 
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candidate regions from the earlier dataset were compared and overlapped with the final 
data, 27 of them were validated and confirmed as co-bound regions in the final ChIP-
seq dataset. The 9 regions I confirmed as bound by Ascl1 and Sox2 by ChIP-qPCR are 
included in the 27. However, 13 regions from the early 40 candidates were not validated 
in the final ChIP-seq dataset. These 13 include the 4 regions I could not confirm as 
bound in the ChIP-qPCR experiment.  
 
 
Figure 3.4. Comparison of early and final ChIP-seq data and ChIP-qPCR 
validation of regions bound by Ascl1 and Sox2. 
27 of the 40 candidate regions co-bound by Ascl1 and Sox2 from early ChIP-seq data have been validated 
also in the final ChIP-seq data. These include the 9 regions validated as bound by Ascl1 and Sox2 in 
ChIP-qPCR. 13 regions of the 40 co-bound from early data have not been validated in the final ChIP-seq 
data. These include the 4 regions that were considered not bound by Ascl1 and Sox2 according to ChIP-
qPCR results and therefore excluded from the dataset of the candidate enhancers. 
 
 
Chapter 3 – Results 
 106 
In conclusion, the ChIP-qPCR confirmed recruitment of both Ascl1 and Sox2 on 9 out 
of 10 regions. These genomic regions represent our dataset of putative regulatory 
elements bound by Ascl1 and Sox2. Our next aim was to functionally evaluate their 
transcriptional activity and their regulation by Ascl1 and Sox2. 
 
3.3.3 Sequence conservation of the genomic elements 
We looked at the sequence conservation of the bound regions among vertebrate species. 
Comparative genomics has successfully identified transcriptional enhancers among 
evolutionary conserved non-coding sequences in the vertebrate genome (Pennacchio et 
al., 2006, Visel et al., 2009b). Indeed, functional regulatory sequences tend to be 
evolutionary constrained, so that non-coding regions conserved and constrained among 
the genomes of different species are more likely to have a function as non-coding 
regulatory elements. With this notion, for each bound region to functionally test in 
transcriptional assay in my study, I cloned a full conserved genomic element into the 
luciferase-containing vector. As a result, the cloned region of DNA is longer than the 
size of the bound region identified by ChIP-seq for each putative enhancer. This 
reduced the likelihood of disrupting the enhancer by missing adjacent sequences that 
make up the entire regulatory element. The length of the genomic regions cloned in the 
luciferase reporter vector is shown in Table 3.2. Ben Martynoga assigned a PhastCons 
score to the conserved sequences with the PhastCons program (Siepel et al., 2005). 
PhastCons program identifies evolutionary conserved elements in a multiple alignment, 
given a phylogenetic tree. It assesses similarity/divergence of aligned sequences among 
species using statistical models of nucleotide substitution and generates a score that 
ranges between 0 and 1, with 0 for non-conserved regions and 1 for conserved regions. 
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PhastCons scores for each cloned region are shown in Table 3.2. As shown in the table, 
the analysis of the conservation demonstrated that among all regions, only 3 out of 9 
(MSB25, MSB24, and MSB26) exhibit the highest level of conservation. Region MSB 
18 shows modest level of conservation with a PhastCons score of 0.271. The remaining 
five regions (MSB4, MSB10, MSB11, MSB22, and MSB23) are only minimally 
conserved (Table 3.2). PhastCons diagrams from the UCSC genome browser in Figure 
3.5 show the area of conservation of genomic sequences among vertebrate species for 
the least conserved and the most conserved regions identified (Figure 3.5). 
In conclusion, the putative regulatory elements identified in this study showed little sign 
of evolutionary constraint, with only 3 regions out of 9 being highly conserved. 
 
Table 3.2. Sequence conservation and size of the putative regulatory elements 
cloned in luciferase vector. 
For each element bound by Ascl1 and Sox2 and selected as putative regulatory element, a full conserved 
genomic region was cloned in the luciferase reporter vector to assess its transcriptional function. The size 
of the genomic regions cloned are shown in the table. Evolutionary conservation of the regions in the 
genome of vertebrate species has been analysed using PhastCons program. A PhastCons score was 
assigned to each region, as shown in the table. The regions selected exhibited little sign of evolutionary 
constraint, with only 3 regions out of 9 being conserved: MSB 25, the most conserved, MSB 24, and 
MSB 26. MSB 18 exhibited a moderate conservation. All other 5 regions were only minimally conserved. 
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Figure 3.5. PhastCons diagram of sequence conservation. 
The sequence conservation among vertebrate species of the putative regulatory regions are shown in 
PhastCons diagrams for the least conserved region (MSB4) and the most conserved region (MSB25). For 
each region, the PhastCons score of conservation and the size of the genomic element cloned in the β-
globin luciferase vector to test in luciferase assay is shown.    
  
3.3.4 Recruitment of p300 on the bound regions: a hallmark for the 
identification of genomic enhancers 
Conservation of non-coding genomic sequences has proved to be limited in the 
identification of regulatory elements, as reported in literature (Visel et al., 2009b, Blow 
et al., 2010). As alternative, specific chromatin signatures have proved to be a valuable 
hallmark in the identification of genomic functional enhancers and other non-coding 
regulatory elements (Heintzman et al., 2007, Heintzman et al., 2009, Mikkelsen et al., 
2007, Creyghton et al., 2010). The recruitment of the transcriptional coactivator p300 is 
among these chromatin marks (Visel et al., 2009a, Blow et al., 2010, Visel et al., 2009b, 
Ghisletti et al., 2010). 
The histone acetyltransferase and transcriptional coactivator p300 is a component of 
enhancer-associated protein assemblies. It has been shown to accurately predict the 
genomic location and activity in vivo of developmental enhancers (Visel et al., 2009b, 
Visel et al., 2009a, Blow et al., 2010). The protein p300 is thought to increase gene 
expression mainly in three ways: by relaxing the chromatin structure at the gene 
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promoter through its intrinsic histone acetyltransferase activity; recruiting the basal 
transcriptional machinery including RNA polymerase II to the promoter; and acting as 
transcriptional adaptor molecule, which mediates specific protein-protein interactions 
and bridges the proteins on the enhancers with the transcriptional machinery on the 
promoter (Vo and Goodman, 2001). 
Therefore, to further confirm the nature of regulatory sequences for the candidate bound 
regions, we performed a ChIP experiment, using antibody against the protein p300. 
Primers flanking the bound regions (Table 2.1 in Materials and Methods) were used for 
amplification of these elements in chromatin from NS5 cells and enrichment of the 
precipitated regions was quantified by ChIP-qPCR. Dll1 ORF served as a negative 
control (on grey background in Figure 3.6), whereas Hom2 and Nes258 served as 
positive controls (on violet background in Figure 3.6), as known enhancers activated by 
Ascl1 and Sox2 (Tanaka et al., 2004). The experiment showed enrichment for p300 on 
all nine genomic regions tested, with fold enrichment values between 2 and 8 times that 
of the negative control. However, also the mock chromatin exhibited high values for 
each region. Nevertheless, the enrichment values for p300 are between 2 and almost 6 
times the mock values for all 9 regulatory regions analysed, supporting the idea that true 
binding of p300 occurs on these regions (Figure 3.5). 
In conclusion, we could confirm recruitment of p300 on all nine selected genomic 
elements, further suggesting their regulatory functions. Besides recruitment of p300, 
ChIP-seq data from Ben Martynoga also showed binding of the histone mark H3K27Ac 
on the bound regions supporting their nature of active enhancer (data not shown) 
(Martynoga et al., 2013).  
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Figure 3.6. Recruitment of the transcriptional coactivator p300 on the putative 
regulatory regions. 
ChIP-qPCR has been performed to quantify enrichment of the protein p300 on the putative regulatory 
regions in chromatin from NS5 cells immunoprecipitated with α-p300 antibody compared to mock 
immunoprecipitated chromatin from the same NS5 cells. All 9 regions tested were enriched and bound by 
p300 (fold enrichment over the ORF, negative control). Negative control and positive controls on grey 
and violet background respectively. 
 
 
3.4 Transcriptional activity of the genomic regions bound by 
Ascl1 and Sox2  
To test the regulatory functions of the nine genomic sequences, we performed 
transcriptional reporter assays. Each genomic element was cloned upstream of the β-
globin minimal promoter driving basal expression of the firefly luciferase gene, as 
described in paragraph 2.3.1 in Materials and Methods. 
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NS5 cells were co-transfected with each enhancer-containing luciferase vector and a 
constitutive lacZ reporter construct to normalise for transfection efficiency. Cells were 
harvested 24 hours after transfection to measure luciferase activity. Luciferase and ß-
galactosidase assays were performed in triplicates or quadruplicates and results 
presented as mean ± standard deviations (SD). The results shown are representative of 
two or three independent repeats.  
 
3.4.1 Basal activity of the bound regions: regulation by endogenous 
TFs in NS5 cells 
Figure 3.7 shows that all regions, except for MSB4 and MSB10, increased basal 
luciferase expression compared to the activity of the enhancer-less vector (empty 
vector). The increase ranged between 4-fold (for MSB22) and 16-fold (for MSB18) the 
activity of the empty vector. Therefore, the selected genomic sequences showed 
regulatory functions, in vitro, with characteristics of enhancers in neural stem cells. It is 
possible that they are activated by endogenous TFs in neural stem cells.  Only regions 
MSB4 and MSB10 did not show basal enhancer activity induced by endogenous TFs.  
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Figure 3.7. Transcriptional activity of the bound regions in neural stem cells by 
luciferase assay. 
Luciferase activity of the regions is expressed as fold change over the activity of the enhancer-less, empty 
vector used as negative control, on light blue background. Almost all regions show basal enhancer 
activity in NS5 cells. Luciferase activity values for almost all regions are between 4 and 16 fold the 
activity of the empty vector, with value of 1. Regions MSB4 and MSB10 do not show luciferase activity. 
Data are presented as the mean ± SD of quadruplicate assays. The experiment shown is representative of 
two independent biological replicates. 
 
3.4.2 Regulation of enhancer activity by Ascl1 and Sox2 
To determine the effect of TFs Ascl1 and Sox2 on the regulation of these elements, we 
tested enhancer activity by cotransfection experiments in NS5 cells. The expression 
vectors pCAGGs-Ascl1 and pCAG-Sox2 were cotransfected into NS5 cells with the 
enhancer-containing luciferase vectors, either alone or together. Cells were harvested 24 
hours after transfection to measure luciferase activity. In these experiments, the activity 
of each enhancer induced by Ascl1 and/or Sox2 overexpression was compared to the 
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As shown in Figure 3.8 A and C, exogenous Ascl1 increased the activity of seven 
enhancers compared to the GFP expression vector condition (MSB4, MSB18, MSB22, 
MSB26 in Figure 3.8A; MSB10, MSB11, and MSB25 in Figure 3.8C) (red bars in the 
graphs).  Similarly, exogenous Sox2 increased the activity of five enhancers (MSB23, 
MSB24 in Figure 3.8B; MSB10, MSB11, and MSB25 in Figure 3.8C) (green bars in the 
graphs), but in this case the activation was moderate. MSB24 and MSB25 revealed the 
highest activation by Sox2 (Figure 3.8B and C, respectively). Finally, when Ascl1 and 
Sox2 were overexpressed simultaneously in NS5 cells, six regions showed activation 
(MSB4, MSB18 in Figure 3.8A; MSB24 in Figure 3.8B; MSB10, MSB11, and MSB25 
in Figure 3.8C) (purple bars in the graphs). 
Interestingly, for almost all enhancers tested, the up-regulation by the two TFs 
overexpressed together was lower than that shown by the overexpression of each single 
TF, either Ascl1 or Sox2. This result suggests that the two TFs, Ascl1 and Sox2, 
counteract each other in the regulation of most co-bound regulatory regions (MSB4, 
MSB18, MSB22, MSB26 in Figure 3.8A; MSB23, and MSB24 in Figure 3.8B). More 
precisely, luciferase reporter assays revealed a potent activation of the regulatory 
regions MSB4, MSB18, MSB22 and MSB26 by Ascl1 (Figure 3.8A). However, when 
Sox2 was overexpressed together with Ascl1, Sox2 was able to block most of Ascl1’s 
ability to induce luciferase activity, suggesting that Sox2 antagonizes Ascl1 on these 
elements. It is possible that Sox2 counteracts Ascl1 in the activation of the target genes 
by competing with the latter TF for shared co-activators or general transcription factors 
(GTFs) when the two TFs are overexpressed together in the NS5 cells, and therefore as 
an effect of transcriptional squelching. Transcriptional squelching occurs when 
increasing concentrations of transcriptional activators paradoxically inhibit the 
transcription of a target gene by titrating one or more GTFs or co-activators in limited 
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supply within the host cell. This mechanism occurs particularly on episomal DNA and it 
is largely observed in transient transfection assays (Natesan et al., 1997).  
Overexpression of Sox2 alone did not have any effect on the activity of these four 
enhancers (MSB4, MSB18, MSB22 and MSB26). Conversely, two regions, MSB23 and 
MSB24, were upregulated by Sox2 and either not induced (MSB23) or repressed 
(MSB24) by Ascl1 in single overexpression of each TF (Figure 3.8B). In this case, 
when Ascl1 was overexpressed together with Sox2, Ascl1 was able to block most of 
Sox2’s ability to induce luciferase activity. Thus, Ascl1 antagonised Sox2 on these 
enhancers. Also in this case the mechanism of counteraction between the two TFs can 
result from transcriptional squelching associated to the experimental conditions of 
transient transfection assays. Finally, on three other regions, MSB10, MSB11, and 
MSB25, the two TFs had a neutral interaction, where the activity in the single and 
double overexpression was very similar (Figure 3.8C). Evidence of synergistic activity 
was not seen on any of the tested enhancers (Figure 3.8A, B, and C). Taken together, 
these findings suggest that Ascl1 and Sox2 act as independent regulators of the 
enhancers identified in this study, and antagonise each other in the regulation of 6 of the 
9 enhancers characterised. 
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Figure 3.8. Interaction of Ascl1 and Sox2 in the regulation of the neural enhancers. 
Neural enhancers were transfected in NS5 cells together with expression vectors for Ascl1 and Sox2 
overexpressed either alone or together. Luciferase activity was measured after 24 hours. For each 
enhancer, luciferase activity is expressed as relative to the activity of the GFP expression vector used as 
control. All 9 enhancers were regulated by exogenous Ascl1 and Sox2. Enhancers in group A were 
strongly activated by exogenous Ascl1 while Sox2 counteracted Ascl1-induced activation when the 2 TFs 
were simultaneously overexpressed in NS5 cells (A). Enhancers in group B were activated by exogenous 
Sox2 whereas Ascl1 counteracted Sox2-induced activation when the 2 TFs were simultaneously 
overexpressed (B). Enhancers in group C showed a neutral interaction between the 2 TFs with the activity 
by exogenous Ascl1 and/or Sox2 being very similar when the 2 TFs were overexpressed either alone or 
together (C). Ascl1 and Sox2 counteract each other in the regulation of 6 out of 9 enhancers (A and B). 
Synergistic activation by the 2 TFs was not observed on any of the enhancers identified. Data are 
presented as the mean ± SD of triplicate assays. The experiment shown is representative of three 
independent biological replicates. 
 
3.4.3 Classification of the enhancers: neural stem cells and neuronal 
enhancers 
Cotransfection experiments demonstrated that Ascl1 and Sox2 counteract each other in 
the regulation of almost all enhancers identified. These experiments also revealed that 
two different patterns of counteraction occur for different enhancers, with some 
activated by Ascl1 and inhibited by Sox2, and others activated by Sox2 and repressed 
by Ascl1. Given that distinct patterns of interaction for the nine enhancers identified are 
possible, we attempted a classification of the enhancers to clarify and understand the 
nature of the transcriptional interaction between Ascl1 and Sox2. The effect of the 
overexpression of the TF Ascl1 on the cellular and molecular context in the neural stem 
cells was also addressed in the classification. It is known that overexpression of Ascl1 
in neural stem cells induces neuronal differentiation (Lee et al., 1995, Farah et al., 
2000). After 24 hours of Ascl1 overexpression, at the time when luciferase activity was 
measured in my experiments, NS5 cells have acquired characteristics of neurons 
(Martynoga, unpublished data, and data not shown). Therefore, we classified the 
enhancers activated by overexpression of Ascl1 as neuronal enhancers active in 
differentiating neurons. According to this, we distinguished enhancers active in neural 
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stem cells from neuronal enhancers. The first category includes enhancers that exhibit 
basal luciferase activity in NS5 cells, therefore neural stem cell active enhancers (Figure 
3.9A). The second category includes enhancers activated by overexpression of Ascl1 in 
NS5 cells, therefore neuronal enhancers (Figure 3.9C). Figure 3.9 illustrates this 
classification made on the basis of basal activity and/or activation by exogenous Ascl1 
shown by the enhancers in luciferase assay experiments.  Enhancers MSB23 and 
MSB24 are examples of enhancers active in neural stem cells (Figure 3.9 A). They 
show basal activity in NS5 cells, but are not activated by exogenous Ascl1. Enhancers 
MSB4 and MSB10 are examples of neuronal enhancers (Figure 3.9 C). They are 
activated by exogenous Ascl1 but do not show basal activity in NS5 cells. The 
remaining 5 enhancers MSB11, MSB18, MSB22, MSB25, and MSB26 show both basal 
activity in NS5 cells and activation by exogenous Ascl1. Therefore they have been 
classified as both neural stem cell active enhancers and neuronal enhancers (Figure 3.9 
B).  
The effect of the overexpression of Sox2 on the regulation of the enhancers was also 
considered and added to the classification. In this way, we identified and distinguished 
enhancers activated by exogenous Sox2 from enhancers inhibited by exogenous Sox2 
(where Sox2 inhibited Ascl1 activity when the two TFs were overexpressed together). 
This second classification is shown in Figure 3.10. The first group includes MSB23, 
MSB24, MSB10, MSB11, and MSB25. These enhancers are either neural stem cell 
active enhancers or NSC/Neuronal enhancers (Figure 3.10 A and B). The second group 
includes the remaining enhancers shown in Figure 3.10 C. These enhancers are NSC 
active/Neuronal enhancers. This group also includes the neuronal enhancer MSB4. 
Table 3.3 summarizes the entire classification of the enhancers. 
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Figure 3.9. Classification of neural stem cells and neuronal enhancers. 
Enhancers have been classified on the basis of the exogenous activation of Ascl1 and the basal enhancer 
activity in neural stem cells. (A) Enhancers with basal luciferase activity in NS5 cells have been classified 
as enhancers active in neural stem cells. (C) Enhancers activated by exogenous Ascl1 have been classified 
as neuronal enhancers, due to the neuronal differentiation induced by overexpression of Ascl1 in NS5 
cells. (B) Enhancers displaying basal luciferase activity in NS5 cells and activated by exogenous Ascl1 
have been classified as both enhancers active in NSCs and neuronal enhancers. (NSC=Neural Stem Cell) 
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Figure 3.10. Classification of the enhancers activated by exogenous Sox2 or 
inhibited by exogenous Sox2. 
Enhancers in both group A and B are activated by exogenous Sox2. Enhancers in group A are NSC active 
enhancers only, according to previous classification in Figure 3.9A. Enhancers in group B are both NSC 
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Table 3.3. Classification of enhancers. 
The Table summarizes the full classification of the enhancers. These have been divided as NSC active 
only or NSC &/or neuronal (rows) if they only display basal luciferase activity in NS5 cells (first group) 
or also activation by exogenous Ascl1 in NS5 cells. This first classification has been done to consider the 
effect of exogenous Ascl1 in NS5 cells, which induces neuronal differentiation and therefore changes the 
cellular and molecular context of the NS5 cells. The enhancers have also been divided as activated by 
exogenous Sox2 or inhibited by Sox2 (= Sox2 inhibits Ascl1-induced activation) (columns). 
 
3.5 Regulation of the neural enhancers by Ascl1-EnR and 
Sox2-EnR 
To further confirm the role of Ascl1 and Sox2 in the regulation of the genomic elements 
through direct DNA binding, dominant repressor forms of the 2 TFs were also 
transfected in NS5 together with enhancer-containing vectors and tested in the 
luciferase assay. The dominant repressor forms, Ascl1-EnR and Sox2-EnR, as 
mentioned earlier, consist of the DNA binding domains of the respective TF fused to 
the engrailed repressor domain, which represses the transcriptional activity of the bound 
region. Also in this case the activity of each enhancer in the presence of the dominant 
repressor forms, Ascl1-EnR or Sox2-EnR, was compared to the activity of the same 
enhancer driven by GFP expression vector used as control.  As expected, all nine 
enhancers were repressed by Sox2-EnR (Figure 3.11). Almost all enhancers were also 
repressed by Ascl1-EnR. However, enhancers MSB11 and MSB24 showed no 
repression by Ascl1-EnR, suggesting that Ascl1 contributes little to their basal activity 
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(Figure 3.11). In conclusion, these experiments suggest that the regulation of enhancer 
activity is driven through direct binding of Ascl1 and Sox2, confirming the role of the 
two TFs in the regulation of the enhancers here characterised. 
 
 
Figure 3.11. Repression of the enhancer activity by Ascl1-EnR and Sox2-EnR. 
Each enhancer was transfected in NS5 cells together with Ascl1-EnR or Sox2-EnR expression vectors. 
Transcriptional activity of the enhancers was measured. All enhancers were repressed by Sox2-EnR 
compared with the activity of the GFP negative control. Enhancers were repressed by Ascl1-EnR with the 
exception of enhancers MSB11 and MSB24. Results of this experiment suggest that Ascl1 and Sox2 




The objective of part of this study was the identification and in vitro characterisation of 
neural enhancers regulated by the TFs Ascl1 and Sox2. Moreover, this study also aimed 
to dissect the nature of the possible interaction between Ascl1 and Sox2 as 
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We started this study with the identification by ChIP-seq of genomic regions where 
Ascl1 and Sox2 could bind in close proximity, suggesting their recruitment on common 
genomic elements. This molecular data set us to investigate any possible interaction 
between the two proteins.  
The computational analysis and the results described in this chapter had primarily the 
purpose to validate the ChIP-seq data and select genomic elements with characteristics 
of regulatory regions. The regions selected were co-bound by Ascl1 and Sox2, 
according to ChIP-seq data. They were associated to genes de-regulated by perturbation 
of Ascl1 and Sox2 according to microarray data. The genes associated to the regions 
were also expressed in the telencephalon of the developing CNS, and some of them in 
the same expression domain of Ascl1 and Sox2 (Figure 3.2). These features strengthen 
the possibility of a functional regulation by Ascl1 and Sox2.  
The sequence conservation of the putative regulatory regions among vertebrate species 
was also considered, since comparative genomic approaches have led to successful 
identification of many functional enhancers. These approaches are based on the notion 
that the sequences of regulatory elements tend to be evolutionary constrained among 
different species, due to the deleterious consequences of their changes (Visel et al., 
2009b). However, in our case the PhastCons analysis revealed that the majority of the 
identified genomic sequences were poorly conserved, with only 3 out of 9 elements 
having score close to 0.5, a medium value of conservation. Indeed, it has been emerging 
that genomic constraint of regions could suffer from some limitations in the 
identification of enhancers. A large part of them are not evolutionary constrained. 
Interestingly, a work by Blow et al. characterized functional active heart enhancers 
weakly conserved among vertebrate species (Blow et al., 2010), identifying a large 
population of developmental enhancers escaping negative evolutionary selection.  
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Recruitment of the transcriptional coactivator p300 has been shown to accurately 
predict the genomic location of active enhancers (Visel et al., 2009a, Blow et al., 2010, 
Ghisletti et al., 2010). Therefore, we analysed the recruitment of this transcriptional 
coactivator on the selected bound regions to strengthen the assumption that they 
function as regulatory regions. ChIP experiment for the protein p300 and ChIP-qPCR 
showed binding on all nine selected genomic elements, suggesting their nature of 
enhancers. This result is also consistent with a p300 ChIP-seq dataset obtained in the 
lab, where peaks were called on the same genomic elements tested here (Martynoga et 
al., 2013).   
At a molecular level, by ChIP-qPCR we could prove that 9 out of the 14 selected bound 
regions were enriched in chromatin from NS5 cells immunoprecipitated with α-Ascl1 
and α-Sox2 antibody, suggesting binding of the two TFs on the same genomic 
elements. At a functional level, we were able to prove that these elements acted as 
enhancers regulated by Ascl1 and Sox2. The elements were tested by luciferase assays 
and most exhibited basal enhancer activity in vitro in NS5 cells, with the exception of 
MSB4 and MSB10, possibly responding to the regulation by endogenous TFs in neural 
stem cells. When testing the effect of the overexpression of Ascl1 and/or Sox2 on the 
activity of the enhancers, they were all responding to their regulation, although in 
different ways. More precisely, 7 out of 9 regions were activated by Ascl1 and 5 out of 
9 were activated by Sox2. However Ascl1 acted as a strong positive regulator of the 
enhancers, increasing the activity of the regions between 2 and 16 fold the activity of 
the GFP control vector. Only MSB24 was repressed by Ascl1. The activation by Sox2 
was often very modest instead. MSB24 and MSB25 showed the highest activation by 
Sox2, but this never exceeded 4 times the activity of GFP control vector. Therefore, it 
can be concluded that most enhancers were more responsive to exogenous Ascl1 than 
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Sox2, besides the suggested recruitment and binding of both TFs on the regions 
characterised. 
The other interesting result emerging from the transcriptional assay was that Ascl1 and 
Sox2 counteracted each other in the regulation of 6 out of 9 enhancers. Specifically, 
Sox2 inhibited Ascl1 activation on MSB4, MSB18, MSB22, and MSB26 which were 
also the enhancers showing the highest activation by Ascl1. Conversely, Ascl1 blocked 
Sox2 activation on enhancers MSB23 and MSB24, with this last one being the enhancer 
activated most potently by Sox2. Mechanisms of transcriptional squelching might 
account for the counteraction observed when the two TFs are overexpressed together in 
co-transfection experiments. A synergistic interaction between the two TFs was never 
seen on the enhancers identified in this study. 
Since the effect of Ascl1 and Sox2 on the regulation of the enhancers was tested by 
overexpression in NS5 cells, the effect of their gain of function on the neural stem cell 
fate needed to be considered. In this study, the effect of the simultaneous 
overexpression of Ascl1 and Sox2 on the neural stem cell fate in vivo was not evaluated. 
However, it is known that gain of function of bHLH proneural proteins, including 
Ascl1, can induce a neuronal fate in undifferentiated progenitor cells (Lee et al., 1995, 
Farah et al., 2000). NS5 cells start to differentiate into neurons already 24 hours after 
transfection of Ascl1 (Martynoga, unpublished data). Therefore, we classified the 
enhancers as active in neural stem cells or neuronal enhancers if they displayed basal 
activity in NS5 cells or were induced by exogenous Ascl1, respectively. Some 
enhancers were active in both cellular and molecular context, therefore were classified 
as both active in neural stem cells and as neuronal enhancers when induced by 
overexpression of Ascl1.  
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In conclusion, the results described in this chapter have identified a group of functional 
neural enhancers in vitro among genomic regions identified through a ChIP-seq 
approach. The TFs Ascl1 and Sox2 were able to regulate the identified enhancers, as 
predicted by their recruitment on the sequences. However, Ascl1 was the strongest 
activator of these elements, whereas Sox2 showed only a modest activation on a smaller 
number of the identified elements. Intriguingly, Ascl1 and Sox2 counteract each other 
in the regulation of most of these enhancers and never appear to interact synergistically 
in the regulation of the regions where they are commonly recruited. Finally, as shown 
from the classification of the 9 enhancers characterised in this study, even within a 
small group of enhancers there is much diversity of regulation, suggesting rather 
complex interactions between Ascl1 and Sox2.     
The identification of TFBSs (Transcription Factor Binding Sites) for Ascl1 and Sox2 
and their involvement in driving the enhancer activity was necessary for further 
characterisation of these enhancers and their mechanisms of transcriptional regulation. 
Such work is described in the next chapter. 
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4. Identification of the E-boxes and Sox binding motifs 




In the previous chapter I demonstrated that the TFs Ascl1 and Sox2 act as regulators of 
the neural enhancers identified. In this chapter, I identified Transcription Factor Binding 
Sites (TFBSs) or Binding Motifs (BMs) for Ascl1 and Sox2 in the sequence of the 
enhancers to assess their role in the enhancer activity and to infer if the regulation 
occurs through direct DNA binding of the TFs to their motifs. To evaluate the function 
of the consensus motifs, I introduced point mutation in their sequences to assess if the 
activity of the enhancers was compromised when TF binding motifs were lost. 
Transcriptional assays of mutant and wt enhancers were performed to answer to this 
question.  
4.2 E-boxes and Sox binding motifs in the neural enhancers 
Transcription factors binding motifs were identified using the TESS software 
(Transcription Element Search System) (http://www.cbil.upenn.edu/cgi-
bin/tess/tess). A list of E-boxes and Sox consensus motifs searched within the 
enhancer sequences is shown in Table 4.1. More precisely, two known E-boxes, E1-box 
and E2-box, were searched as Ascl1 binding motifs (Castro et al., 2006). Several known 
motifs were searched for Sox factors, which all exhibit a preference for the hexameric 
core sequence 5′-WWCAAW-3′, where W indicates A or T (Lefebvre et al., 2007). In 
particular, I searched for the following Sox consensus motifs using the TESS software: 
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the Sox motif identified in the Nestin enhancer and bound by Sox2, as reported by 
Tanaka and colleagues, thus named as Sox Nestin in Table 4.1 (Tanaka et al., 2004); a 
Sox 5 motif obtained from the Jaspar database (Sandelin et al., 2004); two Sox motifs, 
named Sox b and Sox trawl-a in Table 4.1, obtained by Ben Martynoga in a de novo 
motif analysis of Sox2 ChIP-seq data and using the Trawler database (Ettwiller et al., 
2007). All 9 enhancers characterized in this project have at least one binding motif for 
Ascl1 and one binding motif for Sox2. However, no clear similarities in the architecture 
of the enhancers were observed, in term of motif numbers, order, positioning, and 
spacing. The binding motifs identified in the enhancer sequences are shown in Figure 
4.1. E-boxes are shown as red triangle and Sox motifs in green. The purple rectangle 
shows the region where Ascl1 and Sox2 ChIP-seq peaks overlap within the enhancer, 




Table 4.1. Binding Motifs consensus sequences within neural enhancers. 
The BMs consensus sequences listed in the table were searched within the neural enhancers using the 
TESS software to identify E-box and Sox motifs for Ascl1 and Sox factors. The mutated sequences for 
each consensus are also shown in the table. The positions and the nucleotide substitutions are shown in 
red and are underlined. Consensus motifs were obtained from the literature and/or from on line databases, 
such as Jaspar and Trawler, as indicated by the references. The two E-boxes described in Castro et al., 
2006 were mutated also as according to Castro et al., 2006. Sox motifs were all mutated in a similar way, 
according to the nucleotide substitutions of the Nestin core sequence introduced in Tanaka et al., 2004. 
 




Figure 4.1. E-boxes and Sox motifs within the neural enhancers. 
Segments represent the enhancer sequences. The sequence length is shown for each enhancer. E-boxes 
and Sox motifs are represented as red and green triangles respectively, as shown in the legend. Regions 
where Ascl1 and Sox2 ChIP-seq peaks overlap are shown as purple rectangles, as also shown in the 
legend. The numbers indicate the nucleotide positions in the cloned sequence of the enhancer, and they 
indicate the position of the first nucleotide of the binding motif for the E-boxes and the Sox motifs, under 
the red and green triangle respectively. For instance, enhancer MSB4 has a sequence of 336 base pair. 
164 and 209 indicate the position of the first nucleotide of the E-box and Sox motif in the sequence, 
respectively. Therefore the distance between the two binding motifs is 39 bp (209-164-6bp). The region 
where Ascl1 and Sox2 ChIP-seq peaks overlap is between nucleotide 107 and 209 in the cloned sequence 
of the enhancer. 
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To assess if TFs regulate enhancer activity through direct binding to the DNA 
consensus motifs, I introduced point mutation in the motif sequences known to disrupt 
the binding (Tanaka et al., 2004, Castro et al., 2006). In particular, mutations disrupted 
the E-boxes so that Ascl1 should not bind the sequence. Nucleotide substitutions were 
introduced in the two E-boxes as described in Castro et al. (Castro et al., 2006). All Sox 
motifs identified were mutated in the same way so that any Sox factor should not bind 
the sequence. Nucleotide substitutions were introduced in the core positions of the Sox 
motifs as described for the Nestin enhancer in Tanaka et al. (Tanaka et al., 2004). Table 
4.1 shows all point mutations introduced in the binding motifs. The transcriptional 
activity of the mutant and wt enhancers were tested and compared in transcriptional 
assays in vitro in NS5 cells, with the same experimental approach previously described 
for the wt enhancers. 
The following enhancers were mutated, choosing at least one from each class of neural 
stem cell active or neuronal enhancers, with different effects of exogenous Ascl1 and 
exogenous Sox2 activity: enhancers MSB4 (neuronal enhancer), MSB18, and MSB22 
(NSC active and neuronal enhancers) (all these three enhancers are activated by 
exogenous Ascl1 and inhibited by exogenous Sox2); MSB24 (NSC active enhancer, 
activated by exogenous Sox2 and inhibited by exogenous Ascl1); MSB11 (NSC active 
and neuronal enhancer for which no apparent interactions were observed between Ascl1 
and Sox2). To limit the number of binding motifs analysed, for enhancers MSB22 and 
MSB24, I cloned a shorter enhancer element limited to the region where Ascl1 and 
Sox2 ChIP-seq peaks overlap (Figure 4.1, purple rectangles, see diagrams for MSB 22 
and MSB 24). In this way, I limited the mutagenesis analysis to the motifs located in the 
region where the two TFs overlap and bind in close proximity, according to the ChIP-
seq data. The new elements were named MSB22-short and MSB24-short and their 
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activity was tested and compared to the full-length elements MSB22 and MSB24 
(Figures 4.2C and G; 4.3E and H). Enhancer-constructs carrying mutations in each 
single binding motif were generated. Constructs with more mutated motifs combined in 
the same elements were also generated for some enhancers. 
 
4.3 Mutations in the sequence of the binding motifs affect 
enhancer activity 
4.3.1 Basal transcriptional activity of the mutant enhancers 
Mutant and wild-type enhancers were cotransfected in NS5 cells and their basal 
transcriptional activity were tested and compared to the activity of the enhancer-less 
vector (empty vector) by luciferase assay. These experiments should suggest if 
endogenous Ascl1 and Sox2 or other endogenous bHLH and Sox factors expressed in 
the NS5 cells can induce the activity of enhancers in NSCs through direct binding to the 
E-boxes and Sox motifs. Indeed Ascl1 and other bHLH factors bind the same E-boxes, 
and Sox2 and other Sox factors bind the same Sox motifs. The activity of the enhancers 
carrying disrupted motifs should be reduced compared to the activity of the wt 
sequences if binding and regulation by these endogenous TFs occur. 
4.3.1.1 MSB18 Mutants basal activity 
MSB18 is both an enhancer active in neural stem cells since it displayed basal luciferase 
activity in NS5 cells, and a neuronal enhancer induced by overexpression of Ascl1 
(Figure 3.9B, chapter 3). A total of five binding motifs, among E-boxes and Sox motifs, 
were identified in its sequence (Figure 4.2B). Four of them were located in the 
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overlapping binding peaks for Ascl1 and Sox2, and only 1 Sox motif was found out of 
the peak, 85 bp away from the E-box 1. All motifs were mutated individually, 
generating five mutant elements, named M1 to M5 as shown in the diagram.  
Mutation and loss of E-box2 (MSB 18 - M2), E-box3 (MSB 18 - M3), or Sox motif 2 
(MSB 18 - M5) strongly reduced the basal activity of these elements compared with the 
activity of the wt sequence (Figure 4.2A). This result suggests that endogenous TFs 
binding to these motifs, possibly Ascl1 and Sox2 among them, accounted for the basal 
activity of the enhancer observed in neural stem cells. Sox motif 1 (MSB 18 - M4) 
showed a minor reduction, while the luciferase activity of MSB 18 - M1 (E-box1 
mutant) did not show any change compared with the WT, suggesting that this motif did 
not contribute to the enhancer activity in response to endogenous TFs in NS5 cells.  
4.3.1.2 MSB22-short Mutants basal activity 
MSB22 is also both an enhancer active in neural stem cells since it displayed basal 
luciferase activity in NS5 cells, and a neuronal enhancer induced by overexpression of 
Ascl1 (Figure 3.9B, chapter 3). As mentioned earlier, MSB22-short was cloned as 
shorter element of enhancer MSB22 full-length. Thus, we analysed the input of one E-
box and two Sox motifs in the regulation of MSB22-short (Figure 4.2D). Mutation and 
loss of the E-box (MSB 22 short – M1) or Sox motif 1 (M2) reduced the activity of 2-
fold compared with MSB22-short WT (Figure 4.2C), whereas mutation of Sox motif 2 
(M3) did not affect the enhancer activity. Also the activity of the mutant elements where 
mutations of motifs were combined together showed a reduction of the activity 
compared with the wt sequence, although the combination of mutated motifs did not 
further affect the reduction as it could be expected (Figure 4.2C). Altogether, this data 
indicate that endogenous Ascl1 and Sox2 expressed in NS5 cells might activate this 
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enhancer in neural stem cells through direct binding to the motifs identified, precisely 
the E-box and Sox motif 1.  
4.3.1.3 MSB 4 Mutants basal activity 
MSB4 is a neuronal enhancer activated by overexpression of Ascl1 in NS5 cells (Figure 
3.9C, chapter 3). We found one E-box and one Sox motif in its sequence in the region 
where Ascl1 and Sox2 ChIP-seq peaks overlap, suggesting DNA binding of the two TFs 
to the same core region of the enhancer (Figure 4.2F). Mutation and loss of the E-box 
and Sox motif in MSB4 did not affect the transcriptional activity of the enhancer 
(Figure 4.2E). This result is consistent with the lack of basal activity showed by the 
MSB4 enhancer in the neural stem cells, and suggests that binding of endogenous Ascl1 
and Sox factors to this element was not sufficient to induce enhancer activity. 
Conversely, the combined mutation of the two binding motifs in mutant element M3 
increased the enhancer activity compared with the wt element, suggesting that factors 
binding to the E-box and Sox motif may actually repress this enhancer (Figure 4.2E). 
4.3.1.4 MSB24-short and MSB11 Mutants basal activity 
MSB24 is an enhancer active in neural stem cells, due to the basal luciferase activity 
shown in NS5 cells (Figure 3.9A, chapter 3). MSB11 is both an enhancer active in 
neural stem cells, and a neuronal enhancer activated by overexpression of Ascl1 in NS5 
cells (Figure 3.9B, chapter 3). The binding motifs identified in these enhancers are 
shown in the diagrams in Figure 4.2H and J, respectively. The basal activity of MSB24-
short is slightly increased compared with the activity of the full-length enhancer, 
suggesting that binding motifs located in the sequence outside the overlapping Ascl1 
and Sox2 ChIP-seq peaks could repress the activity of the full-length element (Figure 
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4.2G). Mutations and loss of the binding motifs in MSB24-short and MSB11 (Figure 
4.2G and I) did not affect the basal activity of the enhancers or only showed a minor 
reduction, respectively, suggesting that the binding motifs identified and mutated did 
not give great contribution to the transcriptional activity of these elements and to their 
regulation by endogenous TFs in neural stem cells (Figure 4.2G and I).  
In conclusion, the results of the mutagenesis analysis showed that loss of the E-box and 
Sox motifs affected the basal transcriptional activity of some enhancers, such as MSB18 
and MSB22-short. However, other enhancers were not affected when their BMs were 
lost, such as MSB4, MSB24-short, or only showed minor reduction, as for MSB11. 
Furthermore, results also distinguished between different BMs within the same 
enhancer, with some involved in the regulation of the element, as showed by a change 
in the activity of their mutants, and others excluded. Overall, basal luciferase activity of 
some mutants could suggest an input of endogenous Ascl1 and Sox2 in the regulation of 
some enhancers, as for MSB18 and MSB22-short. However, for the other elements, 
MSB24-short, MSB11, and MSB4, loss of the E-box and Sox motif did not greatly 
affect the basal activity of the mutant enhancers. This result might indicate that the BMs 
identified and mutated, and therefore endogenous Ascl1 and Sox2 among the TFs 
possibly binding these sites, did not account for the basal transcriptional activity of the 
enhancers in neural stem cells, as it seems the case for MSB24-short. This element was 
active in the neural stem cell context, as shown in the previous chapter, and was 
activated by exogenous Sox2. Therefore, the results of the mutagenesis suggest that 
other binding motifs here not identified are involved in the regulation of the basal 
activity in NS5 cells. It is also possible that TFs, such as Sox2, bind other less canonical 
motifs and/or regulate the element via indirect DNA binding. In the case of MSB4 
however the result is compatible with the lack of basal activity showed by the wt 
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enhancer in neural stem cells. MSB4 is a neuronal enhancer activated by exogenous 
Ascl1 in differentiating neurons. However, this element is not active in the neural stem 
cell context, as shown in the previous chapter. 

















Figure 4.2. Mutagenesis of the E-box and Sox motifs affects basal luciferase 
activity of the enhancers. 
Wt and mutant enhancers carrying disrupted E-box and Sox motifs were cotransfected in NS5 cells. 
Luciferase activity was measured 24 hours after transfection. Luciferase activity was normalised to the 
activity of the empty vector (on blue background in the pictures). Data are presented as the mean ± SD of 
triplicate assays. Mutant enhancers carrying mutation of a single motif are shown on purple background 
and mutant enhancers carrying combined mutations of more than one motifs are shown on yellow 
background. Panels B, D,F, H, and J represent diagram of each enhancer as in Figure 4.1 and the 
sequence of the motifs within each element. Mutated motifs are labeled in blue at the top of the sequence 
and mutated nucleotides are shown in red. Distances between adjacent motifs are shown as purple arrows 
at the top of the wt element. (A) In enhancer MSB18, mutations of the E-box 2, E-box 3, and Sox motif 2 
strongly reduced the basal activity of the mutant elements compared to the wt (as indicated by the black 
arrows). Mutation of the motifs in mutant elements M4 and M1 show a minor reduction or no change in 
their activity compared with the wt element, respectively. (C) In enhancer MSB22-short, shorter element 
of enhancer MSB22 full-length (corresponding to the purple rectangle in panel D, see text for full 
explanation), only mutation of the E-box (mutant element M1) and Sox motif 1 (element M2) reduced the 
basal activity of the mutant compared with the wt short enhancer. Also mutant elements M4 to M7 with 
combined mutations of motifs (on yellow background) exhibited reduced basal activity compared with 
the wt, but combination of mutated motifs did not further affect the reduction. (E) Mutation of the E-box 
and Sox motif did not change the basal activity of mutant elements M1 and M2 compared with the wt 
enhancer MSB4. Combined mutation of the two binding motifs in mutant element M3 increased the 
enhancer activity compared with the wt element (as indicated by the arrow). (G) and (I) Mutations of the 
E-box and Sox motifs in enhancers MSB24-short and MSB11 did not change or only slightly reduced the 
basal activity of these elements. Basal activity was not changed or only slightly reduced also when 
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4.3.2 Mutagenesis of the E-box and Sox motifs affects the regulation by 
exogenous Ascl1 and Sox factors in the neural enhancers  
Mutant and wt enhancers were cotransfected in NS5 cells together with expression 
vectors for Ascl1 and Sox2 overexpressed either alone or simultaneously. After 24 
hours, cells were harvested and the luciferase activity of the mutant and wt enhancers 
were measured and compared. The purpose of this experiment was to understand if 
mutations of the binding motifs could affect the regulation by exogenous Ascl1 and 
Sox2, suggesting that the two TFs regulate the enhancers through direct DNA binding 
to their motifs. For each enhancer, the luciferase activity was expressed as relative 
luciferase activity compared to the activity of the same construct after overexpression of 
a GFP expression vector used as control.  
4.3.2.1 The neuronal enhancer MSB4 
MSB4 is a neuronal enhancer strongly activated by exogenous Ascl1 overexpressed in 
NS5 cells. Overexpression of Sox2 counteracts Ascl1-induced activity of this element 
(Figure 3.8A, chapter 3). The binding motifs identified in this enhancer and previously 
described are shown in Figure 4.3B. Point mutations of the E-box, known to disrupt the 
interaction of Ascl1 with its consensus (Castro et al., 2006), abolished the activation of 
this enhancer by Ascl1 when the TF was overexpressed either alone or together with 
Sox2, although activation still persisted when the two TFs where overexpressed 
together (Figure 4.3A). This result suggests that exogenous Ascl1 activates this element 
through direct DNA binding to the-E box. Point mutations of the Sox binding motif, 
described to disrupt the interaction of Sox2 with its consensus (Tanaka et al., 2004), did 
not affect the regulation of the mutant M2 by exogenous Sox2. Unexpectedly, the loss 
of the Sox motif disrupted the activation of the enhancer by exogenous Ascl1. The 
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activity of the mutant elements M1 and M2, the E-box mutant and the Sox motif mutant 
elements respectively, were very similar after overexpression of Ascl1 (Figure 4.3A). 
The activation of the mutant M2 was compromised also when Ascl1 and Sox2 were 
overexpressed together. The result of this experiment did not confirm binding and 
requirement of Sox motif for the exogenous Sox2 regulation of the neuronal enhancer 
MSB4. However, it is worth noting that Sox2 did not show regulation of this enhancer, 
as previously described. For clearer conclusions on the mechanism of regulation by 
Sox2, experiments like EMSA (Electrophoretic Mobility Shift Assay) can prove or 
exclude direct binding of Sox2 to its motif.  
In conclusion, the most important result from the experiments of mutagenesis is the 
requirement of the Sox motif for Ascl1-induced activation of the neuronal enhancer 
MSB4. This suggests that Ascl1 might interact with a Sox factor binding to the 
identified Sox motif in the activation of the neuronal enhancer.  
4.3.2.2 The NSC-active and neuronal enhancer MSB18  
MSB18 is both an enhancer active in neural stem cells showing basal luciferase activity 
in NS5 cells, and also a neuronal enhancer activated by exogenous Ascl1. Sox2 
counteracts Ascl1-induced activation of this element (Figures 3.8A and 3.9B, chapter 
3). The five BMs identified and mutated to generate the MSB 18 mutant enhancers are 
shown in Figure 4.3D. Mutagenesis of enhancer MSB18 shows that different binding 
motifs give different contribution to the regulation of the enhancer. More precisely, only 
mutant M1 (E-box1 mutant) showed a reduction of activity when the E-box was 
mutated. When the E-box 1 was mutated, mutant M1 lost the activation by exogenous 
Ascl1 (Figure 4.3C). Loss of the Sox motif in the mutant construct M4 (Sox motif 1 
mutant) did not affect regulation of the enhancer by exogenous Sox2 (Figure 4.3C). The 
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stem cell associated TF Sox2 did not regulate this neuronal enhancer, consistently with 
previous result discussed in paragraph 3.5.2 (Figure 3.8A, chapter 3). Conversely, 
mutants MSB18 M2, M3, and M5 (E-box 2, E-box 3, and Sox motif 2 mutant elements, 
respectively) showed a robust increase of activity by exogenous Ascl1 compared with 
the wt element, when the TF was overexpressed either alone, or together with Sox2. M5 
mutant was also strongly activated by exogenous Sox2 compared with the wt element 
(Figure 4.3C). This result suggests that the Ascl1-induced activation of the wt enhancer 
might be repressed by other TFs, possibly other bHLH proteins, binding to the other E-
boxes 2 and 3, or by a Sox factor binding to the Sox motif 2. The Sox factor not 
identified here binding to Sox motif 2 represses also the activity of Sox2 in the 
regulation of enhancer MSB18. The result distinguishes among the E-boxes bound by 
Ascl1, which might bind E-box 1 rather than the others, according to this experiment.  
In conclusion, results of this experiment suggest that activation of enhancer MSB18 
occur through direct DNA binding of Ascl1 to the E-box1. It is possible that other 
bHLH TFs binding E-box 2 and 3 or a Sox factor binding Sox motif 2 repress Ascl1 and 
Sox2 in the activation of the wt element.  
 4.3.2.3 The NSC-active and neuronal enhancer MSB 22-short  
 MSB22 has been classified as both a neural stem cell active enhancer, and also a 
neuronal enhancer activated by overexpression of Ascl1 in NS5 cells. Sox2 strongly 
counteracts Asc1-induced activation of this element (Figures 3.8A and 3.9B, chapter 3). 
MSB22-short with its motifs is displayed in Figure 4.3G. The regulation of MSB22-
short by exogenous Ascl1 and Sox2 was tested and compared to the activity of MSB22 
full-length (Figure 4.3E). MSB22-short still exhibited characteristics of a neuronal 
enhancer, induced by exogenous Ascl1. However, Ascl1-induced activation of the short 
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element was lower than the full-length element. This suggests that Ascl1 might also 
bind the other two E-boxes of the full-length element with an additive effect in the 
regulation of the entire element (Figure 4.3E and G).  Activation of the short element by 
exogenous Sox2 was increased compared to the full-length element. This is probably 
because the short element has two Sox motifs and only one E-box. Ascl1 and Sox2 still 
appeared to counteract each other in the regulation of MSB22-short, despite the 
different number of motifs present in the sequence. Mutation of the E-box abolished 
activation of enhancer MSB22-short by exogenous Ascl1. This result suggests that 
Ascl1 regulates the activity of the enhancer through direct DNA binding to its 
consensus motif (Figure 4.3F). Mutation of either Sox motif 1 or Sox motif 2 did not 
affect the regulation of the enhancer by Sox2. This was not affected also when the two 
Sox motifs were mutated together in the same mutant element M6 (Figure 4.3F). This 
result suggests that Sox2 might regulate enhancer MSB22-short without direct binding 
to its consensus motifs here identified.  
Interestingly, activation of MSB-22 short enhancer by exogenous Ascl1 was highly 
increased in mutant element M6 where the two Sox motifs were mutated together 
compared with the activity of the wt sequence (Figure 4.3F). This result suggests that 
other Sox factors not identified here might bind to these motifs and repress Ascl1 
activation of the enhancer. A similar result was observed for Sox motif 2 in enhancer 
MSB18.  
In conclusion, results from this experiment show that Ascl1 activates the neuronal 
enhancer MSB22 through direct binding of the E-box identified. However, results could 
not confirm binding of Sox2 to its motifs, suggesting a different mechanism of 
regulation by this TF. The mutagenesis analysis of enhancer MSB22-short suggest that 
also other Sox factors could be involved in the regulation of this element and they might 
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counteract Ascl1 activity. Results reveal a complex and context-specific interaction 
between Ascl1 and the Sox factors in the regulation of this enhancer.     
4.3.2.4 The NSC-active enhancer MSB24-short  
MSB24 is an enhancer active in neural stem cells as shown by basal luciferase activity 
in NS5 cells (Figure 3.9A, chapter 3). This enhancer is activated by overexpression of 
Sox2 in NS5 cells. Ascl1 counteracts Sox2-induced activation of the element when the 
two TFs are overexpressed together (Figure 3.10A). Diagram in Figure 4.3I represents 
MSB24 enhancer and the binding motifs identified and mutated. MSB24-short was 
cloned as shorter element of MSB24. The activity of MSB24-short and MSB24 full-
length were tested and compared in NS5 cells. The two elements display similar pattern 
of activity (Figure 4.3H). Activation of the short element by exogenous Sox2 is 
increased compared with the full-length element. This suggests that a bHLH factor 
binding to the second E-box present in the full-length enhancer contributes to the 
repression of exogenous Sox2 activity (Figure 4.3I). Mutation disrupting the E-box did 
not affect regulation of MSB24-short M1 mutant enhancer by exogenous Ascl1. 
Mutation of the Sox motif exhibited a minor reduction of the activation of the enhancer 
by exogenous Sox2 compared with the WT element (Figure 4.3H, mutant M2 vs wt 
element). 
In conclusion, these results might suggest direct binding of Sox2 to its motif in the 
regulation of the NSC active enhancer MSB24-short, although reduction of the 
activation by exogenous Sox2 is low. EMSA assay can confirm direct DNA binding of 
this TF to its motif and gives better insight in the mechanism of regulation.  
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4.3.2.5 The NSC-active and neuronal enhancer MSB 11  
MSB11 has been classified as both a neural stem cell active and also a neuronal 
enhancer (Figure 3.9B). Diagram in Figure 4.3K represents enhancer MSB11 and the 
binding motifs identified and mutated. Overexpression of Ascl1 or Sox2 shows only 
minimal effect in the regulation of this enhancer (Figure 4.3J). The activity of the wt 
element was minimally increased when the two TFs were overexpressed simultaneously 
in NS5 cells. This suggests additive effects of the two regulators, which might act 
independently. Mutation of the E-box 1 in mutant MSB11-M1 showed a minor 
reduction by exogenous Ascl1 compared with the wt element suggesting that this TF 
might directly bind to its motif for the regulation of this enhancer. Overall, variations of 
the activity of the mutant constructs compared with the wt element are only minimal 
and it is hard to draw conclusions on the interaction between Ascl1 and Sox2 in the 
regulation of this enhancer.  
In conclusion, the mutagenesis of the TF binding motifs of the neural enhancers gave in 
depth insight in the mechanisms of transcriptional regulation, in particular for the 
neuronal enhancers MSB4, MSB18 and MSB22. Results give evidence that Ascl1 
activates these elements through direct DNA binding to the E-boxes here identified and 
mutated. Results also distinguish among binding motifs identified within the same 
regulatory element. For instance, Ascl1 appears to bind specifically E-box 1 but not E-
box 2 and E-box 3 in enhancer MSB 18. 
Mechanisms of regulation of the neural enhancers by exogenous Sox2 appear to be 
more elusive, since mutations of the Sox motifs did not suggest direct binding of this TF 
for most of the elements mutated, with the exception of MSB24 enhancer. In this case, 
mutation of the Sox motif caused a minor reduction of the activation by exogenous 
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Sox2. Direct DNA binding of Sox2 to enhancer MSB24 needs to be further 
investigated. It is possible that Sox2 regulates the neural enhancers without direct DNA 
binding to the identified motifs. However, it is worth noticing that Sox2 acts as a weak 
regulator of the transcriptional activity of all enhancers identified in this study. In this 
perspective, the lack of effect of disrupted Sox motifs in the regulation of these 
enhancers is consistent with a poor function of Sox2 as transcriptional activator of these 
elements. Binding of Sox2 might be non-functional in the transcriptional activity and 
output of these enhancers. Therefore, mutation of the Sox motifs disrupting the binding 
might equally not show any effect in the regulation of the mutated enhancers.  
Moreover, mutagenesis analysis of the Sox motifs shows different roles for different 
Sox motifs identified, suggesting that different Sox factors might be recruited and 
involved in the regulation of the neural enhancers identified in this study. For instance, 
another Sox factor rather than Sox2 might bind to Sox motif 2 and repress the activity 
of enhancer MSB18. Therefore, other experiments are required to gain insight on the 
recruitment of the Sox factors and their regulation of the neural enhancers identified in 
this study.  
Finally, the most interesting result emerging from the mutagenesis analysis is the 
requirement of a Sox motif for Ascl1-induced activation of the neuronal enhancer 
MSB4. This result suggests that a Sox factor binding to this motif might enhance 
recruitment or activity of Ascl1 in the regulation of MSB4. It is also possible that 
protein-protein interactions are involved between Ascl1 and a Sox factor binding to the 
identified motif in the regulation of this enhancer. This mechanism needs to be further 
dissected.  
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Figure 4.3. Mutagenesis of the E-box and Sox motifs affect the regulation by 
exogenous Ascl1 and Sox factors in the neural enhancers. 
Mutant and wt enhancers were cotransfected in NS5 cells together with expression vectors for Ascl1 and 
Sox2 overexpressed either alone or simultaneously (as shown in the legend of the graphs). Luciferase 
activity was measured after 24 h. For each enhancer, luciferase activity was normalised to the activity of 
the same enhancer after overexpression of GFP as control. For each enhancer, luciferase activity of the wt 
element is shown on grey background in the graphs. Data are presented as the mean ± SD of triplicate 
assays. Panels B, D, G, I, K J represent diagram of each enhancer as in Figure 4.1 and the sequence of 
the motifs within each element, as explained in Figure 4.2. (A) Mutation of the E-box abolished the 
activation of enhancer MSB4 by exogenous Ascl1 (as shown by the black arrow in the graph). Mutation 
of the Sox motif did not change the activity by exogenous Sox2. Mutation of the Sox motif also abolished 
activation of the enhancer by exogenous Ascl1 (mutant element M2 vs wt) as shown by the red arrow in 
the graph. The experiment shown for enhancer MSB4 is representative of three independent biological 
replicates. (C) Mutagenesis of enhancer MSB18 shows that different binding motifs give different 
contribution to the regulation of the enhancer. Mutation of the E-box 1 abolished Ascl1-induced 
activation of this neuronal enhancer (mutant element M1 vs wt, as indicated by the arrow in the graph). 
Mutation of the Sox motif 1 did not change the activity by exogenous Sox2, which did not show 
activation of the enhancer. Mutation of the E-box 2, E-box 3 and Sox motif 2 (mutant elements M2, M3, 
and M5 vs wt element) increased strongly the activation of the enhancer by exogenous Ascl1 and also by 
exogenous Sox2 in mutant M5 (as indicated by the three black arrows in the graph) when Ascl1 was 
overexpressed alone or together with Sox2, respectively. (E) Luciferase activity of neuronal enhancer 
MSB22-short compared with MSB22 full-length after overexpression of Ascl1 and Sox2 either alone or 
together. Exogenous Sox2 still inhibited the activation of the enhancer by exogenous Ascl1 in both 
elements. MSB22-short exhibited a reduced activation by exogenous Ascl1 and an increased activation by 
exogenous Sox2 compared with the full-length element. (F) In enhancer MSB22-short, mutation of the E-
box abolished activation of the element by exogenous Ascl1 (as shown by the black arrow) (mutant 
element M1 vs wt element on grey background). Mutation of the Sox motif did not affect regulation by 
exogenous Sox2, also when the two Sox motifs were mutated together in the same element (mutant 
element M6, and also M2 and M3 vs wt). Mutation of the two Sox motifs in mutant element M6 
increased the activation of the enhancer by exogenous Ascl1. The experiment shown for enhancer 
MSB22-short is representative of two independent biological replicates. (H) Enhancer MSB24-short wt 
shows an increased activation by exogenous Sox2 compared with the full-length wt element. Mutation of 
the E-box and Sox motif did not change the values of activity by exogenous Ascl1, which doesn’t 
regulate this NSC active enhancer, as shown in the wt element (either full-length or short). Mutation of 
the Sox motif reduced minimally the activation of the enhancer by exogenous Sox2. (J) For enhancer 
MSB11, overexpression of Ascl1 or Sox2 shows only minimal effect in the regulation. The activity of the 
wt element was minimally increased when the two TFs were overexpressed simultaneously in NS5 cells.  
 
4.4.1 SoxC factors, Sox4 and Sox11, synergise with Ascl1 in the 
regulation of the neuronal enhancers MSB4, MSB18 and MSB22  
Mutagenesis analysis of the binding motif of the neuronal enhancers MSB4 showed the 
requirement of the Sox motif for the Ascl1-induced activation of this element. However, 
given that this enhancer was not induced by Sox2 and since Sox2 appeared to 
counteract Ascl1 in the activation, we hypothesised that other Sox factors rather than 
Sox2 could bind to the same Sox motif and synergise with Ascl1 in the activation of this 
neuronal enhancer. This hypothesis was supported by the fact that Sox factors tend to 
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recognise and bind to the same consensus sequences (Lefebvre et al., 2007). Thus, the 
Sox motifs identified were not exclusively Sox2 binding motifs, but could have been 
targeted by different Sox factors. RNA-seq data generated in our lab showed that other 
Sox factors were transcribed in the NS5 cells, including Sox4, Sox11, and also Sox 8 
(see next paragraph), with Sox4 being the highest transcribed (Martynoga et al., 2013). 
However, at the present we do not have data about expression at protein levels for these 
TFs in the NS5 cells. Also lab data from arrays after Ascl1 Gain of Function (GoF) 
showed induction of Sox4, Sox11, and Sox8, while showing repression of Sox2 
(Martynoga, unpublished data). Moreover, the literature shows that Sox4 and Sox11, 
members of the SoxC family of TFs, are induced by proneural proteins, and have a 
critical role in the establishment of neuronal properties (Bergsland et al., 2006).  
Taken together, our results and the literature prompted us to investigate if SoxC factors, 
in particular Sox4 and Sox11, could activate the neuronal enhancers and if they could 
synergise with Ascl1 in their regulation. We carried on with luciferase assays to assess 
the transcriptional activation of the neuronal enhancers MSB4, MSB18, and MSB22 by 
Sox4 and Sox11. As previously described, the enhancers were transfected in NS5 cells 
with expression vectors for Ascl1, and Sox4/Sox11 overexpressed either alone or 
simultaneously. Cells were harvested 24 hours after transfection and the luciferase 
activity was measured. As shown in Figure 4.4A and B, although the neuronal 
enhancers analysed were not induced by Sox4 and Sox11 when these TFs where 
overexpressed alone, all neuronal enhancers MSB4, MSB22 full-length and the short 
element, and MSB18 were strongly induced by Ascl1 and Sox4/Sox11 when the two 
TFs were overexpressed together. Therefore, we proved in this experiment that SoxC 
factors, Sox4 or Sox11, strongly synergise with Ascl1 in the activation of the neuronal 
enhancers identified in this study (black arrows, figure 4.4A and B).   
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4.4.2 Dual function of Sox8, member of the Sox E family, in the 
regulation of the neuronal enhancers MSB 4, MSB 18 and MSB 22  
RNA-seq data and microarray data from Ben Martynoga mentioned above showed that 
also Sox8, a member of the SoxE family of TFs, is expressed in NS5 cells and is 
induced by Ascl1 GoF. Therefore, we also tested the activity of Sox8 in the regulation 
of the neuronal enhancers in luciferase assays. As showed in Figure 4.4C, Sox8 did not 
activate enhancers MSB4 and MSB18 when it was overexpressed alone, but strongly 
synergised with Ascl1 to activate these neuronal enhancers when the two TFs were 
overexpressed simultaneously (black arrows, Figure 4.4C). Strikingly, the same TF 
inhibited enhancer MSB22, either its full-length element or its short version, by 
counteracting Ascl1 activation of this neuronal enhancer when the two TFs were 
overexpressed together. MSB22 full-length and MSB22-short were indeed strongly 
repressed when Ascl1 and Sox8 where overexpressed together in NS5 cells, with values 
as low as 0.2 (red arrows, Figure 4.4 C).  
In conclusion, these results show a dual role for the TF Sox8 as a transcriptional 
regulator of neuronal enhancer, capable of synergising with Ascl1 in the regulation of 
MSB4 and MSB18, and to strongly repress it in the regulation of MSB22 and MSB22-
short. In the case of enhancer MSB22, Sox8 displayed a similar tendency as Sox2 to 
counteract Ascl1 in the regulation of the identified neuronal enhancers. 




Figure 4.4. Interplay between SoxC or Sox8 factors and Ascl1 in the regulation of 
the neuronal enhancers. 
Neuronal enhancers were transfected in NS5 cells with expression vectors for Ascl1, Sox4/Sox11 or Sox8 
overexpressed either alone or simultaneously (panel A and B for Sox4 or Sox11 overexpression, 
respectively; panel C for Sox8 overexpression). Luciferase activity was measured 24 h after transfection. 
All neuronal enhancers tested (MSB4, MSB22 full-length and short element, and MSB18) were activated 
by exogenous Ascl1 (A, B, and C). Overexpression of Sox4 and Sox11 did not activate the enhancers (A 
and B). All neuronal enhancers were synergistically activated by simultaneous overexpression of Sox4 or 
Sox11, as indicated by the black arrows (in A and B). Overexpression of Sox8 alone did not activate the 
neuronal enhancers (C). Enhancers MSB4 and MSB18 were synergistically activated by simultaneous 
overexpression of Ascl1 and Sox8 (black arrows in C) while Sox8 strongly inhibited Ascl1-induced 
activation of enhancer MSB22 full-length and short (red arrows in C). Data are presented as the mean ± 
SD of triplicate assays. The experiment shown is representative of two independent biological replicates 
for all enhancers but MSB18. 
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4.5 Mutations of E-box and Sox motifs affect the synergy of 
Ascl1 with SoxC factors, or Sox8 in the activation of neuronal 
enhancers 
Once we demonstrated the synergy between Ascl1 and Sox4/11, and, in some cases, 
Sox8 in the regulation of the neuronal enhancers, we wanted to assess if mutation of the 
binding motifs would have affected this synergy. This would suggest recruitment of Sox 
factors (Sox4, Sox11, and Sox8) to their binding motifs and the mechanisms of 
interaction with Ascl1 recruited on the E box. With this purpose, we tested the activity 
of the same mutant enhancers described in paragraph 4.3.1 after overexpression of 
Ascl1 and Sox4/Sox8/Sox11. Mutant enhancers and their wt elements were 
cotransfected in NS5 cells together with expression vectors for Ascl1 and 
Sox4/Sox11/Sox8 overexpressed alone or simultaneously.  
4.5.1 Regulation of MSB4 mutant enhancers by Ascl1 and Sox factors 
MSB4 is a neuronal enhancer activated by overexpression of Ascl1 in NS5 cells. As 
demonstrated in previous experiments (paragraph 4.4.1, Figure 4.4A, B, and C), 
overexpression of the Sox factors Sox4/Sox11 or Sox8 in NS5 cells do not activate this 
enhancer. MSB4 is synergistically activated by simultaneous overexpression of Ascl1 
and Sox4/Sox11 or Sox8 in NS5 cells (Figures 4.5A,B, and C, MSB4 wt element). 
Mutation of the E-box abolished the activation of the enhancer by Ascl1, as previously 
demonstrated, and also the synergy between Ascl1 and Sox4/Sox11 or Sox8, as 
expected (Figure 4.5A, B, and C, mutant element M1). Mutation of the Sox motif 
abolished Ascl1-induced activation of the enhancer, as previously demonstrated, and 
did not affect activity by any of the Sox factors tested, Sox4, Sox11, or Sox8. Mutation 
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of the Sox motif also strongly reduced the synergistic activation of the enhancer by 
simultaneous overexpression of Ascl1 and all Sox factors tested in these experiments 
(Figures 4.5A, B, and C, mutant element M2). These results cannot suggest if the Sox 
factors regulate the enhancer through direct DNA binding to the Sox motif here 
identified. Different experiments, such as EMSA, can confirm or exclude this 
possibility. These results are very similar to those obtained for Sox2 and discussed in 
the previous paragraphs. Thus, mechanisms of regulation of the neuronal enhancer 
MSB4 by all Sox factors analysed in this study need to be further dissected. The 
synergistic activation of MSB4 enhancer by Ascl1 and the Sox4/Sox11 or Sox8 is lost 
either with mutation of the E-box or with mutation of the Sox motif. However, in the 
second case, it is not possible to distinguish if the synergy is lost as a consequence of 
the effect of the mutation of the Sox motif on the activity of the exogenous Ascl1, or as 
an effect of the mutation of the Sox motif on the binding of the Sox factors. Indeed, Sox 
factors might bind to the Sox motif and activate the enhancer in synergy with Ascl1 
whereas they do not exhibit transcriptional activity alone. It is known that Sox factors 
alone do not appear to be functional and they only exert transcriptional activation of a 
bound regulatory region in combination with a partner factor (Yuan et al., 1995, 
Kamachi et al., 2001, Kondoh and Kamachi, 2010).  






Figure 4.5. Mutations of E-box and Sox motifs affect the synergy of Ascl1 with 
SoxC factors, or Sox8 in the activation of neuronal enhancer MSB4. 
Luciferase activity of mutants and wt enhancer MSB4 was measured and compared after overexpression 
of Ascl1, SoxC or Sox8 either alone or simultaneously (as shown in each legend near the graphs). 
Luciferase activity is expressed as relative compared to the activity of the same enhancer after 
overexpression of the GFP vector as control. Luciferase activity of the wt enhancer is shown on grey 
background in A, B, and C for comparison with the mutant elements. The neuronal enhancer MSB4 is 
synergistically activated by simultaneous overexpression of Ascl1 and Sox4/Sox11 or Sox8 (A, B, and C, 
wt element). Mutation of the E-box abolished activation of the enhancer by exogenous Ascl1 and also 
synergistic activation by Ascl1 and Sox4 (A), Ascl1 and Sox11 (B), and Ascl1 and Sox8 (C) (element M1 
vs wt). Mutation of the Sox motif also abolished activation of the enhancer by exogenous Ascl1 as 
previously demonstrated (element M2 vs wt element in A, B, and C) and also the synergistic activation of 
the enhancer by Ascl1 and SoxC or Sox8 (element M2 vs wt in A, B, and C). Mutation of the Sox motif 
did not change the luciferase activity of mutant element M2 after overexpression of the three Sox factors, 
Sox4 in A, Sox11in B, Sox8 in C. The data are presented as the mean ± SD of triplicate assays. 
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4.5.2 Regulation of MSB22-short mutant enhancers by Ascl1 and Sox 
factors 
The neuronal enhancer MSB22-short is also activated by overexpression of Ascl1 in 
NS5 cells. Also in this case as for the other neuronal enhancers analysed, MSB22-short 
is synergistically activated by simultaneous overexpression of Ascl1 and Sox4/Sox11. 
In contrast, Sox8 inhibits Ascl1-induced activation of the enhancer when these two TFs 
are overexpressed together. The Sox factors do not activate the enhancer when they are 
overexpressed alone in NS5 cells (Figures 4.7, wt elements). Mutation of the E-box 
reduced activation of the enhancer by exogenous Ascl1 and also the synergy between 
Ascl1 and Sox4/Sox11 (Figures 4.7, mutant element M1). Mutation of Sox motif 1 did 
not change the regulation of the enhancer by the Sox factors and the synergy between 
Ascl1 and Sox4/Sox11 was not compromised (Figures 4.7, mutant element M2). Also 
for enhancer MSB22-short, the results of the experiments of mutagenesis cannot 
suggest if the Sox factors bind to their motif and regulate the enhancer. However, the 
synergy between Ascl1 and Sox4/Sox11 is not compromised when the Sox motif is 
mutated. In this case, also Ascl1-induced activation of the enhancer is not lost when the 
Sox motif is mutated. These results might suggest that Ascl1 and Sox4/Sox11 synergise 
as proteins in a same transactivation complex without binding of Sox4/Sox11 to the 
identified Sox motif.  




Figure 4.6. Regulation of MSB22-short mutant enhancers by Ascl1 and Sox 
factors. 
Luciferase activity of mutants and wt enhancer MSB22-short was measured and compared after 
overexpression of Ascl1, SoxC or Sox8 either alone or simultaneously (as shown in each legend near the 
graphs). Luciferase activity of the wt enhancer is shown on grey background in A, B, and C. Neuronal 
enhancer MSB22-short is synergistically activated by simultaneous overexpression of Ascl1 and 
Sox4/Sox11 (A and B) while Sox8 inhibits Ascl1-induced activation when these two TF are 
overexpressed together (C). Mutation of the E-box reduced the activation of the enhancer by exogenous 
Ascl1 (A and C, mutant element M1 vs wt) and also synergistic activation by Ascl1 and Sox4/Sox11 (A 
and B, mutant element M1 vs wt). Mutation of the Sox motif did not change the regulation by the Sox 
factors (A, B, and C, mutant element M2 vs wt) nor compromised the synergistic activation between 
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4.6 Discussion 
4.6.1 Identification of E-box and Sox motifs in the neural enhancers 
In the previous chapter I showed that genomic elements identified through a ChIP-seq 
approach acted as enhancers regulated by Ascl1 and Sox2. In this chapter I focused on 
the identification of TF binding motifs in the enhancer sequences and their role in the 
regulation. One of the features of the enhancers is the presence of a dense clustering of 
multiple motifs where TFs bind and regulate the enhancer activity (Dickel et al., 2013, 
Spitz and Furlong, 2012). Using the TESS software and searching for E-box and several 
Sox motifs, I identified BMs for Ascl1 and Sox factors. Mostly, these were located in 
the regions of overlapping ChIP-seq peaks of Ascl1 and Sox2 (Figure 4.1). This finding 
further validates ChIP-seq data and supports the possibility that Ascl1 and Sox factors 
bind in close proximity to a core region of the regulatory sequences. The results 
described in this chapter show that mutation of the BMs affect enhancer activity for 
some of the regulatory regions characterised. These results suggest mechanisms of 
direct DNA binding of the TFs involved in the regulation of the neural enhancers 
identified in this study.  
4.6.2 Mutagenesis of the BMs suggests regulation of the neural 
enhancers by endogenous bHLH factors and Sox factors 
Some experiments here presented aimed to test and compare the basal transcriptional 
activity of mutant enhancers and their wt sequences in neural stem cells. The purpose 
was not only to understand if an intact motif was required for enhancer activity, but also 
to infer the role of the endogenous TFs, in particular endogenous Ascl1 and Sox2, in the 
regulation of the enhancers in neural stem cells. Luciferase assays results showing a 
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reduced basal activity of mutant enhancers carrying disrupted E-boxes and Sox motifs 
compared with the activity of the wt sequences suggest that endogenous bHLH factors 
and Sox factors, possibly Ascl1 and Sox2, account for the enhancer activity observed in 
neural stem cells. These results also suggest that bHLH factors and Sox factors regulate 
basal enhancer activity through direct DNA binding to the identified motifs.  
The transcriptional basal activity of the mutant and wt elements to infer the role of 
endogenous bHLH and Sox factors in the regulation of the identified neural enhancers is 
particularly valuable in the absence of knock down experiments. Indeed gain of function 
of Ascl1 and Sox2 in NS5 cells is the only successful approach undertaken in this study 
to prove the effect of the two TFs in the regulation of the enhancers. Experiments of 
knock down of these TFs have been tried unsuccessfully in this project (data not 
shown).  
The results described suggest that endogenous bHLH and Sox factors, possibly Ascl1 
and Sox2, regulate the basal activity of enhancers MSB18 and MSB22 in neural stem 
cells. Mutations of specific motifs, but not all of them, were functionally deleterious and 
caused reduction of the basal enhancer activity. These results also suggest that 
endogenous bHLH and Sox factors could regulate the basal activity of enhancers 
MSB18 and MSB22 through direct DNA binding to the identified motifs. MSB18 and 
MSB22 were also among the enhancers with the highest basal activity, so the result of 
the mutagenesis study here carried out is consistent with the activity displayed by these 
enhancers in neural stem cells. Mutations of the E-box and Sox motifs in enhancer 
MSB4 did not affect its transcriptional basal activity. The result is consistent with the 
lack of activity of this regulatory element in neural stem cells. MSB4 has been classified 
as a neuronal enhancer since it is only activated by exogenous Ascl1 in NS5 cells. For 
this enhancer, combined mutation of E-box and Sox motif in the same mutant element 
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caused an increase of the basal activity compared with the wt element, suggesting that 
TFs binding to these motifs may actually repress the activity of this enhancer in neural 
stem cells. Finally, mutagenesis analysis of disrupted binding motifs in enhancers 
MSB24 and MSB11 suggest that the BMs identified and mutated either did not account 
or gave only a minor contribution to the basal transcriptional activity of these elements 
in neural stem cells. 
4.6.3 Mutagenesis of the BMs suggests different mechanisms of 
regulation of the neural enhancers by exogenous Ascl1 and Sox2 
Experiments where the effect of the overexpression of Ascl1 and Sox2 were tested on 
mutant enhancers compared with the wt element aimed to gain insight into the possible 
direct binding of the TFs to their DNA binding motifs in the enhancer sequence, and to 
clarify any interaction between Ascl1 and Sox2 in the regulation of the enhancers. 
Loss of the E-box strongly affected exogenous Ascl1 activation of the neuronal 
enhancers MSB4, MSB18 and MSB22, and in a modest measure MSB11. These results 
give evidence that Ascl1 might activate these regulatory regions through direct DNA 
binding to the identified E-box.  
Overall, mutation of the Sox motifs failed to show requirement of these sites for the 
regulation of the enhancers by Sox2 and its direct binding to the DNA, with the 
exception of the NSC active enhancer MSB24-short. It is possible that Sox2 regulates 
these elements through alternative mechanisms. It might bind to non-canonical motifs 
and/or regulate without direct binding to the identified motifs. These mechanisms need 
to be addressed.  However, results of the mutagenesis of the Sox motifs and its effect on 
the transcriptional activity are consistent for the neuronal enhancers MSB4, MSB18, 
and MSB22. These enhancers did not show activation by exogenous Sox2. It is 
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therefore consistent that mutation of the Sox motif did not affect the regulation by this 
TF. Similar results were obtained by Kamachi and colleagues in their study on the 
activation of the DC5 enhancer of the δ-crystallin gene by Pax6 and Sox2 (Kamachi et 
al., 2001). In that work, no differences were observed in the values of luciferase activity 
of the wt and mutant DC5 enhancer carrying mutation of the Sox motif after 
overexpression of Sox2 in cultured liver cells. Sox2 could not activate the enhancer 
when overexpressed alone. However, strong activation was seen in synergy with Pax6 
and cooperative binding was demonstrated for the two TFs on the DC5 enhancer. In 
conclusion, binding of Sox2 cannot be excluded from our results and further 
experiments are needed to understand the mechanism of regulation of the neuronal 
enhancers by this TF. Nevertheless, mutation of the Sox motif affected activation of the 
neuronal enhancer MSB4 by exogenous Ascl1 suggesting the requirement and 
dependence of a Sox motif for Ascl1 induction. This intriguing result might suggest that 
a protein-protein interaction between Ascl1 and a Sox factor binding to the identified 
Sox motif is required for Ascl1-induced activation of this neuronal enhancer. The result 
might also suggest a possible cooperative DNA binding to their motifs of the two 
proteins involved in the regulation of this enhancer. The mechanism emerging needs to 
be further addressed and investigated, also to conclude if it occurs as a general 
mechanism of regulation on other neuronal enhancers.  
4.6.4 Recruitment of different TFs to different BMs in enhancer 
MSB18 
The analysis of the five MSB18 mutant enhancers allowed discrimination between the 
five binding motifs identified, with recruitment of different bHLH and Sox factors 
involved in the regulation of this enhancer. Indeed, only mutation of E-box 1 reduced 
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Ascl1 activation by 4-fold, suggesting binding of the TF to this motif. While mutations 
of the E-box 2, E-box 3 and Sox motif 2 strongly increased activation by exogenous 
Ascl1 compared with the wt element, suggesting that other TFs binding these motifs 
might counteract and repress Ascl1 induction of the enhancer. The results give evidence 
of Ascl1 binding to the E-box 1, while other bHLH TFs bind to E-box 2 and E-box 3 
competing with Ascl1 activation of the neuronal enhancer. When point mutation in 
these other E-boxes prevented these TFs from binding the DNA, Ascl1 transcriptional 
activation of the enhancer increased, as showed for mutant elements M2 and M3 
compared with the wt element (Figure 4.3C and D). These results are consistent with 
results of the basal activity of the mutant elements of enhancer MSB18 since also in that 
case mutation of E-box 1 did not affect the basal transcriptional activity of the element. 
This suggests that this motif and the TF there recruited does not account for the basal 
activity of MSB18 in neural stem cells. While TFs binding E-box 2 and 3, and Sox 
motifs 2 regulate the basal activity of enhancer MSB 18. In conclusion, the results 
suggest that other bHLH factors rather than Ascl1 are responsible for the basal activity 
of enhancer MSB 18 in neural stem cells, together with a Sox factor binding to Sox 
motif 2. The bHLH factor Olig2 might be one of the candidates to regulation of this 
enhancer. Olig2 and Ascl1 bind to the same E-box. Olig2 ChIP-seq data in NS5 cells 
from Ben Martynoga indicate recruitment of this TF to the neural enhancers identified 
in this study (Martynoga, unpublished data). Moreover, luciferase assays performed in 
Olig2 conditional knock out cell line, derived from primary culture, exhibited a strong 
loss of basal activity of enhancer MSB18 when Olig2 was deleted compared with the wt 
cells (data not shown).    
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4.6.5 SoxC and Sox8 factors in the regulation of the neuronal 
enhancers and synergy and counteraction with Ascl1 
Mutagenesis of the neuronal enhancer MSB4 showed the requirement of the Sox motif 
for Ascl1-induced activation of this element. The fact that overexpression of Sox2 did 
not activate the neuronal enhancers and counteracted Ascl1 induction when the two TFs 
were overexpressed together raises the possibility that other Sox factors, rather than 
Sox2, might bind to the same Sox motif and synergise with Ascl1 in the activation of 
these enhancers. This hypothesis is supported by the fact that Sox factors tend to bind to 
a common motif (Lefebvre et al., 2007).  
RNA-seq data generated in our lab showed that Sox4, Sox11 and Sox8 were transcribed 
in NS5 cells, with Sox4 being the highest transcribed, and microarray data following 
Ascl1 GoF showed induction of Sox4, Sox11 and Sox8, and repression of Sox2 (Ben 
Martynoga, unpublished data). This prompted us to investigate a possible interaction 
between Ascl1 and Sox4, Sox11 and Sox8 in the regulation of the neuronal enhancers. 
Moreover, the literature reported that SoxC members, in particular Sox4 and Sox11, 
have a critical role in the specification of neuronal traits downstream of bHLH factors 
(Bergsland et al., 2006) and target the promoters of genes that are induced upon 
neuronal differentiation of adult NSCs, such as the doublecortin (DCX) promoter  (Mu 
et al., 2012).  
The results described in this chapter showed that Ascl1 strongly synergised with Sox4 
and Sox11 in the activation of the neuronal enhancers MSB4, MSB18, MSB22 and 
MSB22-short when the two TFs were overexpressed together. Ascl1 synergised also 
with Sox8 in the activation of enhancers MSB4 and MSB18. However, Sox8 inhibited 
the activity of enhancer MSB22, and its shorter construct MSB22-short, by 
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counteracting Ascl1 induction of this enhancer when the two TFs were overexpressed 
simultaneously. Therefore, Sox8 was able to act as both an activator and a repressor on 
different neuronal enhancers. In particular, Sox8 displayed a similar pattern as Sox2 in 
counteracting Ascl1 on enhancer MSB22. Indeed, the result for MSB22 was consistent 
with data presented in the literature where Sox8 was showed to act as negative regulator 
of myogenin expression, repressing the activity of the myogenin promoter and 
abolishing bHLH MyoD-induced activation of the same element when the two TFs 
where overexpressed together in skeletal muscle differentiating cells (Schmidt et al., 
2003). 
Despite the strong synergy with Ascl1, or the counteraction in the case of Sox8, 
Sox4/Sox11 and Sox8 did not show regulation of the enhancers when they were 
overexpressed alone.  
4.6.6 Two different mechanisms of synergistic activation of the 
neuronal enhancers by Ascl1 and the SoxC factors  
Mutagenesis experiments described at the end of this chapter aimed to demonstrate if 
point mutations of the binding motifs could affect the synergy between Ascl1 and Sox4, 
Sox11 and Sox8 (where it was synergising with Ascl1 on MSB4 and MSB18). This 
would suggest direct binding of the Sox factors on the Sox motifs identified and 
mutated, and also that the synergy requires direct DNA binding of both TFs, Ascl1 and 
Sox factors, to their BMs. It might be possible that the binding of both TFs is required 
for the establishment of protein interactions in the synergistic activation of the neuronal 
enhancers. Results obtained were complex and different for each enhancer studied and 
suggest that more than one mechanism might be involved.  
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It is possible that mechanisms of interaction of Ascl1 and Sox factors are different for 
different elements analysed. For instance, for enhancer MSB4, the synergy between 
Ascl1 and Sox4 or Sox11 was compromised either with mutation of the E-box or with 
mutation of the Sox motif. In this second case, it is not possible to distinguish if the 
synergy is lost as a consequence of the effect of the mutation of the Sox motif on the 
activity of the exogenous Ascl1, or because the mutation of the Sox motif affects 
binding of the Sox factors. Since binding of the Sox factors cannot be excluded at this 
stage, these results can be compatible with a mechanism of regulation where both Ascl1 
and the SoxC factors bind to their DNA motifs, probably in a cooperative way, and 
synergise in the activation of the enhancer that they co-bind and co-regulate. This 
interaction between Ascl1 and Sox4/Sox11 suggests a feedforward loop network in the 
regulation of the neuronal enhancer MSB4. In a feedforward loop motif, a regulator 
activates a second regulator and they both bind a common regulatory target that they 
activate together (Mangan and Alon, 2003, Boyer et al., 2005). Indeed, it is known that 
Ascl1 activates SoxC factors (Bergsland et al., 2006) (and Martynoga, unpublished 
data). It seems possible then that SoxC factors feed forward to help the same Ascl1 to 
activate the neuronal enhancer MSB4 (Figure 6.1B). The mechanism of regulation 
could be different for enhancer MSB22. In this case, the synergy between Ascl1 and 
SoxC factors was compromised only with mutation of the E-box but not with mutation 
of the Sox motif. Therefore, it is possible that Ascl1 and Sox4 or Sox11 synergise in the 
activation of this enhancer as proteins of a same transactivation complex without 
binding of the SoxC factor to the DNA (Figure 6.1C). Binding of the SoxC factors to 
the identified Sox motifs need to be demonstrated or excluded to further support these 
two models.  
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Mutagenesis analysis could not suggest direct binding of the Sox factors tested in this 
study. However, all Sox factors tested show low or no activation of the enhancers 
studied when they are overexpressed alone in NS5 cells. It is known that Sox factors 
tend to activate a regulatory region in interaction with a partner factor rather than alone 
(Yuan et al., 1995, Kamachi et al., 2001, Kondoh and Kamachi, 2010). If binding of the 
Sox factors to their motifs does not correlate with activation of the enhancers, it is 
possible that mutation of the same motifs disrupting the binding will not show effect on 
the luciferase activity of the Sox-motif mutant enhancers compared with the wt 
elements (luciferase activity of both wt and Sox-motif mutant enhancers is low when 
Sox factors are overexpressed alone and it is not affected from the mutation).  
Finally, mutation of some Sox motifs, such as Sox motif 2 (in mutant element M5) in 
enhancer MSB18, increased exogenous Ascl1 activation of the enhancer, suggesting 
that a Sox factor, not yet identified in this study, could repress Ascl1 induction of the 
enhancer. This result further demonstrates that many Sox factors could be involved in 
the regulation of the neural enhancers, some activating and some other repressing the 
transcriptional activity of the regulatory elements. It also demonstrates the existence of 
both activating and repressing modules within the same enhancer, and a complex 
interplay of several TFs bound and involved in their regulation. 
In conclusion, this study has identified a complex interplay of Ascl1 with different Sox 
factors in the regulation of neural enhancers. Results show that Ascl1 and Sox2 
counteract each other, whereas Ascl1 and SoxC factors synergistically activate these 
elements. However, the mechanisms of these antagonistic and synergistic interactions 
need to be further investigated and the requirement of a Sox motif for Ascl1-induced 
activation of the enhancer MSB4 needs to be explained. Moreover, mechanisms of 
regulation of the neural enhancer by Sox factors need to be further dissected. In 
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particular, direct DNA binding of the Sox factors to their motifs needs to be 
demonstrated or excluded. EMSA experiments can prove or exclude direct interactions 
of the TFs with the DNA. EMSA experiments are described in the next chapter.        
Chapter 5 – Results 
 167 
5. In vitro binding of Ascl1 to the neuronal enhancer 
MSB4 
5.1 Introduction 
In the previous chapter I proved that TF binding motifs in most of the enhancers 
characterised were involved in their regulation, suggesting a direct recruitment of Ascl1 
to the E-box. However, the mechanism of regulation by Sox factors appeared more 
elusive. In this chapter I present EMSA (Electrophoretic Mobility Shift Assay) 
experiments to confirm or rule out direct binding of TFs to their DNA motifs, proposing 
models of mechanisms of transcriptional regulation of the identified neural enhancers. 
EMSA is a simple and sensitive assay to detect interactions between DNA binding 
proteins, in this case TFs, and nucleic acid sequences. It is based on the principle that 
when a protein binds a nucleic acid probe, it can retard its migration through a native 
polyacrylamide gel compared with the migration pattern of the free unbound probe. 
Therefore the formation of a protein-DNA complex can be detected on an 
electrophoresis gel. Under appropriate experimental conditions, both qualitative and 
quantitative nature of the binding can be analysed, making the technique a useful tool to 
characterise TFs-DNA interactions, as described since the first applications of the 
method (Hellman and Fried, 2007) (Fried and Crothers, 1981) (Garner and Revzin, 
1981). In particular for the purposes of this thesis, EMSA experiments may demonstrate 
if Ascl1 and/or the Sox factors analysed in this study can bind to the enhancer regions 
and if they can bind simultaneously. Using enhancer constructs carrying mutations in 
the consensus motifs for the TFs may confirm if binding occurs specifically through the 
predicted sites, as a mutated site should prevent a band shift from being observed. By 
titrating different amounts of each TF it may be possible to propose mechanisms of 
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interaction between the TFs. For instance, if there is cooperative binding, where binding 
of one factor helps recruitment of the other, or competitive binding if the binding of one 
may inhibit the binding of the other. For instance, if binding of a TF helps the binding 
of a second TF, a lower concentration of the second TF is required to cause a band shift 
compared to the concentration needed when the second TF binds alone. Conversely, if 
binding of a TF inhibits binding of the second TF then a higher concentration of the 
second factor is required to cause a shift and see the band compared to the concentration 
required when the second TF binds alone without competing.   
5.1.2 Optimisation of the experimental conditions for EMSA 
experiments 
Despite the simplicity of the technique, successful gel shifts require the optimisation of 
several parameters, which influence the ability of TFs to recognise their specific DNA 
sequences. Binding reaction conditions, gel percentage, and gel electrophoresis 
conditions need to be empirically optimised and determined for each TF-probe 
interaction to successfully detect the formation of the complexes.  
The results presented in this chapter required a long optimisation process. Initially the 
use of biotin-labelled DNA probes was attempted for chemiluminescent detection of the 
complex (using Lightshift Chemiluminescent EMSA kit from Thermo Scientific), 
instead of the more traditional use of radioisotope-labelled probe for radioactive 
detection. However, this method failed and was abandoned. We suspected this was 
mainly due to interference of components of the rabbit reticulocyte lysate from the TnT 
in vitro transcription/translation system (see paragraph 2.5.1.1 in Materials and 
Methods) with the chemiluminescent detection, which hampered the clarity and 
detection of the signal. Moreover, the method seems to have a much lower sensitivity 
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compared with the traditional radioactive detection and the use of radioisotope-labelled 
nucleic acid probes. Next, the source of protein and the protein synthesis methods 
required adjustment. While the use of rabbit reticulocyte lysate of the TnT in vitro 
system for protein expression (previously mentioned) proved to be successful as a 
source of native Ascl1 binding the DNA probe, I could not obtain native Sox2-TnT 
functionally binding TF, although the protein could be detected by Western Blot (Figure 
5.1 C and D; and paragraph 2.5.1.1 for description of the method). Probably this was 
due to misfolding of the native protein in the cell-free TNT system. I was able to obtain 
results only when producing Sox2 by overexpression of Sox2 plasmid in the 293T cell 
line, as described in paragraph 2.5.1.2 of Materials and Methods. Finally, the detection 
of Sox2-DNA complex required further optimisation of binding buffers, percentage of 
polyacrylamide gel and electrophoresis conditions to obtain and resolve the complex on 
the native gel. Besides these further optimisations, results obtained for Sox2 in these 
experiments indicate that the binding of this factor to the MSB4 probe is very weak 
and/or the EMSA conditions are not fully optimised for this transcription factor (data 
not shown). Therefore the EMSA experiments with Sox2 have not been shown in this 
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Figure 5.1 – Western blot to verify Ascl1 or Sox2 protein expression using either in 
vitro TnT system or transfection of 293T cells. 
Western blot was carried out to assess expression of Ascl1 (panels A and B) or Sox2 (panels C and D). 
Samples were prepared using TnT system (panels A and C) or transfection of 293T cells (panels B and 
D). Panel A and B lanes: 1, mock; 2, Ascl1-E47. Panel C lanes: 1, mock; 2, Sox2. Panel D lanes: 1, 
mock; Sox2-pcDNA3.1; 3, Sox2-pCAG. * indicates position of Ascl1-E47; Ɨ  indicates position of Sox2. 
 
At the time of writing this thesis I have been able to obtain results from EMSA 
experiments for Ascl1 binding on the MSB 4 enhancer. I could not obtain binding of 
SoxC factors, in particular Sox11, on the same enhancer but also on a control probe (the 
Tubb3 promoter-probe used by Bergsland and colleagues) despites attempts, as 
conditions proved not to be optimal for the purpose (Bergsland et al., 2006). Therefore, 
further EMSA experiments will be needed to achieve more complete results of this 
chapter.  
5.2 Ascl1 binds in vitro to the E-box in enhancer MSB4  
First, I asked whether native Ascl1 was able to bind to the E-box consensus in the 
enhancer MSB4. I chose enhancer MSB4 for the first EMSA experiments because of its 
simple architecture, with only one E-box and one Sox motif present in the sequence. 
Furthermore, MSB4 showed an interesting feature in the regulation by Ascl1 and Sox 
factors, more precisely the requirement of the Sox motif for the activation of the 
element by exogenous Ascl1. A 63 bp 32P-labelled DNA probe corresponding to the 
region of MSB4 enhancer containing both the E-box and the Sox motif, named MSB4 
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wt probe, was incubated with a whole cell lysate from 293T cells overexpressing Ascl1. 
The expression vector contained a fusion protein Ascl1 tethered to E47, which is known 
to bind strongly to an E-box consensus sequence (Castro et al., 2006). It is known that 
proneural proteins bind the DNA as heterodimers formed with the ubiquitously 
expressed E proteins, such as E12 and E47 in mammals (Massari and Murre, 2000, 
Castro et al., 2006). Therefore, the use of the fusion protein Ascl1-E47 has the 
advantage of strong and specific binding to the E-box in the sequence of the probe in 
the in vitro binding assay. The binding mixture was resolved on a native polyacrylamide 
gel. A major complex between the DNA probe and the Ascl1-293T cell lysate was 
detected (Figure 5.2 A, lane 3 vs 2 with Mock-293T cell lysate). To prove the identity 
of Ascl1 as binding protein in the complex with the DNA, a supershift assay was 
performed. In this control experiment, the use of an antibody against the protein of 
interest should recognise and bind specifically the protein. Two are the possible 
outcomes of the control experiment if the antibody detects and binds the protein of 
interest in the complex: either it further retards the migration of the complex causing a 
“supershift” or it competes with the DNA probe for binding to the protein and therefore 
weakens the intensity of the band due to reduced amount of the specific protein-DNA 
complex in the binding mixture. In this experiment, the addition of a mouse Ascl1 
antibody led to the supershift of the complex, while the control mouse IgG antibody did 
not affect its mobility (Figure 5.2 A, lanes 7 and 8). Therefore, this indicates that it is 
specifically Ascl1-E47 to bind to the probe and to form a complex with the DNA. To 
prove that Ascl1-E47 binds specifically to the sequence of enhancer MSB 4, a specific 
competitor analysis was also carried out. The addition of a 200-fold excess of 
unlabelled specific probe (thus referred to as cold probe), MSB 4 cold, with the same 
sequence than the 32P labelled one, successfully competed for Ascl1 binding, strongly 
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reducing the detection of the band, as showed in lane 4 (Figure 5.2 A, compare lane 4 
and 3). This proves that Ascl1 tethered to E47 binds specifically to the MSB4 enhancer 
sequence. Next, I examined the requirement of an intact E-box and Sox motifs within 
the MSB4 enhancer in the formation of the Ascl1-DNA complex. Mutation of the E-box 
prevented Ascl1-E47 from binding when MSB4 M1 (E-box mutant probe) was added to 
the binding reaction mixture instead of MSB4 wt; while mutation of the Sox motif did 
not affect formation of the complex and detection of the band when MSB4 M2 (Sox 
mutant probe) was used instead of the wt probe (Figure 5.2 A, lanes 5 and 6). This 
proved that Ascl1 tethered to E47 needs an intact E-box for binding, and it can bind 
independently from the Sox motif. 
Consistently, a similar experiment where the Ascl1-E47 fusion protein was expressed 
using the “cell-free” rabbit reticulocyte lysate TNT system for in vitro translation led to 
the same results, as showed in Figure 5.2B. In this experiment also an unrelated probe 
corresponding to the Nestin enhancer sequence, Nes probe, without known Ascl1 
binding motif in the sequence, was used alternatively to the MSB4 probe to further 
prove sequence-specificity of the binding (Tanaka et al., 2004). Indeed, no band was 
observed in the absence of an Ascl1 binding motif when Nes probe was added to the 
binding reaction instead of MSB4 wt (Figure 5.2 B, lane 7). In conclusion, these results 
showed that Ascl1 binds to the MSB4 enhancer specifically through an intact E-box, 
and it is able to bind independently from the Sox motif.  
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Figure 5.2. Ascl1 binds in vitro to the MSB 4 enhancer sequence. 
(A) EMSA experiments were used to analyse the interaction between native Ascl1 and a 63 bp 32P-
labelled probe corresponding to MSB 4 wt sequence containing the E box and the Sox motif. Whole cell 
lysate from 293T cells transfected with a Ascl1-tethered to E47 construct was used as source of the 
protein. Fusion protein Ascl1-E47 was capable to form a specific complex with the wt probe as confirmed 
by supershift analysis with mouse anti-Ascl1 Antibody (α-Ascl1) (lanes 3, 7 and 8). 200x-fold excess of 
cold specific competitor probe, MSB 4 wt cold, could compete for binding with Ascl1, as proved by 
strong fainting of the band (lane 4). Use of a MSB 4 probe mutated in the E box, MSB 4 M1, could 
prevent the binding, showing requirement of an intact E box (lane 5) while the use of a MSB 4 probe 
mutated in the Sox motif, MSB 4 M2, did not affect the binding, proving that Ascl1 can bind 
independently from the Sox motif on the MSB 4 enhancer sequence (lane 6). Lane 1 shows the migration 
pattern of the free unbound wt probe, MSB 4 WT. Lane 2 is the control mock lysate from untransfected 
293T cells. (B) The same EMSA experiment as in figure A was carried out using rabbit reticulocyte 
lysate TNT system as source of the fusion protein Ascl1-E47. Results were consistent in both cases. In 
lane 7 an unrelated probe was used, Nes probe, to confirm sequence-specificity of the binding, as no band 
was detected when using this probe, according to predictions.  
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5.3 Discussion 
The results of the EMSA experiments proved that the TF Ascl1 binds directly to the 
MSB4 enhancer sequence. The use of mutant probes carrying aberrant E-box and Sox 
motif proved that binding of Ascl1 requires specifically an intact E-box and is 
independent from the Sox site. The results for Ascl1 are consistent with its 
transcriptional activation of the same enhancer, as shown in luciferase assay. 
Furthermore, in luciferase assay loss of activation of the mutant enhancer with disrupted 
E-box by Ascl1 correlates with loss of binding of the same TF to the mutated probe 
observed in EMSA.  
In the future, it will be important to optimise the experimental condition of EMSA to 
determine if the Sox factors analysed in this study, in particular Sox2 and the SoxC 
factors Sox4 and Sox11, bind directly to the Sox motif of the same neuronal enhancer 
MSB4. It will be important to determine if they bind independently or simultaneously 
and cooperatively with Ascl1. Results from luciferase assays so far suggest that Ascl1 
and Sox2 might not bind to neuronal enhancer MSB4 simultaneously since they 
counteract each other in the transcriptional regulation of this element. Conversely, 
results from luciferase assays can be compatible with cooperative binding of SoxC 
factors with Ascl1 to this enhancer to explain their synergistic activation of this 
element. In conclusion, the functionality of the Sox binding to this enhancer and the 
requirement of the Sox motif for the transcriptional activation of this element by 
exogenous Ascl1 needs to be further understood.   
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6. Final discussion and future work 
Complex relationships between transcription factors and their enhancers and the 
resulting transcriptional output have profound impact in the gene regulation during 
development. An emerging aspect of developmental enhancers is that they undergo 
progressive changes that are essential for their functions and the time of their activity 
during development (Spitz and Furlong, 2012). A succession of regulators belonging to 
the same family of TFs or interplay between synergistic or antagonistic factors on the 
enhancers also contribute to changes in their transcriptional output and to the spatial and 
temporal regulation of their activity in the progression and specification of 
developmental processes (Kamachi et al., 2001, Tanaka et al., 2004, Bergsland et al., 
2011, Aksoy et al., 2013).  
The work presented in this thesis has identified and characterised nine neural enhancers 
regulated by a complex interplay between Ascl1 and Sox factors during NSC self-
renewal and neurogenesis. This work started with the identification by ChIP-seq of 
genomic regions co-bound by Ascl1 and Sox2 in neural stem cells, raising questions 
about the possible interactions of these factors as transcriptional regulators on common 
regions. An analysis of the enhancer sequences revealed that despite tending to be 
relatively poorly conserved, they all bind the transcriptional coactivator p300 (Figure 
3.6) and are marked by the enhancer-associated epigenetic mark H3K27ac (Martynoga 
et al., 2013). This data support the nature of regulatory elements for these bound 
regions, as previously discussed (paragraph 3.6). Luciferase assays have demonstrated 
that 7 out of 9 regions act as enhancers in vitro in NS5 cell, as shown by their basal 
transcriptional activity. Luciferase assays have also demonstrated that overexpression of 
Ascl1 and Sox2 have an effect on the activity of all nine enhancers studied, although in 
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different ways for different enhancers. The different transcriptional output identified for 
a small group of nine enhancers points out that there is high heterogeneity in the 
regulation by Ascl1 and Sox2 on different enhancers. Most of the enhancers are more 
responsive to exogenous Ascl1 rather than Sox2, which appears to be a weaker 
regulator of these elements. One of the objectives of my study was the characterisation 
of the interaction between these two TFs as transcriptional regulators. Interestingly, my 
results indicate that Ascl1 and Sox2 counteract each other in the regulation of 6 out of 9 
enhancers that they co-bind, and do not act synergistically in the regulation of any of the 
elements identified. These results are consistent with in vivo activities of these TFs in 
neurogenesis. A previous study in chick developing neural tube has demonstrated that 
vertebrate neurogenesis is counteracted by SoxB1 TFs (Sox1-2-3). These proteins keep 
neural stem cells undifferentiated by counteracting the activity of the proneural proteins. 
Conversely, proneural proteins can induce neurogenesis by repression of SoxB1 factors 
expression in neural progenitor cells (Bylund et al., 2003).  
Another main objective of my work was to dissect the molecular mechanism of 
regulation by the TFs Ascl1 and Sox2 of the neural enhancers identified. All of the 
enhancers studied contained one or more E-box and Sox motifs (Figure 4.1). Mutations 
of these binding motifs affected enhancer activity for most of the elements analysed, 
suggesting a mechanism of direct TF-DNA binding in the regulation of the enhancers. 
The mutagenesis analysis has also demonstrated that different motifs within the same 
enhancer have different functions. Both activating and repressing modules have been 
identified within the same enhancer. Enhancers MSB18 and MSB22 are an example of 
this modularity, as demonstrated by mutagenesis analysis of their motifs (Figures 4.3 C 
and F; and paragraphs 4.6.2 and 4.6.4). This may be partly explained by the binding of 
other bHLH (for instance Olig2, as discussed in paragraph 4.6.4) and Sox factors 
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beyond those analysed in this study to the different motifs identified, for instance for 
enhancer MSB18. The transcriptional output seems likely to be a sum of the activity 
occurring at different motifs. Moreover, an analysis of the architecture of the enhancers 
did not reveal any reoccurring pattern in the arrangement of the E-boxes and Sox motifs 
within the sequences of different enhancers. Altogether, the enhancers studied in this 
work seem to serve as information display for binding of different TFs and their 
autonomous transcriptional activity, with only few requirements of interdependent 
motifs, as discussed later. As an information display, close TF binding motifs and their 
associated TFs are independently interpreted by the transcriptional machinery (Kulkarni 
and Arnosti, 2003). In this perspective, the neural elements characterised resemble the 
billboard model of enhancer architecture if compared to the more constrained 
arrangement of motifs of the enhanceosome model (Kulkarni and Arnosti, 2003, 
Arnosti and Kulkarni, 2005, Spitz and Furlong, 2012, Dickel et al., 2013). A small 
group of only 9 regulatory elements display a high level of heterogeneity in the 
enhancer architecture and possible different mechanisms of regulation for each of them. 
These findings are in line with the picture emerging for mammalian developmental 
enhancers, which also show high degree of heterogeneity in their architecture and TF 
binding pattern. This variability is functional to changes to their spatio-temporal 
activities and regulation during development (Spitz and Furlong, 2012, Dickel et al., 
2013). 
One of the most intriguing findings arising from this study was that mutation of the Sox 
motif was shown to prevent Ascl1-induced activation of the neuronal enhancer MSB4 
suggesting the requirement of this Sox motif for exogenous Ascl1 activity. The fact that 
Sox2 counteracts Ascl1-induced activation of this element and that different Sox factors 
tend to bind to the same motif prompted us to extend our analysis to other Sox factors 
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that could synergise with Ascl1 in the regulation of neuronal enhancers (Harley et al., 
1994, Wegner and Stolt, 2005, Lefebvre et al., 2007). Cotransfection experiments and 
luciferase assays presented in this thesis demonstrated that Sox4 or Sox11 strongly 
synergise with Ascl1 in the activation of the neuronal enhancers MSB4, MSB18, and 
MSB22 when these TFs were cotransfected in NS5 cells. However, single 
overexpression of Sox4 or Sox11 was not sufficient to induce enhancer activity. This 
result is consistent with the literature reporting that Sox proteins in general need 
cooperation with other TFs for efficient transcriptional activation of the regulated 
targets (Kondoh and Kamachi, 2010). The synergy between Ascl1-SoxC factors 
presented in this study is a novel interaction between these TFs previously unreported in 
the regulation of neuronal enhancers in neuronal differentiation. Previous studies have 
reported that Sox4 and Sox11 could directly regulate and target the promoters of genes 
induced in neuronal differentiation, such as the Tubb3 promoter and the Doublecortin 
(DCX) promoter (Bergsland et al., 2006, Mu et al., 2012). However, an interaction with 
Ascl1 or other proneural proteins has never been considered. In particular, Bergsland 
and colleagues exclude such interaction, as Ngn2 could not regulate the Tubb3-LacZ 
reporter in their transcriptional assay experiments, which identified Sox4 and Sox11 as 
transcriptional activators of this promoter (Bergsland et al., 2006). Mu and colleagues 
instead hypothesised a possible interaction with the Brn proteins since putative binding 
sites for these factors were identified in the DCX regulatory region in proximity of the 
Sox11 binding sites (Mu et al., 2012) and since Sox11-Brn proteins interaction has been 
previously reported in the regulation of the Nestin enhancer in the SVZ of the 
developing spinal cord (Tanaka et al., 2004). In support of my results, a similar synergy 
between the bHLH factor MyoD and Sox11 has been described in the activation of the 
myogenin promoter in cell culture in an in vitro model of myogenic differentiation 
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(Schmidt et al., 2003). The transcriptional assay results presented in my thesis are 
remarkably similar to those reported by Schmidt and colleagues in their study.  
I have previously discussed that two different models of synergistic Ascl1-SoxC 
activation of neuronal enhancers can be proposed, according to the results of the 
mutagenesis experiments (paragraph 4.6.6). In some neuronal enhancers, such as 
MSB22 studied here, Ascl1 and Sox4 or Sox11 were still able to synergistically activate 
enhancer activity in the absence of a functional Sox motif, suggesting that these factors 
might interact as proteins in the same transactivation complex without direct binding of 
the SoxC factors to the DNA. Results also suggest that Ascl1 and Sox4 or Sox11 might 
establish a feedforward loop in the regulation of the neuronal enhancer MSB4 through 
direct binding of both TFs to their DNA binding motifs and synergistic activation of this 
neuronal enhancer (paragraph 4.6.6). Therefore, Ascl1 activates SoxC factors and these 
feed forward and help the same Ascl1 to activate enhancer MSB4. The diagram in 
Figure 6.1 (B and C) depicts both models of synergistic activation of the neuronal 
enhancers. In the future, it will be important in EMSA experiments to confirm or 
exclude direct binding of the SoxC factors to the Sox motifs in the enhancers analysed. 
Additionally, coimmunoprecipitation experiments will prove if Ascl1 and SoxC factors 
are in the same protein complex and can interact in the regulation of the enhancers 
where this mechanism of interaction is supported. A feedforward loop involving Sox2, 
Oct4 and Nanog has been described in the regulation of genes underpinning the stem 
state in ESCs (Boyer et al., 2005). According to the results presented in this thesis, it 
seems to be possible that a feedforward loop involving Ascl1 and the SoxC factors is 
also essential to the transcriptional regulatory network controlling neuronal 
differentiation, at least for one of the neuronal enhancers analysed. Future experiments 
will need to prove the proposed models. 
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The interplay between Ascl1 and the Sox factors described in this study has been 
dissected through overexpression of Ascl1 and Sox factors in NS5 cells. Overexpression 
of Ascl1 in NS5 induces neuronal differentiation and 24 hours after overexpression of 
this TF, NS5 cells start to acquire neuronal characteristics (Martynoga, unpublished 
data). In this cellular and molecular context underpinning neuronal differentiation, 
Ascl1 and Sox2 tend to counteract each other in the regulation of enhancers that they 
both bind and regulate. Conversely, Ascl1 and Sox4 or Sox11 synergise in the 
activation of the neuronal enhancers (the only enhancers tested at the present in this 
study). It is very likely that the interplay of Ascl1 and Sox factors we describe reflects 
the context of neuronal differentiation. It will be interesting in the future to understand 
if any other possible interaction is possible for Ascl1 and Sox2. For instance, it will be 
interesting to understand if they might ever synergise in the regulation of commonly 
bound enhancers active in the neural stem cell context. The GoF approach undertaken in 
this study excludes the characterisation of this status. Sox2 appears as a weaker 
regulator of the enhancers here characterised compared with Ascl1. It is possible that 
Sox2 is a weak activator of this enhancer because, as other Sox factors, it requires 
cooperative interactions with other TFs for an efficient activation of the regulated target, 
as previously mentioned in this thesis several other times (Kondoh and Kamachi, 2010). 
It is evident that Ascl1 is not the partner required for the transcriptional activation of the 
regulated enhancers. However, it could be speculated that Sox2 might also have 
architectural role and it might bind and bend the DNA to facilitate recruitment of Ascl1 
or even of the other Sox factors bound at later stage of the neuronal differentiation 
process (Wegner, 1999, Lefebvre et al., 2007). This might explain the requirement of 
the Sox motif for exogenous Ascl1-induced activation of the neuronal enhancer MSB4 
not fully understood at the present in this study. In this perspective, binding of 
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exogenously expressed Sox2 might not have evident functional consequences in the 
activity of the enhancers. Pre-binding of Sox2 on enhancers that will be later activated 
upon binding of Sox4 or Sox11 and their synergistic interaction with Ascl1 would be 
another possibility in the regulation of the neuronal enhancers characterised in this 
study. This role would be consistent with the study of Bergsland and colleagues, who 
proposed a succession of Sox factors, more precisely Sox2, Sox3, and Sox11 to 
common targets at subsequent phases of the neuronal lineage (Bergsland et al., 2011).  
A better characterisation of the cellular and molecular contexts underpinning the neural 
stem state and the neuronal differentiating state associated to Ascl1 overexpression is 
needed in the future. For instance, it would be important to test if in the cellular context 
of Ascl1 and Sox2 overexpression in NS5 cells Sox2 blocks Ascl1-induced 
neurogenesis and if SoxC factors synergise with Ascl1 to increase and accelerate the 
production of neurons, as suggested from the transcriptional network uncovered in this 
study. Furthermore, performing ChIP experiments for the Sox factors in NS5 cells 
before or after Ascl1 overexpression could help in the molecular characterisation of the 
stem state or neuronal state. In this way, a rewiring of different Sox factors induced by 
Ascl1 could be demonstrated in the progression of the neural lineage from neural stem 
cells to differentiating neurons, if this occurs. 
In conclusion, this study has identified a transcriptional regulatory network dependent 
on Ascl1 in the regulation of neuronal enhancers in differentiating neurons. In this 
network, Ascl1 and Sox2 counteract each other in the regulation of neuronal enhancers. 
Conversely, Ascl1 synergise with Sox4 or Sox11 in the activation of the neuronal 
enhancers. The diagram in Figure 6.1 illustrates the models of regulation that can be 
proposed from the results presented in this thesis.  




    
Figure 6.1 Models of interplay between Ascl1 and Sox factors in the regulation of 
the neuronal enhancers. 
(A) Ascl1 and Sox2 counteract each other in the regulation of the neuronal enhancers. (B and C) Ascl1 
and SoxC factors synergise in the regulation of the neuronal enhancers. (B) Feedforward regulatory loop 
for neuronal enhancer MSB4. Ascl1 induces activation of the neuronal enhancer and also induces SoxC 
factors. SoxC factors activate the neuronal enhancer in synergy with Ascl1 through direct DNA binding 
to the same regulatory sequence. The black dashed arrow indicates a direct DNA binding that still need to 
be tested in future experiments. (C) Ascl1 and SoxC factors synergise in the activation of the neuronal 
enhancers, although there are no evidence of direct SoxC factors binding to the DNA. The ovals represent 
TFs; the rectangles represent genes whose names are printed in italics; the red and green triangles 
represent E-boxes and Sox motifs, respectively.  In all three pictures the blue dashed arrows or inhibitory 
link have been reported in the literature (e.g. Bergsland et al., 2006) and/or have been showed in 
microarray experiments (data from Ben Martynoga). The black arrows showing direct binding of Ascl1 to 
the E-boxes in the enhancer sequences have been directly demonstrated in EMSA experiments (MSB4 
enhancer) or supported by results of mutagenesis of the E-boxes for all enhancers mutated. 
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